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Parkinson’s disease (PD) is a prevalent neurodegenerative movement disorder 
characterised pathologically by the loss of dopaminergic neurons in the 
substantia nigra. The current pharmacotherapies of PD are facing limitations on 
side effects, such as motor fluctuations, drug-induced dyskinesia, and 
psychosis. This thesis seeks to address these limitations by discovering new 
chemical entities (NCEs) targeting adenosine hA2A and dopamine hD2 receptors 
as potential therapeutics of PD. Three computational methods, namely support 
vector machine (SVM) models, Tanimoto similarity, and hierarchical clustering, 
were utilised for the identification of compounds containing the [indole + 
piperazine + pyrimidine] (IPP). Subsequent synthesis and testing of IPP-
containing compounds led to the discovery of compounds 69 and 70, which 
acted as hA2A binders in the radioligand competition assay (Ki = 8.71~11.2 µM) 
and hD2 binders in the artificial cell membrane assay (EC50 = 22.5~40.2 µM). 
These two novel compounds did not exhibit mutagenicity (up to 100 µM), 
hepatotoxicity (up to 30 µM) and cardiotoxicity (up to 30 µM), although they 
suffered from poor aqueous solubility, poor membrane permeability, and 
metabolic instability. More importantly, in Drosophila models of PD, these two 
compounds showed improvement in movement and mitigation of the loss of 
dopaminergic neurons. Together with recommendations given for future 
optimisation, these two compounds have paved the way for novel PD 
therapeutics. 
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CHAPTER 1    PARKINSON’S DISEASE (PD) 
 
1.1    Introduction to PD 
The term “Parkinson’s disease” originated from the monograph “An Essay on 
the Shaking Palsy” published in 1817 by the British physician James Parkinson. 
At the very beginning of chapter 1 of this monograph, the shaking palsy was 
defined as “involuntary tremulous motion, with lessened muscular power, in 
parts not in action and even when supported; with a propensity to bend the trunk 
forwards, and to pass from a walking to a running pace: the senses and intellects 
being uninjured.” (Parkinson, 2002). These manifestations observed by James 
Parkinson in his time have been evolved into the currently accepted 
classification, namely, motor and nonmotor symptoms. The cardinal motor 
features include tremor, rigidity, bradykinesia and postural instability. PD 
tremor occurs at rest, and decreases when the patient is in action, mental 
concentration or writing. Rigidity refers to the resistance to movement, and this 
stiffness may occur in the neck, shoulders, hips, wrists or ankles. Bradykinesia, 
which is defined as extreme slowness of movements and reflexes, is the most 
characteristic feature of PD, and it encompasses decreased amplitude of 
movement, arrests in ongoing movement, and decreased spontaneous 
movements such as eye blinking, swallowing, or arm swing in walking. 
Generally, tremor, rigidity and bradykinesia (the typical motor triad) occur at 
the early stages of PD, whereas postural instability manifests as a late feature. 
A PD patient with postural instability has difficulty in recovering balance to 
maintain an upright posture when jostled, and may result in a fall (Jankovic, 
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2008). The nonmotor symptoms are divided into four categories: sleep 
disorders, neuropsychiatric symptoms, autonomic symptoms, and sensory 
symptoms. Virtually all PD patients suffer from sleep disruption. Specifically, 
rapid eye movement sleep behaviour disorder (RBD) and excessive daytime 
sleepiness affect 33% and 50% of patients, respectively. Moreover, depression, 
visual hallucinations, and dementia occur in 10~45%, 40%, and 40% of PD 
patients, respectively. Other major neuropsychiatric symptoms associated with 
PD include anxiety, apathy and psychosis. Autonomic symptoms involve 
orthostatic hypotension, constipation, and bladder disturbances. Sensory 
symptoms cover olfactory dysfunction, which affects up to 90% of PD patients, 
ageusia, pain and paresthesia (Chaudhuri et al., 2006). Some nonmotor 
symptoms may precede PD motor dysfunctions by years. Currently, PD is a 
prevalent neurodegenerative disease, and the number of individuals with PD 
over age 50 was projected to be 9 million by 2030 (Dorsey et al., 2007). 
The traditional view of PD pathogenesis holds that the dopaminergic neurons 
located in the substantia nigra pars compacta (SNc) of midbrain degenerate, 
resulting in the depletion of striatal dopamine. Figure 1 shows the four major 
dopaminergic pathways (i.e. nigrostriatal pathway, mesolimbic pathway, 
mesocortical pathway and tuberoinfundibular pathway) which project diffusely 
onto other areas of the brain and use modulatory dopamine (DA) as the 
neurotransmitter. The nigrostriatal pathway originates from SNc and extends its 
fibers into the dorsal striatum, and it is believed to be the most germane 
dopaminergic pathway to PD. The mesolimbic and mesocortical pathways arise 
from dopaminergic neurons residing in the ventral tegmental area (VTA), but 
they project to the limbic system (via the nucleus accumbens) and frontal cortex, 
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respectively. The mesolimbic and mesocortical dopaminergic neurons are often 
intermingled with each other, and are therefore collectively referred to as the 
mesocorticolimbic system which plays an important role in reward, memory, 
motivation and schizophrenia (Chinta and Andersen, 2005). The 
tuberoinfundibular pathway starts with dopaminergic neurons in the 
hypothalamus, and it is involved in the inhibition of the hormone prolactin 
secretion (Ben-Jonathan, 1985). In the normal brain, dopamine within striatum 
is essential for the initiation of willed movements of the body, and this 
dopamine input is realised by the nigrostriatal pathway which is composed of 
dopaminergic neurons whose cell bodies are located in the SNc. In contrast, at 
the onset of PD, patients have usually lost 60% of SNc dopaminergic neurons, 
and the striatal DA has been depleted by 80%. Why do these neurons die? 
Figure 1. The four major dopaminergic pathways in the brain (modified from 
thebrain.mcgill.ca) (under copyleft ). 
 
Over the past 197 years (i.e. 1817–2014), there have been tremendous advances 
in the understanding of the pathogenesis associated with PD, and these studies 
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have suggested that the neuronal cell death in PD is caused by an interwoven 
tapestry of molecular events. Since the dopaminergic neurons of the 
nigrostriatal pathway are surrounded by a number of non-dopaminergic neurons 
(e.g. cholinergic and GABAergic neurons) and non-neuronal cells (e.g. 
microglia and astrocytes), it is increasingly recognised that PD pathogenesis is 
a combination of cell-autonomous (i.e. occurring inside the degenerative 
neurons) and non-cell-autonomous (i.e. occurring outside the degenerative 
neurons) mechanisms (Hirsch et al., 2013). All cell-autonomous mechanisms 
revolve around mitochondrial dysfunction. Mitochondria are intracellular 
organelles that produce most of the ATP for the cell by the electron transport 
system, but their dysfunction accounts for the production of reactive oxygen 
species (ROS), which play roles in ageing, ischemia-reperfusion injury, 
neurodegenerative diseases, and cancer. In 1998, it was identified that the 
mutations of parkin gene cause autosomal recessive juvenile parkinsonism 
(Kitada et al., 1998). Later on, an important discovery was the identification of 
a new parkin interacting substrate (PARIS), which is a transcriptional repressor 
of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), 
and it accumulates following parkin inactivation (Shin et al., 2011). PGC-1α 
stimulates mitochondrial electron transport as well as suppresses ROS levels, 
so it protects neural cells (St-Pierre et al., 2006). The benefit of inducing PGC-
1α in the PD brain was further confirmed by the analysis (Zheng et al., 2010) 
where 10 gene sets (encoding proteins involved in the glucose sensing, glucose 
utilisation, mitochondrial electron transport chain, and mitochondrial 
biogenesis) identified to be associated with PD were commonly regulated by 
PGC-1α, the underexpression of the PGC-1α responsive genes in patients with 
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PD was observed, and the overexpression of PGC-1α was shown to protect 
neuronal damage. Collectively, the altered Parkin-PARIS-PGC-1α pathway and 
its resulting defects in cellular bioenergetics have been considered to be one of 
the contributing mechanisms to PD pathogenesis (Figure 2).     
 
Figure 2. The diseased molecular events inside and outside the dopaminergic 
neurons (Hirsch et al., 2013) (reprinted with permission). 
 
In addition, the mitochondrial oxidant stress in the dopaminergic neurons in 
SNc was found to be associated with calcium homeostatis (Chan et al., 2007; 
Guzman et al., 2010). These neurons drive their rhythmic pacemaking by 
distinct L-type voltage-gated calcium channels with α1 subunit CaV1.3, making 
them distinguished from dopaminergic neurons in the VTA. This selective 
engagement of L-type calcium channels augments with age, and the resultant 
increase in cytosolic Ca2+ ions elevate oxidative stress in the mitochondria. It 
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provides an explanation of why SNc dopaminergic neurons are comparatively 
vulnerable. Since this Ca2+ influx is not necessary for pacemaking, there have 
been some endeavours to develop selective antagonists of CaV1.3 L-type Ca2+ 
channels as potential PD therapeutics (Chang et al., 2010; Kang et al., 2012; 
Kang et al., 2013). Furthermore, the proposed mitochondrial quality-control 
system suggests that the defective mitochondria undergo parkin-mediated 
autophagy (mitophagy) through ubiquitin-proteasome system (UPS) in a 
PINK1-dependent manner (Okatsu et al., 2012). If parkin/PINK1 mutates (as 
seen in familial PD), the build-up of and the stress caused by damaged 
mitochondria will eventual lead to neuronal death. 
The non-cell-autonomous mechanisms include α-synuclein transfer and 
neuroinflammation. The presence of Lewy bodies (LBs) composed of α-
synuclein deposition is often observed in the surviving neurons (both 
dopaminergic and non-dopaminergic neurons) of affected PD brains (Spillantini 
et al., 1997). The discovery that LB-like structures and α-synuclein aggregates 
develop in grafted neurons of a PD patient who died 14 years after 
transplantation implies that α-synuclein might be able to transfer between cells 
in PD brains (Kordower et al., 2008). How α-synuclein leaves cells, how it 
propagates to a new cell, and how it enters this new cell have been reviewed 
elsewhere (Steiner et al., 2011). For innate immune system, activated microglia 
cells have been found in the substantia nigra of PD patients, and it is likely that 
microglial activation poses harm to SNc neurons by releasing pro-inflammatory 
cytokines, reactive nitrogen species (RNS), and ROS (Figure 2). For adaptive 
immne system, evidence has shown that CD4+ T cells invaded postmortem 
human PD brain, and neuronal death was attenuated by the removal of CD4+ T 
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cells (Brochard et al., 2009). Taken together, the pathogenesis of PD represents 
a complex network of events in which dopaminergic neurons, non-
dopaminergic neurons and nonneuronal cells participate. The susceptibility of 
neurons in SNc to many stressors outlined above calls for a PD therapy capable 
of protecting neurons from multiple possible insults. 
 
1.2    Current PD Pharmacotherapeutics 
The development of PD therapies has been largely focused on improving motor 
symptoms which are caused by dopamine deficiency. Relatively few 
approaches are targeted to alleviate nonmotor symptoms, which are attributed 
to the degeneration of both dopaminergic and non-dopaminergic neurons. In 
addition to symptomatic alleviation, an agent that displays neuroprotective or 
disease-modifying properties remains an unmet clinical need. In this section, 
only treatments for PD motor symptoms will be reviewed. 
 
1.2.1    Dopamine replacement therapies 
In 1957, Arvid Carlsson understood that dopamine itself could not penetrate the 
blood-brain barrier (BBB), so he injected 3,4-dihydroxyphenylalanine (DOPA), 
the amino-acid precursor of dopamine, into mice and rabbits that had been 
treated with reserpine. The animals almost resumed normal behaviours after 
DOPA injection (Figure 3) (Carlsson et al., 1957; Carlsson et al., 1958). This 
led him to conclude that dopamine depletion induces the PD syndromes, and 
that DOPA treatment restores the dopamine level. In 1970, L-DOPA was 
approved by the US Food and Drug Administration (FDA) for the treatment of 
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PD. Later, research was conducted and showed that L-DOPA enters the brain 
through an amino acid transporter (Kageyama et al., 2000).   
 
Figure 3. Reserpine-induce rabbits before (top) and after (below) treatment of 
DOPA. The figure is taken from Arvid Carlsson’s Nobel Lecture, © The Nobel 
Foundation 2000. Source: Nobelprize.org. Direct link:  
http://www.nobelprize.org/nobel_prizes/medicine/laureates/2000/carlsson-
lecture.html (reprinted with permission). 
 
Following that was the development of dopamine receptor agonists, which 
mimic dopamine in its postsynaptic receptors, as well as inhibitors of two 
dopamine-degrading enzymes, catechol-O-methyltransferase (COMT) and 
monoamine oxidase (MAO) isoenzyme B (Figures 4 and 5). Representative 
MAO-B inhibitors and dopamine receptor agonists are listed in Figures 11 and 
25, respectively. Over the past 40 years, L-DOPA remains the most effective 
PD therapy for improving motor symptoms. However, several years after the 
introduction of L-DOPA, it was observed that patients developed motor 
complications, such as drug-induced dyskinesia. The mechanisms of dyskinesia 
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are complex, inasmuch as they involve dopaminergic, glutamatergic, opioid, 
serotonergic, GABAergic, adenosine, cannabinoid, adrenergic, histaminergic, 
cholinergic neurotransmission systems, as well as the intracellular events (Huot 
et al., 2013).    
 
Figure 4. Current major dopamine replacement therapies for PD act at four 
points as shown in 1 to 4. 1, L-DOPA, the precursor of dopamine; 2, dopamine 
receptor agonists; 3, COMT inhibitors; 4, MAO B inhibitors. The figure is 
modified from Lecht’s publication (Lecht et al., 2007) (reprinted with 
permission). 










































Figure 5. The biosynthesis and breakdown of dopamine. 
 
1.2.2    Non-dopaminergic therapies 
In addition to dopamine replacement therapies, there are other potentially anti-
PD agents modulating various receptors, including adenosine A2A receptor, 
metabotropic glutamate receptor type 4 (mGluR4), and metabotropic glutamate 
receptor type 5 (mGluR5). A2A receptor is localised richly in striato-pallidal 
 CHAPTER 1  
11 
 
neurons and functionally opposes the effect of dopamine D2 receptor. Blockade 
of A2A receptor has been demonstrated to help restore the motor impairment of 
PD (Schwarzschild et al., 2006). In addition, most metabotropic glutamate 
receptors (mGluRs) are found in neurons in different brain regions, such as basal 
ganglia, and preclinical studies have suggested that selective ligands for 
mGluR4 and mGluR5 are potential PD treatments. Dopaminergic neuron loss 
in PD patients leads to the  hyperactivity (i.e. disinhibition) from the striatum to 
the external globus pallidus (GPe), and activating mGluR4, which is expressed 
in the presynaptic terminal of the striatal-pallidal projection, has been shown to 
reduce GABAergic transmission at this synapse (Conn et al., 2009). The 
hypothesis that activating mGluR4 has utility for treating PD is being tested, 
with encouraging results that L-(+)-2-amino-4-phosphonobutyric acid (L-AP4), 
a mGluR4 receptor agonist, reduced motor symptoms in rodent models of PD 
(Konieczny et al., 2007), and N-phenyl-7-
(hydroxylimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) (Marino et 
al., 2003), a selective positive allosteric modulator (PAM) of mGluR4, provided 
symptomatic relief and neuroprotective effects in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-lesioned mice (Battaglia et al., 2006). Also, the 
expression level of mGluR5 is increased in parkinsonian monkeys with L-
DOPA-induced dyskinesia (LID), and there have been several mGluR5 negative 
allosteric modulators (NAMs) proven to be useful to reduce LID both in 
preclinical models (Morin et al., 2013) and in phase 2a clinical studies (Nickols 
and Conn, 2014).  
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1.3    Opportunities of Polypharmacology in Treating PD 
In view of the fact that PD is a disease with changes in neuronal activities in the 
basal ganglia motor circuit on which a multitude of ionotropic and metabotropic 
receptors modulate excitatory/inhibitory neurotransmission, it is conceivable 
that a therapeutic agent specifically targeting one subtype of biological 
macromolecule is necessary but may not be sufficient to treat PD. Indeed, apart 
from PD, some other multifactorial diseases, including cancer, psychiatric 
diseases, bacterial infections, epilepsy, inflammation, and malaria, cannot be 
treated effectively by focusing only on one aberrant event. Rather, evidence has 
shown that many approved drugs bind to multiple proteins (Bain et al., 2007; 
Peters, 2013), and there have been a number of attempts to deliberately design 
a compound acting at multiple relevant targets for the treatment of 
schizophrenia (Lowe et al., 1991), depression (Ryckmans et al., 2002), 
Alzheimer’s disease (Toda et al., 2003), pain (Daniels et al., 2005) and PD 
(Pretorius et al., 2008). 
 
1.3.1    Approaches to multi-targeting 
In the late 19th to the early 20th century, scientists/clinicians tested potentially 
therapeutic agents directly in animals or patients. For example, in 1891, Paul 
Ehrlich used methylene blue in patients with malaria, and the patients were 
apparently cured. The continual hunt for malaria treatment led to the surprising 
discovery of phenothiazine, which is structurally analogous to methylene blue 
but not antimalarial. Minor structural modification on phenothiazine resulted in 
chlorpromazine that was confirmed to be antipsychotic and antimanic 
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(Frankenburg and Baldessarini, 2008). Chlorpromazine was marketed in France 
in the autumn of 1952, and it is still a useful antipsychotic medication today 
(Sneader, 2002). Imipramine, an analogue of chlorpromazine, was clinically 
proven to have an antidepressant therapeutic effect by Roland Kuhn, and was 
marketed in Switzerland in late 1957 (Lopez-Munoz and Alamo, 2009). Until 
1970s, most drugs were first assessed in animal models, and researchers utilised 
these phenotypic assay results to direct their drug discovery programmes. The 
advantage of this in vivo pharmacology approach is the high relevance of the 
assay results to the human conditions, yet when compounds show no effect, it 
is often difficult to know whether this is because they do not bind to the desired 
target(s) or simply fail to deliver to the site of action. Also, the lack of 
mechanistic evaluation of toxicity aggravates the difficulty in compound 
optimisation. Not surprisingly, many drugs discovered in 1950s elicited side 
effects, which were later confirmed to be ascribable to their interactions with 
undesired targets (i.e. off-target effects). In 1970s, the appreciation of how 
pharmacological promiscuity of drugs, namely the activity of a single 
compound at multiple targets, leads to adverse drug reactions (ADRs) is 
exemplified by subtype selectivity of β-adrenergic receptors. The β1 receptor is 
predominantly expressed in the cardiac muscle, whereas the β2 receptor is 
mainly located in the lung muscle. Propranolol, which was developed by James 
W. Black in 1960s, blocks both subtypes and thus causes bronchoconstriction. 
The β1-selective atenolol was later developed (in 1976) to reduce the risk of 
bronchospastic reactions. Also, in September 1997, U.S. FDA announced 
withdrawal of appetite-suppressant drug fenfluramine and its active metabolite 
dexfenfluramine due to their risks of pulmonary hypertension and valvular heart 
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disease (Abenhaim et al., 1996; Connolly et al., 1997). The later screening 
revealed that dexfenfluramine activated serotonin 5-HT2B receptor, which is 
abundant in cardiac valvular endothelium (Setola and Roth, 2005). Other 
frequently encountered antitargets (Vaz and Klabunde, 2008) include, but are 
not limited to, the human ether-à-go-go-related gene (hERG) potassium 
channel, blockade of which leads to cardiac arrhythmia (Sanguinetti and 
Tristani-Firouzi, 2006), and adrenergic α1A receptor, whose antagonism results 
in adverse orthostatic hypotension. These observations on how off-target effects 
caused serious toxicity provide the impetus for establishing the screen of a panel 
of ADR-associated targets in the early phase of drug discovery to ensure drug 
safety (Whitebread et al., 2005), as well as for developing compounds 
exquisitely selective to one particular subtype of a receptor class. This 
reductionist, hypothesis-driven, “one disease-one target” approach (i.e. “magic 
bullet” proposed by Paul Ehrlich) has dominated pharmaceutical industries 
since 1990s. Undeniably, single-target-based drug discovery (Sams-Dodd, 
2005) with the concept that modulation of one validated target by ligands with 
high affinity and selectivity is adequate to confer maximal efficacy and minimal 
toxicity has resulted in many successful drugs. The most notable example may 
be the development of anti-human immunodeficiency virus (HIV) drugs. Two 
enzymes, reverse transcriptase and protease, play important roles in the HIV 
replicative cycle, and each of them has been selectively targeted for 
chemotherapeutic intervention for more than 30 years. At present, there are 12 
reverse transcriptase inhibitors (didanosine, zidovudine, stavudine, abacavir, 
lamivudine, zalcitabine, emtricitabine, delavirdine, etravirine, rilpivirine, 
efavirenz, nevirapine) (Appendix A) and 10 protease inhibitors (tipranavir, 
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darunavir, fosamprenavir, atazanavir, ritonavir, saquinavir, indinavir, lopinavir, 
amprenavir, nelfinavir) (Appendix B) approved for clinical use (De Clercq, 
2013). The design processes for these drugs rely on the high-resolution X-ray 
crystallographic structures of drug-enzyme complex, leading to the 
identification of highly potent and selective single-enzyme-targeting agents 
(Zhan et al., 2013). Undoubtedly, the strategy of targeting one protein allowed 
for the implementation of rational drug design, and was also suitable for high-
throughput screening for potential drug candidates. Hence it has been proven to 
be a powerful approach to discovering treatments for many diseases. However, 
since 2004 (Morphy et al., 2004; Roth et al., 2004), there has been an increasing 
awareness that the effectiveness of a drug depends not only on minimising the 
interactions with unintended targets but also on maximising the interactions 
with multiple relevant therapeutic targets. This entails the understanding of the 
functions of all targets in the network context of a drug, so that the knowledge 
on which beneficial targets are to be aimed and which detrimental targets are to 
be avoided may be utilised in the drug design. The changing paradigms of drug 
discovery are illustrated in Figures 6 and 7. 
Figure 6. The evolution of approaches to drug discovery over the past century. 
 




Figure 7. Single-target-based drugs (upper) are selective to a validated target 
responsible for a cellular mechanism, whereas polypharmacological drugs 
(lower) selectively bind to multiple therapeutically beneficial targets. 
 
At the beginning of the twenty-first century, data showed that the two major 
causes of attrition during drug development are lack of efficacy and failure to 
meet the toxicological standard (Kola and Landis, 2004). In a sense, these two 
causes correlate with intended/unintended targets discussed above, meaning 
that it is probable that the single-target-based strategy is responsible for lack of 
efficacy and some unidentified binding targets result in toxicity (Figure 7). 
Obviously, a plausible solution to reduce attrition rates is to have a drug that 
binds to a group of therapeutically valuable targets, that is, multi-targeting, to 
enhance efficacy and does not bind to any safety-related antitargets to reduce 
side effects (Bowes et al., 2012). Whilst the elimination of interactions with 
unintended targets has gained appreciation since 1970s as shown in the case of 
adrenergic β1/β2 receptors selectivity, the practice of deliberately designing a 
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compound that binds to multiple intended targets is currently being recognised. 
The essentiality of a drug that binds to several beneficial proteins can be 
understood by the concept of biological networks which emphasise on nodes 
(e.g. gene products) connected by links (e.g. protein-protein interactions). It 
implies that perturbing only one node usually triggers the compensatory 
mechanism that offsets the effect of a drug (Barabasi et al., 2011). For instance, 
the fbaA gene deletion in Escherichia coli MG1655 can be rescued by additional 
deletion of either aceA or sucAb gene to the optimal state, suggesting that 
knocking out a select pair of synthetically viable genes may be necessary for 
restoring the lost function, as well as providing a basis for inhibiting two 
enzymes to achieve therapeutic effectiveness (Motter et al., 2008). It has been 
documented that such biological robustness, which refers to the maintenance 
and persistence of cellular functions under genetic perturbations or 
environmental uncertainties (Stelling et al., 2004), is manifested in the 
intracellular feedback of Escherichia coli (Alon et al., 1999), the stable pattern 
formation of Drosophila melanogaster (von Dassow et al., 2000), the metabolic 
enzyme system in Salmonella enterica (Becker et al., 2006), and tumour cells 
(Kitano, 2003). More importantly, a study (Mestres et al., 2008) from databases 
DrugBank and WOMBAT determined that a drug binds to 2.7 targets on 
average, and such compound promiscuity can be further illustrated by the fact 
that clozapine, which is the gold-standard among antipsychotic medications, 
interacts with 5 dopamine receptors, 10 serotonin receptors, 5 muscarinic 
acetylcholine receptors, 5 α-adrenergic receptors, and 3 histamine receptors. 
The multi-targeting property displayed by clozapine to mitigate or control the 
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robustness of central nervous system may account for its superior efficacy in 
treating schizophrenia.  
In general, there are two approaches to multi-targeting, that is, combination 
therapies and polypharmacological drugs, both of which aim at reducing the 
problems attendant on binding to one target tightly and selectively. 
Combination therapies include (i) drug cocktails, and (ii) fixed-dose 
combination (FDC). Drug cocktails refer to two or more tablets, with different 
active pharmaceutical ingredients (APIs) in each. Reduction of side effects 
arosed from high-dose of each drug component by drug cocktails was shown in 
an analysis conducted in 2009, providing evidence that anti-bacterial, anti-viral 
and anti-inflammation synergies increased the safe treatment window as well as 
conferred greater selectivity to particular cellular phenotypes over individual 
drugs (Lehar et al., 2009). In contrast, FDC refers to a tablet with two or more 
different APIs in a fixed ratio of doses. The commercial success of FDCs can 
be illustrated in treatments for respiratory and cardiovascular systems. 
ADVAIR, an approved combination inhaler containing fluticasone, an inhaled 
corticosteroid having anti-inflammatory effects, and salmeterol, a long-acting 
adrenergic β2 receptor agonist acting as a bronchodilator, was developed by 
GlaxoSmithKline to treat asthma and chronic obstructive pulmonary disease 
(COPD) with a global sales of US$8.3 billion (data in 2010), and importantly, 
a meta-analysis has demonstrated that the single inhaler of ADVAIR offers 
superior efficacy over its two components administered concurrently via 
separate inhalers (Nelson et al., 2003). CADUET, launched by Pfizer in 2004, 
is a combination of atorvastatin, an inhibitor of 5-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMG-CoA) to reduce the level of low-density 
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lipoprotein cholesterol (LDL-C), and amlodipine, a calcium channel antagonist 
to lower blood pressure, and it is indicated for treating patients with 
hypertension and hyperlipidaemia. Studies have shown that treatment with a 
single-tablet CADUET led to synergistic increase compared with using either 
of its constituent agents in the production of nitric oxide (NO), a 
cardioprotective molecule in the vasculature (Jukema and van der Hoorn, 2004; 
Mason et al., 2008). With regard to polypharmacological drugs (Anighoro et al., 
2014; Peters, 2013), they refer to one API, with a balanced profile of 
pharmacological activities to multiple therapeutic targets in an optimal ratio, 
formulated in a tablet. Case studies of polypharmacology in cancer therapy and 
antipsychotics are given in Appendices C and D, respectively. In consonance 
with combination therapies, several lines of evidence have suggested that 
polypharmacological drugs reduce side effects resulted from merely interacting 
with one target. (Here it is worth noting that toxicity can stem from interacting 
with either antitargets, as shown in Figure 7, or intended targets.) For instance, 
tapentadol, an analgesic which acts as µ-opioid receptor agonist and 
norepinephrine reuptake inhibitor, displayed less side effects seen in morphine 
which acts only through opioid receptor agonism (Tzschentke et al., 2007). 
Moreover, rapacuronium, a neuromuscular blocking agent, was withdrawn from 
the market due to bronchoconstriction, with a possible mechanism for this fatal 
side effect being the selective antagonism of muscarinic M2 receptor shown in 
the radioligand displacement experiments (Jooste et al., 2003). By contrast, 
some other neuromuscular blocking agents (e.g. pancuronium) which are M2 
and M3 dual-acting antagonists are still in clinical use.   
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The advantages of polypharmacological drugs over FDCs lie in the elimination 
of drug-drug interactions (DDIs) and the easier regulatory approval. DDIs, 
which can alter pharmacokinetics through either gastrointestinal absorption, 
plasma protein binding, transport carrier, or liver metabolism (Ito et al., 1998),  
is particularly prominent in the elderly patients who live with chronic 
comorbidities, have reduced immunity, and use two to six medications  (Stewart 
and Cooper, 1994). A recent examination on the issues of polypharmacy and 
medication-related problems facing 89 elderly HIV-positive patients with 
comorbid conditions, including depression, diabetes mellitus, hypertension, 
hyperlipidaemia and HIV-associated neurocognitive disorders, revealed that 
96% patients in this study took at least five medications. The authors identified 
283 potential DDIs in these 89 patients, providing evidence that older HIV 
patients are at a higher risk of DDIs (Greene et al., 2014). In addition, an FDC 
pill needs to pass more stringent regulatory criteria and takes lengthy time 
before marketing approval. The World Health Organization (WHO) requires 
that, in the submission of an FDC finished pharmaceutical product (FDC-FPP) 
for a marketing authorisation, quality/medical/bioavailability considerations 
should be made, evidence that the combination has a greater efficacy than any 
of the component ingredients should be provided, the safety data of the 
individual agents should be demonstrated, and lower cost as compared with that 
of individual components should be presented. This is clearly stated in WHO 
Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-
ninth Report (published in 2005). 
Like tapentadol and pancuronium, many polypharmacological drugs on the 
market were not prospectively designed, and their multi-targeting properties 
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were in fact discovered retrospectively. A recent trend, known as designed 
multiple ligands (DMLs), however, has been deliberately to design ligands that 
selectively act on multiple targets which are deemed relevant to the 
pathogenesis of a given disease (Morphy et al., 2004). In general, there are three 
strategies—linked, fused or merged—to generate a knowledge-based DML that 
has activities at two targets (Figure 8). Some linked DMLs are composed of two 
ligands (Note: Each of the ligands is selective for their respective targets.) 
connected by a metabolically stable linker, whilst some are intentionally 
endowed with a cleavable linker for the purpose of releasing the two ligands in 
vivo. Linked DMLs are excellent tools for probing target combinations, and they 
could potentially be used as intravenous (i.v.) drugs with stronger affinity, 
enhanced subtype selectivity, as well as synergistic effect. As shown in Figure 
9, a heterodimeric conjugate containing naltrindole (a δ-opioid receptor 
antagonist) and ICI-199,441 (a κ-opioid receptor agonist) linked by 
oligoglycines was developed as a pharmacological tool to prove the existence 
of opioid receptor dimerisation (Portoghese, 2001). NCX-4016, or nitroaspirin, 
however, consists of aspirin and an NO-releasing moiety linked by an ester-
based spacer. It is metabolised by esterase to release aspirin. In fused DMLs, 
the two ligands are directly attached to each other, and ziprasidone may be the 
classic example (Appendix D). Merged DMLs, which have the maximal degree 
of overlap of two ligands, produce a single compound with minimal molecular 
weight. In fact, it was well documented that DMLs are, on average, larger in 
size compared to marketed oral drugs. The increase in molecular size and 
complexity are often associated with poor oral bioavailability (Veber et al., 
2002). (Bioavailability is defined as the extent to which an administered drug 
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reaches systemic circulation unchanged, and the rate at which this occurs.) 
Therefore, merging two ligands becomes the more likely way to produce an 
orally active DML (Morphy and Rankovic, 2006). An example of merged 
DMLs is seen in fentanyl (a µ-opioid receptor agoinist) merged with agmatine 
(an I2-imidazoline receptor ligand), resulting in a single compound active at 
both receptors (Montero et al., 2002).             
Figure 8. Three strategies to generate knowledge-based, dual-acting DMLs 
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1.3.2    Polypharmacology in PD 
1.3.2.1    An example: MAO-B inhibitor + A2A antagonist 
Monoamine oxidase (MAO) catalyses the oxidation of numerous biogenic 
monoamine neurotransmitters (e.g. dopamine, norepinephrine, epinephrine, 
histamine and serotonin) in the CNS and peripheral tissues to form the 
corresponding aldehyde and hydrogen peroxide (Figure 10). Around 1970, one 
subtype of MAO that was sensitive to clorgyline (Figure 11) was defined as 
MAO-A (Johnston, 1968), and the one more sensitive to pargyline and 
selegiline (Figure 11) was MAO-B (Knoll and Magyar, 1972). In terms of 
substrate specificity, MAO-A preferentially binds to serotonin, norepinephrine, 
and dopamine, whereas MAO-B preferentially binds to phenylethylamine and 
benzylamine. MAOs are located in the outer membrane of mitochondria in 
rodent, cat, primate and man. In the rat brain, MAO-A and MAO-B distribute 
mainly in the locus coerulus and raphe nuclei, respectively (Jahng et al., 1997). 
The intravenous injection of 11C-labelled clorgyline and selegiline 
noninvasively to the human brain analysed by PET imaging showed that the 
distribution of MAOs was highest in striatum, thalamus and brainstem. In the 
90-minute time course analysis, the magnitude of uptake for [11C]selegiline was 
stronger than that of [11C]clorgyline, reflecting the higher concentration of 


















Figure 10. MAO-catalysed oxidative deamination of dopamine starts with the 
formation of the iminium species 2. Subsequent hydrolysis leads to the aldehyde 
product. 
 





















Figure 11. Five inhibitors of monoamine oxidases. Clorgyline is a MAO-A 
inhibitor. Pargyline, selegiline, rasagiline and safinamide are MAO-B 
inhibitors. 
 
There was no decrease in dopamine concentration observed after treatment with 
60 mg/kg of MPTP, an agent used to induce PD conditions, in MAO-B knockout 
mice experiments, demonstrating the requirement of MAO-B for MPTP toxicity 
(Grimsby et al., 1997). In view of the fact that 40% decrease in MAO-B level 
was evidenced in the brains of smokers (Fowler et al., 1996), a PET study used 
21 non-smokers with ages from 23 to 86 years old and confirmed that MAO-B 
increased with ageing (Fowler et al., 1997). By contrast, in a post-mortem study 
using radioligands and enzyme autoradiography in 27 human subjects, no 
obvious increase in MAO-A concentrations in several brain areas was observed 
(Saura et al., 1997). The strong association of PD with altered MAO-B, but not 
MAO-A, was also revealed in the combined treatment of L-DOPA and a MAO-
B inhibitor in patients with PD (Birkmayer et al., 1975). The development of 
selective MAO-B inhibitors as potential PD therapeutic agents was therefore 
pursued. In a clinical study involving 800 PD patients carried out by Deprenyl 
And Tocopherol Antioxidative Therapy Of Parkinsonism (DATATOP), the use 
of selegiline, a selective MAO-B inhibitor, with the dose of 10 mg/day as 
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monotherapy showed the delay of disability by approximately 50% and 
improvement in function in the early stage of PD (Shoulson et al., 1993; 
Shoulson et al., 1989). A controlled trial conducted by the Parkinson Study 
Group in 472 L-DOPA-treated PD patients with motor fluctuations 
demonstrated that treatment (1.0 mg/day) with rasagiline (Figure 11), a selective 
MAO-B inhibitor, decrease the mean daily off time (motor impairment) from 
baseline by 1.85 hours, suggesting the benefit of rasagiline in alleviating motor 
symptoms in PD patients (Parkinson Study, 2005). In addition to the 
symptomatic amelioration, some MAO-B inhibitors were reported to have 
neuroprotective effect. Known as ADAGIO (Attenuation of Disease 
Progression with Azilect Given Once Daily), the delayed-start clinical study for 
1176 PD patients was performed to assess the disease modifying effect of 
rasagiline in 2005–2006 (Olanow et al., 2009). The disease-modifying effect by 
early treatment with rasagiline was sustained for at least 18 month at the dose 
of 1 mg/day. To date, two irreversible MAO-B inhibitors, selegiline and 
rasagiline, have been approved by FDA as monotherapy at the early PD or as 
adjunct therapy with L-DOPA later in the disease. A reversible MAO-B 
inhibitor, salfinamide (Figure 11), has completed the phase 3 trial (Borgohain 
et al., 2014), and its New Drug Application (NDA) was submitted to FDA in 
May 2014. 
Adenosine, a purinergic modulator that regulates many physiological processes 
with effects on CNS, cardiovascular system, renal system, respiratory system, 
immunological system, gastrointestinal system, and metabolic system, exerts its 
action via four distinct subtypes (i.e. A1, A2A, A2B and A3) of cell-surface G 
protein-coupled receptors (GPCRs) (Collis and Hourani, 1993). For GPCR 
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basics, readers may refer to Appendix E. Whilst the distribution of A1, A2B and 
A3 subtypes in the brain is widespread, ligand binding and in situ hybridisation 
studies showed that A2A subtype localises primarily in striatum, olfactory 
tubercle, and nucleus accumbens where dopamine D2 receptor-enriched indirect 
pathway in the basal ganglia is present (Dunwiddie and Masino, 2001). Since 
adenosine A2A receptor agonists decrease the affinity of dopamine D2 receptor 
for dopamine (Ferre et al., 1991), antagonism of A2A receptor were presumed to 
have therapeutic effects in PD (Armentero et al., 2011). The consumption of 
caffeine (Figure 12), the dietary psychoactive substance in coffee and tea, was 
associated with the lower incidence of PD (Ross et al., 2000). By using 
[3H]cyclohexyladenosine binding to mouse brain membranes, the correlation 
between stimulant effect of caffeine in locomotor activity and its competeing at 
adenosine receptors was demonstrated, strongly suggesting the blockade of 
adenosine receptors by caffeine (Snyder et al., 1981). In a more integrated level, 
caffeine was reported to increase rotation behaviour (Fredholm et al., 1976), 
increase striatal dopamine (Morgan and Vestal, 1989), show neuroprotection in 
MPTP-treated mice by A2A receptor blockade (Chen et al., 2001), and more 
recently, a pilot open-label study confirmed motor and nonmotor benefits of 
caffeine (Altman et al., 2011). Caffeine-derived xanthine derivatives (Figure 
12) with adenosine A2A selectivity versus other subtypes were thus developed 
as potential treatments for PD. With the consideration that caffeine 
nonselectively binds to adenosine receptors with highest affinity for A2A 
subtype (KD values of caffeine: hA1 = 12 µM, hA2A = 2.4 µM, hA2B = 13 µM, 
hA3 = 80 µM), xanthine scaffold was used to develop selective A2A antagonists. 
Different modifications were made at the positions C-1, C-3, C-7 and C-8, 
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resulting in 3,7-dimethyl-1-propargylxanthine (DMPX) with good aqueous 
solubility (Seale et al., 1988) and in its analogue 3 with higher affinity (Müller 
et al., 1998). Further substitution at the position C-8 with styryl group led to m-
chlorostyrylcaffeine (CSC) and KW-6002 (Figure 12). In March 2013, KW-
6002 was approved in Japan as the adjunct therapy with L-DOPA in advanced 


































          


















Ki(rA2A) = 54 nM
Ki(baboon MAO-B) = 81 nM
3DMPX
KW-6002
Ki(hA2A) = 12 nM
Ki(hA1) = 841 nM
Ki(hA2B) > 10,000 nM
Ki(hA3) = 4,470 nM  
Figure 12. Xanthine and its derivatives. 
 
The attenuation of striatal dopamine loss by CSC, a selective adenosine A2A 
receptor, in an MPTP-induced mice model of PD, together with the observation 
that the level of MPP+, the active neurotoxin which can be produced from the 
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oxidation of MPTP catalysed by MAO-B (Figure 13), significantly reduced in 
CSC-treated mice, raised the hypothesis that CSC may act as a MAO-B 
inhibitor. The direct effect of CSC on MAO-B was investigated by the enzyme 
kinetic analysis using mitochondria from mouse brain, and the results showed 
that CSC, but not other xanthine derivatives such as caffeine, DMPX, and 1,3-
dipropyl-8-cyclopentylxanthine (CPX), potently (with Ki ~ 100 nM) and 
selectively (versus MAO-A) inhibited MAO-B. The inhibitory effect of CSC on 
MAO-B was further substantiated in adenosine A2A knockout mice, confirming 
this unexpected property of MAO-B inhibition is independent of the known A2A 
antagonism (Chen et al., 2002). Given both A2A antagonists and MAO-B 
inhibitors were suggested to be potential PD treatments with symptomatic relief 
as well as neuroprotective effect, efforts was subsequently made to synthesise 
CSC derivatives to discover better dual-acting drug candidates for PD. 
Structure-activity relationship (SAR) studies revealed that the C-3 and C-4 
substituents (e.g. Cl, CF3, CH3 and F) on the styryl ring of (E)-8-styrylcaffeine 
have a considerable impact on the MAO-B inhibition (Vlok et al., 2006). In 
addition to (E)-8-styrylcaffeines, (E)-2-styrylbenzimidazoles (van den Berg et 
al., 2007), (E,E)-8-(4-phenylbutadien-1-yl)caffeines (Pretorius et al., 2008), 9-
deazaxanthines (Rivara et al., 2013), and 4H-3,1-benzothiazin-4-ones (Stossel 
et al., 2013) were developed as dual-acting compounds which exhibit MAO-B 
inhibition and antagonistic effect at A2A receptor (Figure 14).           
  














Figure 13. The metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) by MAO-B in the brain. The discovery of MPTP as a parkinsonian-
inducing agent arised from a clandestine laboratory whose intention was the 
synthesis of 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP) with MPTP as 
the by-product. Four individuals who used virtually pure MPTP (with trace 
amounts of MPPP) intravenously developed PD symptoms within one week 
after the injection (Langston et al., 1983). MAO is the principal brain enzyme 
that catalyses the 4-electron oxidation of MPTP to 1-methyl-4-
phenylpyridinium species (MPP+), the active toxin interfering with 
mitochondrial oxidative phosphorylation which in turn causes cell death. The 
evidence from HPLC retention times, chemical ion mass spectra, diode array 
UV, coupled with the trapping agent NaCN, confirmed this oxidation proceeds 
via the unstable 1-methyl-4-phenyl-2,3-dihydropyridinium species (MPDP+) 
(Peterson et al., 1985). MPTP has been proved to be a useful agent for 













Ki(baboon MAO-B) = 17 nM






IC50(hMAO-B) = 200 nM







IC50(hMAO-B) = 35 nM




Figure 14. Polypharmacological drug candidates inhibiting MAO-B and 
antagonising A2A receptor. 
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1.3.2.2    An opportunity:  D2 agonist + A2A antagonist  
In addition to A2A receptor, GPCRs implicated in the pathophysiology of PD 
and also served as potential targets for PD drug development include dopamine 
receptors (Heimer et al., 2006), metabotropic glutamate receptors (mGlu4 
subtype, Cuomo et al., 2009) (mGlu5 subtype, Mela et al., 2007), muscarinic 
acetylcholine receptors (M1 subtype, Xiang et al., 2012) (M4 subtype, Tzavara 
et al., 2004), and serotonin receptors (5-HT1A and 5-HT1B subtypes, Munoz et 








































































Figure 15. Drugs (either in clinical use or under development) targeting GPCRs 
implicated in PD. 
 
Of these GPCRs implicated in the pathogenesis of PD, the adenosine A2A 
receptor represents an ideal target for developing novel therapeutics, which was 
described in Section 1.3.2.1. This is attributed to its high levels of expression in 
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the striatum (Svenningsson et al., 1997) and, as will be described in this Section, 
its interactions with the dopamine D2 receptor in the striatopallidal GABAergic 
neurons (Ferraro et al., 2012) (Figure 16). In the 1990s, the binding experiments 
on the rat striatal membranes have shown that the activation of adenosine A2A 
receptor decreased the binding of dopamine D2 receptor to dopamine and the 
existence of antagonistic A2A-D2 receptor-receptor interactions on GABAergic 
striatopallidal neurons was suggested (Ferre et al., 1991; Fuxe et al., 1993). The 
A2A-D2 heteroreceptor complexes localised in the striatum were further 
confirmed by their co-aggregation study (Hillion et al., 2002), and fluorescent 
and bioluminescent resonance energy transfer (FRET and BRET) techniques 
(Canals et al., 2003). The in vivo study also corroborated the A2A-D2 
heteroreceptor complexes by showing that A2A agonists caused the decrease in 
quinpirole-mediated yawing but did not affect the motor deficits induced by a 
D1 receptor agonist (Rimondini et al., 1998). In addition, behavioural studies on 
6-hydroxydopamine (6-OHDA)-lesioned rats indicated that a selective A2A 
antagonist (SCH 58261) potentiated turning behaviours induced by a D2 agonist 
(Popoli et al., 2000), and it did not develop tolerance after repeated treatment 
(Pinna et al., 2001). Recently, it was demonstrated that A2AR-D2R oligomer 
formation was reduced in 6-OHDA-lesioned rats using proximity ligation assay 
(PLA), suggesting that A2AR-D2R oligomerisation is an emerging therapeutic 
target for the treatment of PD (Fernandez-Duenas et al., 2015). All these results 
clearly suggest that adenosine A2A receptors, which have unique CNS 
distribution in the striatopallidal GABAergic neurons, functionally interact with 
dopamine D2 receptors in an antagonistic manner. That is, antagonising A2A 
receptors increases D2R-mediated signalling, reduces the activity of the indirect 
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pathway, and thus serves as a potential approach to treat PD. Indeed, one 
selective A2A antagonist, KW-6002 (Figure 12), has gone through clinical trials 
(Hauser et al., 2003) and culminated in the approval in Japan in March 2013 










Figure 16. Dopamine (D1, D2) and adenosine (A2A) receptors located in the 
striatopallidal GABAergic neurons. In the normal state, dopamine activates D1 
receptor, which in turn, recruits stimulatory Gs protein to increase the direct 
pathway. In contrast, the activation of D2 receptor results in the recruitment of 
inhibitory Gi protein so as to decrease the indirect pathway. The basal ganglia 
motor circuit involving direct and indirect pathways is elaborated in Appendix 
F. DA: dopamine; AC: adenylyl cyclase; cAMP: adenosine 3’,5’-cyclic 
monophosphate; PKG: protein kinase G; sGC: soluble guanylyl cyclase; NO: 
nitric oxide; PP1: protein phosphatase 1; DARPP-32: dopamine- and cAMP-
regulated phosphoprotein, Mr 32 kDa; Cav 1.3: calcium channel, voltage-
dependent, L type, alpha 1D subunit; M1: muscarinic M1 acetylcholine receptor 
(Calabresi et al., 2007) (reprinted with permission).  
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1.4    Chapter Conclusion 
In summary, literature revealed the following three facts: (i) the successful A2A 
antagonist KW-6002 (Figure 12) for the treatment of PD, (ii) the integration of 
MAO-B inhibition and A2A antagonism in one single molecule (Figure 14), and 
(iii) the strong evidence of A2A-D2 interactions in biochemical, biophysical and 
animal experiments (Figure 16). Combining these three facts point to an 
opportunity for the development of novel PD therapeutics—integration of A2A 
antagonism and D2 agonism in one single molecule.  
















CHAPTER 2    HYPOTHESIS AND AIMS 
  
Since half of the world's older population lives in Asia, neurodegenerative 
diseases including Parkinson’s disease (PD) become a serious health problem 
that warrants investigation in greater depth in this region. Indeed, there have 
been huge efforts made towards the identification of new, effective and safe 
drugs for the successful therapy of PD. Previous approaches focused on highly 
selective compounds targeting individual proteins (i.e. “one compound-one 
target” approach). As shown in Table 1 (statistics prior to the year 2011), the 
small-molecule compounds in later stages of clinical development for PD were 
initially designed for one particular target class, such as dopamine receptor, 

















































































 CHAPTER 2   
38 
 
Meanwhile, combination therapies have gained much interest, owing to the fact 
that heterodimerisation of adenosine A2A receptors and dopamine D2 receptors 
in the brain was established. In MPTP-treated marmosets (Callithrix jacchus), 
three combination therapies—(i) KW-6002 + quinpirole, (ii) KW-6002 + 
SKF80723, and (iii) KW-6002 + L-DOPA—were tested (KW-6002: an 
adenosine A2A receptor antagonist; quinpirole: a dopamine D2 receptor agonist; 
SKF80723: a dopamine D1 receptor agonist). The marked enhancement of anti-
PD activity was observed in the combinations of (i) and (iii). This is one 
example of “cocktail drugs-multiple targets” approaches (Kanda et al., 2000). 
Although such multi-component therapies have been preclinically proven 
promising, they are often associated with side effects, due to the complicated 
interactions among drugs and different pharmacokinetic/pharmacodynamic 
profiles of each component drug. This motivated us to explore the possibility of 
“one compound-multiple targets” in PD treatment.  
As mentioned in Section 1.3.2.2, there are a couple of GPCRs implicated in the 
pathogenesis of PD, so in principle any two of them could be potentially 
targeted for the development of dual-acting ligands. On account of the recent 
approval of KW-6002 (Figure 12) (Dungo and Deeks, 2013), adenosine A2A 
receptor is likely to be a validated target. The second target we chose was 
dopamine D2 receptor. The reasons we did not attempt to integrate the activities 
of [A2A antagonist + L-DOPA], but of [A2A antagonist + D2 agonist], into one 
compound are as follows. First, whilst L-DOPA is still the gold-standard to treat 
PD, there are reports where patients treated with dopamine (DA) agonists 
demonstrated better preservation of the nigrostriatal system than those treated 
with L-DOPA (Marek et al., 2002; Whone et al., 2003). Second, the antagonistic 
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receptor-receptor interactions in the striatal A2A-D2 heteromers have been well 
documented (Fuxe et al., 2014). Thus, the hypothesis of this thesis is that 
antagonising A2A and agonising D2 receptors using the 
polypharmacological approach can lead to novel and more effective 
treatments for Parkinson’s disease. 
 
To test this hypothesis, the aims of this thesis are to: 
I. identify novel scaffolds that simultaneously bind to two receptors—
adenosine A2A receptor and dopamine D2 receptor—implicated in PD 
pathogenesis, by computational tools and virtual screening (Chapters 3 
and 4); 
II. design and synthesise promising scaffolds based on the information 
gathered from computational analyses (Chapter 4); 
III. perform in vitro binding and functional assays of newly synthesised 
compounds at these two receptor subtypes (Chapters 4 and 5); 
IV. analyse drug-like properties of newly synthesised compounds in vitro 
(Chapter 5); and 
V. evaluate efficacy of newly synthesised compounds in Drosophila 






CHAPTER 3    LIGAND-BASED VIRTUAL 
SCREENING AND ANALYSES 
 
Dr. Ma Xiaohua in Professor Chen Yu Zong’s lab (Department of Pharmacy, 
National University of Singapore) performed SVM and similarity analyses of 
collected compounds. Radioligand binding assays for adenosine A2A receptor 
were done through collaboration with Professor Karl-Norbert Klotz (Institut 
für Pharmakologie und Toxikologie, Universität Würzburg, Germany). 
 
3.1    Receptor Agonism and Antagonism 
The concept of “receptor” originated from John Newport Langley’s findings 
that nicotine and curare acted upon the “muscle substance”, rather than upon the 
nerve-endings. The then “muscle substance” (or, “accessory substance”, 
“receptive substance of the muscle”) is now known as nicotinic acetylcholine 
receptor (nAChR) (Langley, 1905). Based on the receptor concept, the 
subsequent “receptor theory” was established and is still being evolved (Maehle 
et al., 2002). Receptor theory provides a theoretical framework that allows 
quantitative assessment of receptor-drug interactions by different mathematical 
models, such as classical model (Ariens, 1954), operational model (Black and 
Leff, 1983), two-state theory (Del Castillo and Katz, 1957), and ternary complex 
model (De Lean et al., 1980), all of which are based on Michaelis-Menten 
equation used in enzyme kinetics. The assumption of receptor theory is that the 
effect is proportional to the drug concentration, and such concentration-effect 
relationships are important for understanding drug action. Consider a receptor 
R and a drug D form a receptor-drug complex RD in equilibrium, 
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and the dissociation constant, KD, equals [R][D]/[RD]. Similar to how 
Michaelis-Menten equation can be derived, receptor-drug relationships can be 
expressed as 
ED/EM = e[D]/(KD + [D])                                                                                    (1) 
where ED is the effect produced by drug D, EM is the maximum effect produced 
by drug D, and e is the efficacy (or, intrinsic activity). Any drug that can induce 
maximum activation of a receptor (EM) if the drug concentration is sufficiently 
high is termed a full agonist (e = 1). Some agonists, even if they occupy all 
receptors at high drug concentration, are unable to elicit maximum effect. These 
agonists have lower efficacy (0 < e < 1), and are termed partial agonists. 
Antagonists block the receptor site where the endogenous ligand binds (i.e. the 
orthosteric site), thus precluding the receptor from further activation by agonists 
(e = 0). Inverse agonists (e < 0) refer to those compounds that stabilise less 
active receptor conformations and thus decrease constitutive receptor activity 
(Bond and Ijzerman, 2006). Figure 17 illustrates concentration-effect curves for 
drugs with different efficacies at a receptor with constitutive activity (Bylund 
and Toews, 2014). Additional mechanisms of receptor modulation include non-
competitive antagonism (i.e. an antagonist covalently and irreversibly binds at 
the orthosteric site) (Kenakin et al., 2006), allosteric modulation (i.e. an agent 
that can modulate the receptor by acting at the site other than the orthosteric 
site) (Kenakin, 2010), and biased agonism (i.e. an agonist that selectively 
activates a particular or a subset of signalling pathways) (Kenakin, 2011). For 
more details on allosteric modulation and biased agonism, readers are referred 
to Appendix E.       
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Figure 17. The sigmoid relationships between the base 10 logarithm of ligand 
concentration and the activity magnitude of induced receptor. The upper solid 
curve is a full agonist capable of raising receptor activation to a maximum of 20 
units from the constitutive activity of 6 units. The upper dashed curve is a partial 
agonist, causing an partial increase of receptor activity (6 → 13) with e = (13 – 
6)/(20 – 6) = 0.5. The middle bold dotted curve is an antagonist which neither 
increases nor decreases the receptor activity with e = 0. The lower dashed curve 
is a partial inverse agonist which reduces the receptor constitutive activity by 
50% (6 → 3), so its e = (3 – 6)/(6 – 0) = –0.5. The lower solid curve is a full 
inverse agonist which completely suppresses the receptor constitutive activity 
(6 → 0) with e = (0 – 6)/(6 – 0) = –1 (Bylund and Toews, 2014) (reprinted with 
permission). 
 
3.1.1    Preclinical studies on two-drug cocktail (KW-6002 + a D2 agonist) 
As mentioned in Chapter 2, the approach in the thesis is both to antagonise A2A 
receptor and to agonise D2 receptor with the aim of discovering new chemical 
entities (NCEs) for the treatment of PD. For early-stage PD patients, dopamine 
agonists are given as the first-line therapy, and when loss of efficacy occurs, L-
DOPA is introduced. However, the use of high doses of dopamine agonists and 
L-DOPA results in dopaminergic side-effects, such as dyskinesia, vascular 
change, compulsive behaviours, psychosis and hallucinations. To minimise 
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these dopaminergic side-effects, an A2A antagonist KW-6002 (Figure 12) was 
developed to improve wearing-off phenomena of later-stage PD patients under 
L-DOPA treatment (launched by Kyowa Hakko Kirin Co., Ltd. in Japan in May 
2013). This shows the synergistic effect of KW-6002 and L-DOPA (Mizuno et 
al., 2013). Concurrently, in view of the close interactions between A2A and D2 
receptors in the basal ganglia (Figures 16 and A8), Kyowa Hakko Kirin has 
conducted co-administration of KW-6002 with a D2 agonist (quinpirole, 
ropinirole or pergolide) in marmosets. The results were promising—the KW-
6002 addition not only enhanced anti-PD activity of the D2 agonist but also 
avoided dose escalation of that D2 agonist (Kanda et al., 2000; Uchida et al., 
2015). It therefore gave us more confidence to test our hypothesis (Chapter 2). 
 
3.1.2    Compounds capable of agonising one receptor but antagonising 
another 
Despite Kyowa Hakko Kirin’s encouraging results of combination drugs (i.e. 
an A2A antagonist + a D2 agonist) in preclinical models of PD (vide supra), the 
aim of the thesis is even more challenging—to integrate A2A antagonism and D2 
agonism into one compound. Prospective design of a compound acting as an 
agonist of one receptor and antagonist of another has been documented in 
various drug discovery programmes (Figure 18). The clinical candidate TD-
5959 (in phase 2b trial), an inhaled muscarinic antagonist-beta2 agonist 
(MABA), was developed by the alliance agreement between Theravance 
Biopharma and GlaxoSmithKline (GSK) as a bi-functional bronchodilator for 
patients with chronic obstructive pulmonary disease (COPD) (Hughes et al., 
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2015). Compound 4 was recently reported to be a partial agonist of M1 
muscarinic acetylcholine receptor, an antagonist of dopamine D2 receptor, and 
an antagonist of serotonin 5-HT2A receptor, for the treatment of schizophrenia 
(Szabo et al., 2015). Compound 5 modulates opioid receptors (ORs) by its dual 
δ OR antagonistic/µ OR agonistic activities, and has successfully completed 
phase 2 trials in patients with diarrhea-predominant irritable bowel syndrome 
(IBS-D) (Breslin et al., 2012). Arpromidine, a positive inotropic agent, has 
histamine H1-antagonistic and H2-agonistic properties through merged DML 
approach (Buschauer, 1989). Due to these four successful examples, it was 


















pKi(M3 antagonist) = 8.7







Ki(M1 partial agonist) = 4.2 uM
Ki(D2 antagonist) = 17.7 nM












Ki(delta OR antagonist) = 1.3 nM











pA2(H1 antagonist) = 7.65
pD2(H2 agonist) = 8.01
Figure 18. Four examples of prospective DMLs that antagonising one receptor 
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3.1.3    Compounds capable of agonising D2 receptor but antagonising A2A 
receptor 
In fact, there have been reports on integrating A2A antagonistic and D2 agonistic 
activities into one compound using linked, fused or merged DML approaches 
(Figure 8). As shown in Figure 19, 2-(4-(2,6-dioxo-1,3-dipropyl-2,3,4,5,6,7-
hexahydro-1H-purin-8-yl)phenoxy)acetic acid (XCC) and 6-((4-
aminophenethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol (PPHT-
NH2), acting as an A2A antagonist and a D2 agonist, respectively, were linked 
by Lys-Lys-[PEG/polyamide]3-Lys-Glu. This heterobivalent ligand 6 showed 
higher affinity to each receptor than its monovalent controls, and was used to 
specifically detect the occurrence of A2A-D2 heteromers in native tissues 
(Soriano et al., 2009). Recently, compound 7, consisting of ZM241385 (an A2A 
antagonist) and ropinirole (a D2 agonist) linked by amides and ether functional 
groups, was developed, and exhibited potencies at the two receptors (Jorg et al., 
2015). Whilst heterobivalent ligands 6 and 7 are excellent pharmacological 
tools to probe receptor heteromers, they require long synthetic procedures (e.g. 
19 steps for the synthesis of 7) and have unfavourable structural properties as 
CNS drugs (Rankovic, 2015). The details of CNS drug requirements will be 
discussed in Chapter 6. Fused and merged DMLs for integrating A2A 
antagonistic and D2 agonistic activities into one compound are shown in Figure 
20. Compound 8 was built without incorporating any spacer, and it was 
therefore considered as a fused ligand. Compound 9 was the ligand in which 
ZM241385 merges with ropinirole, with its molecular weight less than the sum 
of ZM241385 and ropinirole. Both fused and merged compounds showed 
potencies at the two receptors. Notably, the merged ligand 9 displayed 
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brain:blood partition ratio (Kbb) of 1.29, suggesting its high likelihood to be 
CNS penetrant (The Kbb of ZM241385 is 0.76). The percentage of fraction 
unbound (% fu) of compound 9 in the brain is 15.33, indicating that sufficient 
amount of free compound is able to reach the site of action in the brain. (The % 
fu of ZM241385 in the brain is 8.49.) (Jorg et al., 2015) Hence, compound 9 
developed via a merged DML strategy may be more suitable, compared to 


































6PPHT-NH2 (D2 agonist) XCC (A2A antagonist)
KDB1(A2A antagonist) = 50 nM
KDB1(D2 agonist) = 1.8 nM




















IC50(A2A antagonist) = 41 nM
EC50(D2 agonist) = 501 nMropinirole (D2 agonist)
ZM241385 (A2A antagonist)
 
Figure 19. Linked DML strategy for integrating A2A antagonistic and D2 
agonistic activities into one compound. 




















IC50(A2A antagonist) = 63 nM














IC50(A2A antagonist) = 912 nM
EC50(D2 agonist) = 88 nM
Kbb = 1.29
% fu(brain) = 15.33
Figure 20. Fused and merged DML strategies for integrating A2A antagonistic 
and D2 agonistic activities into one compound. 
 
3.1.3.1    Comparison between A2A agonism and antagonism  
How compounds 6-9 modulate A2A receptor as well as D2 receptor with respect 
to receptor function? That is, what are the structural determinants of activating 
and inhibiting these two receptors?  
Exploration of A2A antagonists starts with xanthines. Structure-activity 
relationships (SARs) of xanthine-based derivatives as A2A antagonists have 
been extensively explored and discussed in Section 1.3.2.1 (Figure 12). One 
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important information that can be extracted from these SAR studies is the 
contribution of styrene moiety at the 8 position to the binding and antagonism 
of A2A receptor (Jacobson et al., 1993). One example of these 8-styrylxanthines 
is 3-chlorostyrylcaffeine (CSC) which exhibits high A2A affinity (Ki for rat A2A 
receptor = 54 nM) and 560-fold selectivity in comparison to rat A1 receptor. In 
summary, the pharmacological results suggest that the introduction of propargyl 
(e.g. compound 3), methyl (e.g. CSC) or ethyl (e.g. KW-6002) group at the 1 
position of xanthine, methyl (e.g. CSC) or ethyl (e.g. KW-6002) group at the 3 
position of xanthine, methyl group at the 7 position of xanthine, as well as 
aromatic ring (e.g. phenyl or thienyl) attached to an ethenyl group at the 8 
position of xanthine, appear to constitute a xanthine-based potent and selective 
A2A antagonist.  
It is noted that the xanthine core of A2A antagonists listed in Figure 12 is 
structurally similar to the adenine moiety of adenosine (Figure 21). Moreover, 
non-xanthine-based A2A antagonists, such as ZM241385, also generally have a 
nitrogen-containing heterocyclic core, be it mono-heterocyclic, bi-heterocyclic 
or tri-heterocyclic one (Appendix H). X-ray crystal structures of A2A receptor 
in complex with adenosine, ZM241385 and caffeine (Figure 22) provide the 
structural basis for A2A agonism and antagonism. Comparison of the 
ZM241385-bound with the adenosine-bound structures indicates that both 
triazolotriazine and adenine form hydrogen bonds with Glu169 in extracellular 
loop 2 (EL2) and Asn253 in helix 6 (H6), and have π-stacking with Phe168 in 
EL2 in common. The main structural difference between these two structures 
lies in the orientations of furan and ribose groups. The furan ring of ZM241385 
forms a hydrogen bond with the amide NH2 of Asn253, whereas the hydroxy 
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groups on the ribose of adenosine form hydrogen bonds with Ser277, His278 in 
H7, and His250 in H3. It is the inward shift of H3 and H7 that makes the A2A 
receptor activation happen (Lebon et al., 2011). These structural pieces of 
evidence are consistent with previous SAR observations on A2A agonists, that 
is, the alterations of the ribose, except at the 5’ position, generally result in loss 
of agonistic activity (Siddiqi et al., 1995). It may be speculated that the similar 
orientation between adenine of adenosine and triazolotriazine of ZM241385 is 
attributed to the common exocyclic NH2 groups. Interestingly, superposition of 
ZM241385-bound and caffeine-bound A2A crystal structures reveals the 
coplanar mode between xanthine of caffeine and triazolotriazine of ZM241385, 
with the observation that the exocyclic C6 carbonyl carbon of caffeine forms a 
hydrogen bond with Asn253 (Figure 22) (Dore et al., 2011). The dual HB 
donor/acceptor property of the side chain of Asn253 in H6 seems to be crucial 




















































Figure 21. The nitrogen-containing cores of adenosine (an A2A agonist), 
caffeine (an A2A antagonist), KW-6002 (an A2A antagonist), and ZM241385 (an 
A2A antagonist) are shown in the bracket.   
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Figure 22. Comparison of ligand-binding sites for A2A receptor in complex with 
ZM241385, adenosine and caffeine. The ligands (yellow and gray) and amino 
acid residues are depicted as sticks. Oxygen atoms are shown in red, and 
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3.1.3.2    Comparison between D2 agonism and antagonism  
SAR studies on dopamine agonists start with the preferred trans- molecular 
conformations of dopamine (i.e. the  catechol ring and the ethylamine on the 
same plane), which include α- and β-conformers (Cannon, 1975) (Figure 23). 
In the α-conformer, the meta-hydroxy group projects above the plane, whilst in 
the β-conformer it is below the plane. Conformational rigidisation results in the 
formation of 2-dipropylamino-5,6-dihydroxytetralin (10) and 2-dipropylamino-
6,7-dihydroxytetralin (11). Investigations on nitrogen substitutions, that is, R 
and R’ in compounds 10 and 11, with combinations of hydrogen, methyl, ethyl, 
propyl, and butyl led to an important observation that N-propyl group confers 
optimal dopaminergic agonist effect (Cannon et al., 1977). The position of the 
hydroxy groups on the catechol ring is also critically important. Generally, 5,6-
dihydroxy aminotetralins showed higher dopaminergic activity than 6,7-
dihydroxy derivatives, suggesting that the dopamine in its α rotameric 
disposition may be preferred for activating dopamine receptors. In addition, the 
meta-hydroxy group plays more roles in agonist-receptor interactions than the 
para-hydroxy group, as exemplified by the endeavours in aporphine derivatives 
(Saari et al., 1974). This led to the identification of two dipropylaminotetralins 
(DPATs), (S)-5-OH-DPAT and (R)-7-OH-DPAT, and their tricyclic derivatives 
12 and 14. Strikingly, whilst one carbon extension of 12 (i.e. compound 13) 
retained its D2 agonistic activity, the corresponding analogue of 14 (i.e 
compound 15) were shown to be D2 inactive (Wikstrom et al., 1987). This 
implies that the cavity occupied by the butyl group of compound 13 is different 
from that surrounding the butyl chain of compound 15.  



































































Figure 23. SAR studies on dopamine D2 agonists. 
 
To better understand such discrepancy, D2 homology model was constructed 
using an agonist-bound serotonin 5-HT1B receptor (Krogsgaard-Larsen et al., 
2014). Compounds 12 and 14 were docked into this D2 receptor model (Figure 
24). In agreement with the recently published D2 agonist pharmacophore model 
(Malo et al., 2012), the specific receptor-ligand interactions shared by 
compounds 12 and 14 are: (i) the salt bridge between Asp114 in TM3 and the 
protonated amine, (ii) the hydrogen bond between Ser193 in TM5 and the 
hydroxyl group, and (iii) the edge-to-face π-π interactions between residues in 
TM6 (e.g. Phe390, His393) and the aromatic ring. However, the distinct 
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orientation of the alkyl group induced by the stereochemical difference of these 
two compounds accounts for the inactivity of compound 14. Whilst the propyl 
group of 12 protrudes to the extracellular loop region that is able to 
accommodate larger substituent, the propyl chain of 14 poses inwardly and has 
hydrophobic interactions with Cys118, Trp386, Phe389, Thr412, and Tyr416. 
This hydrophobic cavity is known as the “propyl cleft”. The homology model 
studies presented here (Figure 24) complement the SAR data (Figure 23) and 
enhance our understanding of D2 receptor-agonist interactions. Currently, the 
commonly prescribed dopamine agonists for treating PD include rotigotine, 
pramipexole, apomorphine and ropinirole (Figure 25), all of which are either 
derived from DPAT or analogous to DPAT.     
It was predicted that the interactions with Asp114 in TM3 and serine residues 
(i.e. Ser193 and Ser197) in TM5 of D2 agonists provide the motion flexibility 
to TM6, which is required for receptor activation. In contrast, D2 antagonists 
lack strong interactions with serine residues in TM5, have minimal contact with 
TM5, and prevent the motions between TM3 and TM6 (Kalani et al., 2004). 
According to this prediction, which is also supported by mutation studies (Cox 
et al., 1992), what distinguishes D2 agonists from D2 antagonists appears to be 
their strong coupling between TM3 and TM5 via interactions with serine 
residues in TM5.  
 
 




Figure 24. The molecular docking pose of compounds 12 (pale green) and 14 
(dark green). The hydrogen bonds are shown in yellow dotted lines 


















Figure 25. The commonly prescribed dopamine agonists for the treatment of 
PD. The Ki (D2R) are 13.5 nM for rotigotine (Scheller et al., 2009), 3.9 nM for 
pramipexole (Kvernmo et al., 2006), 32 nM for apomorphine (Hsieh et al., 
2004), and 7.2 nM for ropinirole (McCall et al., 2005). 
 
3.2    Support Vector Machine Models 
In order to identify novel compounds integrating A2A antagonism and D2 
agonism in one single molecule, three computational tools: (i) support vector 
machine (SVM) (Section 3.2), (ii) Tanimoto similarity (Section 3.3), and (iii) 
hierarchical clustering (Section 4.1) were utilised. 
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3.2.1    Introduction 
Support vector machine (SVM), based on statistical learning theory (Cortes and 
Vapnik, 1995) and structural risk minimisation principle (Burges, 1998), is one 
of the supervised machine learning (ML) types, and its basic functionalities 
include classification, regression, ranking and kernel functions. When used in 
classification, it harnesses the power of statistics to build mathematical models 
based on training samples, and these models are then used to classify 
independent testing samples. As a classifier, it is defined by constructing an N-
dimensional hyperplane that optimally separates the data into two categories. 
The optimal separation is achieved by a hyperplane that has the largest distance 
to the nearest training data point (Figure 26). In ligand-based virtual screening 
(LBVS) (Appendix G), a SVM model is generally built by training a set of 
confirmed active compounds, confirmed inactive compounds, and putative 
inactive compounds represented by molecular descriptors, and tested by an 
independent set of data. SVM has been proved to outperform other ML 
algorithms in the study on dihydrofolate reductase inhibitors (Burbidge et al., 
2001), and also excels other VS tools in terms of enrichment factors (Han et al., 
2008). In addition, SVM has been applied in the selection of compounds for 
testing (Warmuth et al., 2003), classification of drugs and non-drugs (Byvatov 
et al., 2003), and lead hopping (Saeh et al., 2005). The most relevant application 
of SVM to the thesis is the prediction of novel active compounds, be they single-
target agents such as compounds targeting kinase (Liew et al., 2009), 
cytochrome P450 (Sun et al., 2011), and acetylcholinesterase (Lv and Xue, 
2010), or compounds with multi-target activity (Wassermann et al., 2009). 
Other SVM applications germane to drug discovery and development include 
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aqueous solubility prediction (Cheng et al., 2011), ADME prediction (Shen et 
al., 2010), toxicity prediction (Bhavani et al., 2006), resistance prediction (Ding 
et al., 2013), synthetic accessibility prediction (Podolyan et al., 2010), drug-
likeness prediction (Muller et al., 2005), permeability prediction (Kortagere et 
al., 2008), druggability prediction (Volkamer et al., 2012), and prioritisation of 
docking poses (Li et al., 2011).  
Figure 26. Two data sets represented by red squares and blue circles are 
separated by several possible hyperplanes (green straight lines). High prediction 
performance of a SVM model requires maximum distance between the 
hyperplane and nearest data (Source: 
http://docs.opencv.org/doc/tutorials/ml/introduction_to_svm/introduction_to_s
vm.html) (reprinted with permission).   
 
3.2.2    Methods 
3.2.2.1    Molecular descriptors 
A total of 98 descriptors calculated by the MODEL programme (Li et al., 2007) 
were used (Table 2). These descriptors were computed from the three-
dimensional structures of the compounds converted from two-dimensional 
structures using CORINA programme (Sadowski et al., 1994), and were 
inspected to ensure the correctness of chirality. The two-dimensional structure  
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number of C,N,O,P,S, number of total atoms, 
number of rings, number of bonds, number of non-
H bonds, molecular weight, number of rotatable 
bonds, number of H-bond donors, number of H-
bond acceptors, number of 5-member aromatic 
rings, number of 6-member aromatic rings, 
number of N heterocyclic rings, number of O 
heterocyclic rings, number of S heterocyclic rings 
 
chemical properties (3) sanderson electronegativity, molecular 
polarisability, ALogP  
 
molecular connectivity 
and shape (35) 
schultz molecular topological index, Gutman 
molecular topological index, Wiener index, Harary 
index, gravitational topological index, 
molecular path count of length 1-6, total path 
count, Balaban Index J, 0-2th valence connectivity 
index, 0-2th order delta chi index, Pogliani index,  
0-2th solvation connectivity index, 1-3th order 
Kier shape index, 1-3th order kappa alpha shape 
index, Kier molecular flexibility index, topological 
radius, graph-theoretical shape coefficient, 





sum of estate of atom type sCH3, dCH2, ssCH2, 
dsCH, aaCH, sssCH, dssC, aasC, aaaC, sssC, 
sNH3, sNH2, ssNH2, dNH, ssNH, aaNH, dsN, 
aaN, sssN, ddsN, aOH, sOH, ssO, sSH; sum of 
estate of all heavy atoms, all C atoms, all hetero 
atoms, sum of estate of H-bond acceptors, sum of 
H estate of atom type HsOH, HdNH, HsSH, 
HsNH2, HssNH, HaaNH, HtCH, HdCH2, HdsCH, 
HaaCH, HCsats, HCsatu, Havin, sum of H estate 
of H-bond donors 
 
of each compound was manually drawn on ChemDraw or downloaded from 
PubChem and MDDR. Salts, like sodium or calcium salts, were removed. All 
geometries were optimised to ensure that there were no symmetry restrictions. 
To ensure that each descriptor makes an unbiased contribution to predictive 
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models, range scaling (Livingstone, 2000) was done before the descriptor was 
employed. 
 
3.2.2.2    Generation of putative inactive compounds 
The generation of putative inactive compounds started with clustering known 
compounds according to their molecular descriptors into different families. By 
using a K-means method (Bocker et al., 2006) and molecular descriptors 
computed from MODEL (Li et al., 2007; Xue et al., 2004), 8,993 compound 
families were generated from 13.56 million and 168,000 compounds in the 
PubChem (Bolton et al., 2008; Wang et al., 2012) and MDL Drug Data Report 
(MDDR) databases, respectively. These families are consistent with the 12,800 
compound-occupying neurons (regions of topologically close structures) for 
26.4 million compounds of up to 11 atoms (Fink and Reymond, 2007) and the 
2,851 clusters for 171,045 natural products (Koch et al., 2005). After compound 
families were produced, the family to which each of the collected active and 
inactive compounds belongs was identified. The putative inactive compounds 
were generated by randomly selecting eight representative compounds from 
each family that did not contain collected active compounds. Specifically, it was 
identified that 8,000 families did not contain any of the collected 1,969 A2A 
antagonists and 810 D2 agonists. 
 
3.2.2.3    Support vector machine classification 
As shown in Figure 27, SVM models based on training samples separate 
members (biologically active compounds) from non-members (biologically 
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inactive compounds) by a border called hyper-plane. A given compound in the 
testing samples is then projected unto this classification system for determining 
to which class it belongs according to its relative position to the hyper-plane. If 
it falls on the member (non-member) side, it is predicted to be an active 
(inactive) compound.    
In linearly separable cases, SVM constructs a hyper-plane to separate active and 
inactive classes of compounds with a maximum margin. A compound was 
represented by a vector xi composed of its molecular descriptors. The hyper-
plane was constructed by finding another vector w and a parameter b that 
minimises 2w  and satisfied the following conditions:  
1,  fo r 1i ib y     w x  Class 1 (active)                                                                 (2) 
1,  for 1i ib y     w x    Class 2 (inactive)                                                                      (3) 
where yi is the class index, w is a vector normal to the hyper-plane, /b w  is 
the perpendicular distance from the hyper-plane to the origin, and 2w  is the 
Euclidean norm of w. Based on w and b, a given vector x can be classified by 
f(x) = sign[(w • x) + b]. A positive (negative) f(x) value indicates that the vector 
x belongs to the active (inactive) class. 
In nonlinearly separable cases, which frequently occur in classifying 
compounds of diverse structures (Jorissen and Gilson, 2005), SVM projects the 
input vectors into a higher dimensional feature space by using a kernel function 
K(xi, xj). RBF kernel, which was extensively utilised and consistently shown 
better performance than other kernel functions (Burbidge et al., 2001), was used. 
The linear SVM was then applied to this feature space based on the following 
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Figure 27. Schematic representation of using support vector machine for binary 
classification of compounds. The vector (hj, vj, pj) denotes the physicochemical 
features (hydrophobicity, volume, polarisability) of a compound (Han et al., 
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3.2.2.4    Model validation 
The process of model development can be divided into two steps. 
In the first step, active and inactive (i.e. confirmed + putative) compounds were 
each divided into separate training, testing and independent validation sets. 
Specifically, active and inactive compounds were each clustered into groups 
based on their distance in the molecular descriptor space by using a hierarchical 
clustering method (Ruecker and Ruecker, 1993). An upper-limit of the largest 
separation of 20 was used for each cluster. One representative compound was 
randomly selected from each group to form a training set that is sufficiently 
diverse and broadly distributed in the descriptor space. One or up to 50% of the 
remaining compounds in each group were randomly selected to form the testing 
set. The selected compounds from each group were further checked to ensure 
that they are distinguished from those of other groups. The remaining 
compounds were used as the independent validation set, which are also of 
reasonable level of diversity. Moreover, an analysis of the compounds in each 
cluster showed that the majority of the compounds in a cluster are substantially 
different. Thus, the testing and independent validation sets are expected to have 
certain level of usefulness for performing their task of fine-tuning the 
parameters of a SVM model and for evaluating its prediction performance.  
In the second step, SVM models were trained by using the training set, and their 
parameters were optimised by using the testing set. The models were then 
internally validated using 5-fold cross validation (CV) and externally validated 
using independent validation sets. In 5-fold cross validation, compounds were 
randomly divided into five subsets with each subset being approximately equal 
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size. Four subsets were used as the training set for developing a model; the 
remaining one was used as a testing set to evaluate the prediction performance 
of that model. This process was repeated five times such that every subset was 
used as a testing set once. The average accuracy of the five time models was 
used for measuring the generalisation capability of that method. In view of the 
limitation of cross validation in its underestimation of the prediction capability 
of a classification model, especially when important molecular features are 
present in only a minority of the compounds in the training set (Mosier and Jurs, 
2002), it was suggested that an independent validation set may better gauge the 
predictive power of the model (Golbraikh and Tropsha, 2002). Compounds in 
MDDR database were used as the independent validation set. The SVM model 
with the best overall performance on both the testing and independent validation 
sets was selected as a VS tool. 
The classification performance of SVM models before virtual screening was 
evaluated by the numbers of true positive (TP, meaning an agent with desired 
pharmacological properties), true negative (TN, meaning an agent without 
desired pharmacological properties), false positive (FP, meaning an agent 
without desired pharmacological properties but wrongly predicted to be so), and 
false negative (FN, meaning an agent with desired pharmacological properties 
but wrongly predicted not to be so). In 5-fold cross validation studies, the 
prediction accuracy for actives and inactives was measured by sensitivity SE = 
TP/(TP + FN) × 100 and specificity SP = TN/(TN + FP) × 100, respectively. 
The overall performance of SVM models was measured by using prediction 
accuracy (Q) (Matthews, 1975). 
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ܳ ൌ ்௉ା்ே்௉ା்ேାி௉ାிே                                                                                               (4) 
 
3.2.3    Results and discussion 
3.2.3.1    Collection of adenosine A2A receptor antagonists 
At the time of compound collection (i.e. January–July 2011), compound 6 had 
been reported but compounds 7-9 had not (Figures 19 and 20). Heterobivalent 
ligand 6 and its derivatives reported in 2009 (Soriano et al., 2009) were excluded 
from collection because of their high molecular weight ranging from 1247 to 
2858. Whilst there are a number of small-molecule databases available online, 
such as BindingDB (Liu et al., 2007), ZINC (Irwin and Shoichet, 2005) and 
ChEMBL, (Gaulton et al., 2012) for people to collect compounds with desired 
properties, it was decided to manually create our own data sets in view of the 
quality alert for public chemistry databases (Williams and Ekins, 2011). 
Adenosine A2A receptor antagonists were collected from journal papers which 
focused on identifying antagonists for A2A receptor. The source and number of 
collected compounds are listed in Appendix I. Each compound with reported 
binding or antagonistic activity at A2A receptor therein was manually drawn by 
ChemDraw (Evans, 2014), and the relevant pharmacological data were noted 
down on ChemFinder. A total of 1969 adenosine A2A receptor antagonists with 
reported binding data (inhibition constant Ki, in most cases) were collected from 
69 papers, and they comprised 94 major scaffolds (Appendix J). Most scaffolds 
are composed of either a xanthine or nitrogen-containing heterocyclic nucleus 
(Appendix H). Of these 1969 compounds, 418 compounds were tested for 
binding at A2A receptor and further shown to be active in advanced assays 
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relevant to PD, including the ability to block cAMP generation (Katritch et al., 
2010), mouse catalepsy model (Vu et al., 2004), rat catalepsy model (Neustadt 
et al., 2007), as well as Ca2+ mobilisation assessment via a fluorescence imaging 
plate reader (FLIPR) assay (Gillespie et al., 2009).  
 
3.2.3.2    Collection of dopamine D2 receptor agonists 
Similar to the approach used in collecting A2A antagonists, manually creating 
our own data sets was decided. Dopamine D2 receptor agonists were collected 
from journal papers which focused on identifying agonists for D2 receptor. The 
source and number of collected compounds are listed in Appendix K. Each 
compound with reported binding or agonistic activity at D2 receptor therein was 
manually drawn by ChemDraw, and the relevant pharmacological data were 
noted down on ChemFinder. A total of 810 dopamine D2 receptor agonists with 
reported binding data (inhibition constant Ki, in most cases) were collected from 
71 papers, and they comprised 78 major scaffolds (Appendix L). There was no 
compound found in both A2A and D2 collections, revealing that at that time there 
was not any reported drug-like entity with dual-acting property. This is very 
different from searching for dual kinase inhibitors, which was shown to be 
relatively easier than identifying A2A/D2 dual-acting ligands in that there is 
generally an existing compound that shows inhibitory activity at multiple 
relevant kinases and thus can be directly used for optimisation (Ma et al., 2010). 
The discrepancy between kinase combinations and A2A/D2 in the availability of 
reported dual-acting agents might be due to the fact that the adenosine 
triphosphate (ATP)-binding pockets are highly conserved amongst kinases, so 
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a molecular scaffold which binds one kinase usually binds another kinases. In 
contrast to kinases, the orthosteric sites between A2A receptor and D2 receptor 
are less conserved, as can be seen in A2A crystal structures in Figure 22 and the 
D2 model structure in Figure 24, narrowing the chemical space that fits the 
binding pockets of the two receptors. Notwithstanding the challenge, analysis 
of these 78 scaffolds led to the observation that, in addition to the classical 
DPAT core (Figure 23), many reported D2 agonists have the feature of 
piperazine linked directly to an aromatic ring. Selected examples of such 
compounds are shown in Figure 28. In light of this observation, there seemed 
worth revisiting the collected A2A antagonists to see whether the aromatic 
piperazine moiety could also be found in some A2A antagonists. Few, but not 
many, of reported A2A antagonists did possess the aromatic piperazine moiety 
linked to a bi-heterocyclic or tri-heterocyclic nucleus, as shown in Figure 29. 
Of these 810 compounds, 332 compounds were tested for binding at D2 receptor 
and further shown to be active in advanced assays relevant to PD, including 
[35S]GTPγS binding experiments in striatal membranes (Giorgioni et al., 2010), 
percentage of maximal efficacy (Pettersson et al., 2010), [3H]-thymidine uptake 
assay (Johnson et al., 2011), Ca2+ mobilisation assessment via a fluorescence 
imaging plate reader (FLIPR) assay (Favor et al., 2010), changes in intracellular 
cAMP levels (Yan et al., 2010), cGMP content in rat neostriatal membranes (Di 
Stefano et al., 2005), rabbit ear artery test (Weinstock et al., 1987), 
electrophysiological assay (Menegatti et al., 2003), and whole cell forskolin-
dependent adenylyl cyclase inhibition assay (Vangveravong et al., 2011).  
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3.2.3.3    N-arylpiperazine—a privileged substructure  
The observation that some D2 agonists and few A2A antagonists share the 
aromatic piperazine prompted me to wonder whether this common substructure 
could potentially be used as the starting point to construct dual-acting ligands at 
A2A and D2 receptors. A recent patent research on N-phenylpiperazine 
derivatives published from 2006–2012 showed that the majority of their 
therapeutic use was for the treatment of CNS disorders, such as schizophrenia 
and depression. Moreover, their modes of action described therein are to target 
dopamine receptor, serotonin receptor, and adrenergic receptor (Maia Rdo et 
al., 2012). Indeed, N-arylpiperazine is a privileged moiety mimicking biogenic 
amines including dopamine, serotonin, and epinephrine (Figure 30). It is mainly 
composed of an aryl group to confer the intrinsic activity, and a basic amine 
(pKa values ranging from 8 to 10) located 3-atom away from the aryl ring. A 
variety of aryl groups, such as phenyl, pyridinyl, pyrimidinyl, and naphthalenyl 
groups, were observed in the compound collection.  The term “1,4-disubstituted 
aromatic piperazine (1,4-DAP)” was coined to address the compound having 
N-arylpiperazine moiety (Kortagere et al., 2004). The basic tertiary amine in the 
piperazine ring is to simulate the amine group of the aforementioned 
neurotransmitters. Another aromatic residue is usually linked to the piperazine 
via a spacer, as shown in the R group in Figure 30, to control affinity and 
subtype selectivity. Recently, a molecular dynamics (MD) simulations study 
based on an active-state model of D2 receptor in complex with Gαi1 compared 
the binding mode of aripiprazole (DeLeon et al., 2004), which is a partial D2 
agonist with 1,4-DAP moiety and is an atypical antipsychotic in the market, 
with that of dopamine, a full D2 agonist (Kling et al., 2014). The study shows 
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that dopamine forms strong hydrogen bonds with Ser1935.42 and Ser1975.46, 
which brings Ser1945.43 in close proximity to His3936.55. This facilitates the 
formation of a hydrogen bond between Ser1945.43 and His3936.55. In contrast, 
although aripiprazole binds D2 receptor at the same site as where dopamine 
does, it causes a greater flexibility on Ser1945.43, which weakens hydrogen 
bonding between Ser1945.43 and His3936.55. As a result of this reduced 
stabilisation between TM5 and TM6, TM6 is more re-orientated by aripiprazole 
towards TM7, impairing the inward movement of TM5 needed for D2 receptor 
activation (Figure 31). This MD simulations study on the binding mode of N-
arylpiperazine is consistent with Goddard’s first-principles-based prediction of 
D2 receptor structure in complex with agonists and antagonists (Kalani et al., 
2004), as well as with mutation studies on His3936.55 important for D2 receptor 
agonism (Tschammer et al., 2011). Importantly, it provides a plausible 
structural explanation for the partial, but not full, agonistic activity of 
aripiprazole at D2 receptor. In addition to acting as D2 partial agonists, efforts 
have been made to develop N-arylpiperazine derivatives as D2 antagonists, such 
as ziprasidone (Figures 9, A3, A4 and 30). Despite numerous SAR studies on 
1,4-DAPs as ligands against dopamine (Ehrlich et al., 2009) and serotonin 
receptors (Salerno et al., 2014), 1,4-DAPs were neither used as a starting point 
to develop A2A antagonists nor fit the A2A antagonist pharmacophore model 
(Wei et al., 2010). By and large, whilst literature review gave me confidence 
that 1,4-DAPs were very likely to bind D2 receptor, the outstanding question 
that remained was how they affect A2A receptor.      



































D2 antagonist (Ki = 4.8 nM)
Figure 30. The N-arylpiperazine substructure is to mimic neurotransmitters 
(e.g. dopamine, serotonin and epinephrine), and can be found in many CNS 
drugs (e.g. aripiprazole and ziprasidone). 
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Figure 31. The ligand-binding pockets of D2 receptor in complex with 
dopamine (A) and aripiprazole (B). Ligands and important residues stabilising 
ligands are shown as either balls-and-sticks or sticks. The D2 receptor is shown 
as ribbons. Hydrogen bonds are shown as black dotted lines (Kling et al., 2014).  
 
3.2.3.4    Generation of putative inactive compounds 
A caveat in ligand-based virtual screening is the less amounts of inactive data 
available than those of active data for a given receptor, resulting in high false 
positive rate. This was proved to be true during the collection of reported A2A 
and D2 ligands, and may affect the performance of SVM-based virtual screening 
(Heikamp and Bajorath, 2013). Given the scarcity of experimentally confirmed 
non-antagonists of A2A receptor and non-agonists of D2 receptor, putative 
inactive compounds were generated by Prof Chen Yu Zong’s previous method 
(Han et al., 2008) illustrated in Figure 32. A total of 8,000 compound families 
were selected as the realm of putative inactive compounds. Admittedly, it was 
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definitely possible that undiscovered active compounds existed in any of these 
8,000 families, which may increase the false negative rate. Such misclassified 
compounds were, however, expected to be less in numbers compared with true 
active compounds, given the extensive efforts that have been made to identify 
A2A antagonists and D2 agonists over the past 30 years. Since SVM has been 
shown to have high tolerance to noise even at the level that the numbers of false 
negatives and true positives are equal (Glick et al., 2006), the impact of possible 
undiscovered active compounds in the putative inactive families on the 
reliability of SVM models was deemed to be minimal. Also, previous SVM 
studies employing this putative-inactive-compound approach showed the small 
effects of such misplacement on the identification of active compounds for 
many biological target classes (Han et al., 2008; Liew et al., 2009; Ma et al., 
2008). Hence, a total of 64,000 putative inactive compounds were collected 
from these 8,000 families. The advantages of generating putative inactive 
compounds for SVM models are twofold. First, it can enlarge the applicability 
domain of SVM models, enabling more coverage of molecular descriptors for 
screening large compound libraries, such as PubChem. Any compound in 
PubChem whose descriptors are not within the hyper-rectangle descriptor range 
defined by the training set is to be excluded from classification, so it is desirable 
to maximise the applicability domain of SVM models used for screening 
databases so as not to abandon potential actives. This was particularly necessary 
for the thesis because the number of collected compounds in Sections 3.2.3.1 
and 3.2.3.2 (ca. 2800 compounds) was much less than 13.56 million in 
PubChem database that was used for virtual screening. Second, it can reduce 
the false positive rate of SVM models. The number of experimentally confirmed 
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inactive compounds is limited versus confirmed active compounds for a given 
target of interest, as opposed to the distribution of true inactive and active 
compounds in chemical space. That is, whilst the number of reported inactive 
compounds is less, all true inactive compounds for a given target should be 
much more than all true actives. Therefore, it is not unreasonable nor 
unexpected that the SVM model built solely on the reported compounds without 
incorporating putative inactive compounds generally resulted in high false 
positive rate since the model is short of sufficient learning examples of inactive 
compounds. Both of the aforementioned advantages can be better appreciated 
by a published SVM model for virtual screening of lymphocyte-specific protein 
tyrosine kinase (Lck) inhibitors—an  increase in coverage percentage of MDDR 
compounds (47.49 → 99.99%) and a sharp decrease in false positive rate at 
MDDR screening (61.2 → 0.52%) for the SVM model endowed with putative 
inactive compounds (Liew et al., 2009). 
 
Figure 32. The diagram illustrating how putative inactive compounds are 
generated. The blue circles indicate compound families, the green dots indicate 
confirmed active compounds, and the red dots indicate confirmed inactive 
compounds. The blue arrow means the removal of families that contain 
confirmed active compounds from the full set of compound families (at the left 
of the arrow). The reduced set of compound families (at the right of the arrow) 
is where putative inactive compounds are generated. 
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3.2.3.5    Establishment of SVM models for virtual screening 
With compound collection from literature (Sections 3.2.3.1 and 3.2.3.2) and 
putative inactive families (Section 3.2.3.4) at hand, two ligand-based 
computational tools—SVM models (Section 3.2.3.5) and Tanimoto similarity 
(Section 3.3)—were used to analyse these collections. 
Since MDDR covers compounds published in patent literature, 309 A2A 
antagonists and 173 D2 agonists extracted from MDDR were added to the 
collection from journal papers. Compounds from both journal papers and 
MDDR were then categorised into active (i.e. either A2A antagonists or D2 
agonists) and inactive (i.e. either non A2A antagonist or non D2 agonists) 
compounds by the cutoff values Ki ≤ 30 µM and Ki ≥ 50 µM, respectively. 
Compounds with Ki values between 30 µM and 50 µM were discarded from the 
data sets. After the removal of duplicate compounds, the number of compounds 
(i.e. confirmed actives + confirmed inactives) used for building SVM models 
and compound families to which these compounds belong are given in Table 3.  
 
Table 3. Compound Data Sets 
 A2A antagonista D2 agonista 
binder 1,595 (412) 569 (253) 
functional binder 404 (138) 236 (138) 
MDDR 295 (155) 170 (106) 
inactive 96 (74) 39 (33) 
am(n): the number of compounds (the number of compound families) 
 
As discussed in Section 3.2.3.4, the number of confirmed inactives were scarce 
(i.e. 96 for A2A antagonists, 39 for D2 agonists), so 64,000 putative inactives 
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from 8,000 compound families that did not contained confirmed actives were 
included for building SVM models to better represent the true distribution of 
actives and inactives in chemical space. Due to the differences between binding 
and function activities at a given GPCR, both binding and function models for 
each receptor were taken into consideration. For function-directed models, since 
the reliability of function data of compounds in MDDR was unknown, two 
models—one based solely on compounds collected from journal papers, and the 
other one based on compounds from both journal papers and MDDR—were 
built. Specifically, the 1,595 compounds together with (96 + putative) inactives 
were used for A2A binding-directed SVM model, SVMAB. The 404 compounds 
together with (96 + putative) inactives were used for A2A function-directed 
SVM model, SVMAF1. The (404 + 295) compounds together with (96 + 
putative) inactives were used for A2A function-directed SVM model, SVMAF2. 
Similarly, the 569 compounds together with (39 + putative) inactives were used 
for D2 binding-directed SVM model, SVMDB. The 236 compounds together 
with (39 + putative) inactives were used for D2 function-directed SVM model, 
SVMDF1. The (236 + 170) compounds together with (39 + putative) inactives 
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Table 4. Classification Performance of SVM Models 
           aSE: sensitivity. bSP: specificity. cQ: accuracy.  
 
One of the objectives for a prospective model is its reliable prediction of the 
pharmacological properties of compounds that are not experimentally tested. It 
is therefore important to evaluate the predictive ability of the built model. In 
Table 4, the prediction accuracy of a SVM model was assessed by sensitivity 
(SE), specificity (SP) and overall accuracy (Q). SE is the ability of a model to 
correctly classify a truly active compound as an active one, whereas SP is the 
ability of a model to correctly classify a truly inactive compound as an inactive 
one. In other words, SE is the probability of being classified as an active 
compound when it is a truly active one, whilst SP is the probability of being 
classified as an inactive compound when it is a truly inactive one. The overall 
classification accuracy Q considers both active and inactive compounds. The 
accuracy percentages for predicting A2A actives and A2A inactives are 
84.98~91.29% and 99.70~99.87%, respectively. The accuracy percentages for 
 A2A antagonist D2 agonist 
SVMAB SVMDB 
SEa (five fold CV) 91.29% 84.18% 
SPb (five fold CV) 99.70% 99.82% 
Qc (five fold CV) 99.49% 99.65% 
Yield of inactive 54.17% (52/96) 33.33% (13/39) 
Yield of MDDR 56.95% (168/295) 44.12% (75/170) 
 SVMAF1 SVMDF1 
SE (five fold CV) 88.14% 71.63% 
SP (five fold CV) 99.85% 99.82% 
Q (five fold CV) 99.74% 99.72% 
Yield of inactive 88.54% (85/96) 41.03% (16/39) 
Yield of MDDR 34.24% (101/295) 37.65% (64/170) 
 SVMAF2 SVMDF2 
SE (five fold CV) 84.98% 79.82% 
SP (five fold CV) 99.87% 99.80% 
Q (five fold CV) 99.71% 99.67% 
Yield of inactive 88.54% (85/96) 38.46% (15/39) 
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predicting D2 actives and D2 inactives are 71.63~84.18% and 99.8~99.82%, 
respectively. The overall prediction accuracy percentages are 99.49~99.74% 
and 99.65~99.72% for A2A and D2 receptors, respectively. The prediction 
accuracy of six SVM models here was comparable to the previous SVM model 
developed for screening Lck inhibitors (Liew et al., 2009). Subsequently, the 
models were externally validated by confirmed inactives and actives extracted 
from MDDR. The yield of screening is mostly 33.33~56.95% which was 
comparable to 22~55% that was obtained in a SVM model for the screening of 
a 98,400-compound library (Han et al., 2008). Remarkably, the screening of 
confirmed A2A inactives using SVMAF1 and SVMAF2 identified more than 88% 
of truly inactives, suggesting that for A2A antagonism, SVM models built on 
larger percentage of functional binders were more reliable in classifying 
inactive compounds than those built on compounds with only binding data 
available. Taken together, the six SVM models developed for A2A antagonists 
and D2 agonists performed well internally in predicting actives (SE = 
84.98~91.29% for A2A, 71.63~84.18% for D2) and inactives (SP = 
99.70~99.87% for A2A, 99.80~99.82% for D2), and showed acceptable 
prediction accuracy to external data composed of confirmed inactives and 
MDDR actives.  
These six SVM models were then used to screen 168,000 compounds in the 
MDDR database and 13.56 million compounds in the PubChem database. The 
result is given in Table 5. First, for each receptor, three screens were done using 
one binding model and two function models of that receptor, followed by one 
screen using the “combined model” (i.e. the combination of one binding and 
two function models) of that receptor. The reason for using the combined model 
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was to understand which compounds can simultaneously fit three models as 
well as to narrow down the number of possible hits. It was noticed that 
6,100~8,000 compounds from PubChem and 230~480 compounds from MDDR 
fit the combined model of each receptor. The performance of these six SVM 
models in screening single-target agents (i.e. either A2A antagonists or D2 
agonists) from PubChem and MDDR was assessed by yield (percentage of 
identified actives in all actives) and false positive rate (percentage of inactives 
identified as actives). These six SVM models can identify 43.2~73.5% yield of 
the reported compounds, and the false positive rates were < 1.5% and < 0.64% 
for MDDR and PubChem databases, respectively. Such yield performance was 
higher in comparison to a previous SVM model developed for predicting Lck 
inhibitors, and the low false positive rates resulted from the screening by these 
six SVM models suggests the reliability of classification. Next, three sets of 
“dual model” consisting of one A2A model and one D2 model were used for 
screening, since the aim of the thesis was to identify ligands acting on both, 
rather than only one, receptors. A drastic reduction in the number of hits by 2~3 
orders of magnitude was observed when using a dual model compared to a 
model specific to one receptor, suggesting the sparse distribution of compounds 
in PubChem and MDDR databases that can fit both A2A models and D2 models. 
Whilst using each set of dual models resulted in few hits, no compound was 
identified after screening with the “combined-dual model”, namely all six 
models. This may suggest that a dual ligand acting as A2A antagonist and D2 
agonist had not been reported. Therefore, a total of 172 hits (162 from PubChem 
and 10 from MDDR) coming from each set of dual models were collected. This 
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was similar to the situation when the intersection of three sets was null, union 
of three sets became the choice (Figure 33). 
 
Table 5. SVM-Based Virtual Screening of PubChem & MDDR Databases 
 A2A antagonist D2 agonist A2A antagonist + 
D2 agonist 
 SVMAB SVMDB SVMAB+SVMDB 
PubChem 86,844 22,308 141 
MDDR 1,470 1,358 2 
 SVMAF1 SVMDF1 SVMAF1+SVMDF1 
PubChem 17,687 18,927 18 
MDDR 400 997 5 
 SVMAF2 SVMDF2 SVMAF2+SVMDF2 
PubChem 36,869 27,922 31 








PubChem 8,073 6,164 0 
MDDR 238 486 0 
   total hits 
PubChem   162 
MDDR   10 
 
 
Figure 33. The diagram of union and intersection of three sets (Source: 
Wikipedia) (ineligible for copyright). 
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In Christopher A. Lipinski’s highly cited (times cited in Web of Science Core 
Collection: 3,477, as at 19 February 2015) review published in 1997 (Lipinski 
et al., 1997) and its reprints in 2001 and 2012, favourable intestinal absorption 
properties (mainly aqueous solubility and permeability) of an oral drug were 
strongly emphasised to complement but not compromise its in vitro potency 
generated by HTS technique. Indeed, each drug, except for those administered 
by the intravenous route, need to translocate from its site of administration to 
the site of its intended target through systemic circulation. Its movement into 
the systemic circulation is called “drug absorption”. Aqueous solubility and 
permeability are main determinants of intestinal absorption of an orally 
administered drug. Aqueous solubility of a compound refers to the maximum 
concentration it can reach in water under a given condition, and poor aqueous 
solubility limits intestinal absorption of a drug. Another major factor that affects 
intestinal absorption of a drug is its permeability, which is defined as the 
velocity of drug passage through a biological membrane. In order to provide a 
guideline for eliminating compounds that were unlikely to be orally active in 
the drug discovery pipeline, Lipinski collected a library composed of 2,245 
compounds that had entered phase 2 studies. The assumption was that most 
compounds with poor solubility and poor permeability had been weeded out 
before entry to phase 2. Four structural parameters associated with solubility 
and permeability were analysed for each compound in the library, namely (i) 
molecular weight (MW), (ii) lipophilicity, (iii) the number of hydrogen bond 
donor (HBD) groups, and (iv) the number of hydrogen bond acceptors (HBA) 
groups. For MW consideration, the general guiding principle was that 
compounds with low MW tended to  favour their oral bioavailability (Navia and 
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Chaturvedi, 1996). In this library, it was found that there were 89% of 
compounds with MW ≤ 500. Lipophilicity is the tendency of a drug to partition 
into a lipid matrix versus a water matrix, and it has effects on almost all areas 
of pharmacokinetic/pharmacodynamics properties of that drug. Lipophilicity is 
usually estimated by calculated logarithm of the octanol/water partition 
coefficient (CLogP) of a drug. In this library, it was found that there were about 
90% of compounds with CLogP ≤ 5. The smaller amount of HB groups in a 
compound has been linked to better permeability, and particularly, the 
correlation of intramolecular HB bonding with increased permeability (Goetz 
et al., 2014) was also established. In this library, it was found that there were 
92% of compounds with the sum of OHs and NHs ≤ 5, and 88% of compounds 
with the sum of Ns and Os ≤ 10. Based on the results derived from this library, 
Lipinski proposed the “rule of 5” (RO5), stating that a compound is less likely 
to be absorbed if it fulfils two or more of the following conditions: MW > 500, 
CLogP > 5, HBD > 5 and HBA > 10. Since its proposal in 1997, the RO5 filter 
has been used widely as the tool for assessing drug-like properties of a 
compound, and as the first step for achieving good oral bioavailability by many 
drug discoverers. It is possible, however, that a compound which fails the RO5 
has good oral activity, and that a compound which passes the RO5 does not 
guarantee its oral absorption. The former exception is exemplified by 
cyclosporine, atorvastatin and montelukast which break more than one 
parameter of RO5, and such RO5-noncompliance gave an impetus to the 
development of a gradated instead of binary estimate of drug-likeness 
(Bickerton et al., 2012). The latter exception was documented by Lipinski 
himself (Lipinski, 2004). Despite these limitations, RO5 is to a large extent 
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useful in predicting the distribution of compounds with oral activity. Moreover, 
because generating compounds in tablet forms for oral administration is the 
main goal in CNS drug discovery (Alelyunas et al., 2010), which is also the 
topic of the thesis, RO5 was used to filter the 172 hits shown in Table 5. Of the 
162 hits identified from PubChem, 89 fulfilled the requirements of RO5. These 
89 compounds, together with the 10 hits identified from MDDR (listed in 
Appendix M) were subjected for further analysis. 
Of these 99 hits, the two largest scaffold classes are Scaffold A and 1,4-DAP 
(Figure 34). Compounds with Scaffold A were those with 1-aza-4-
azoniabicyclo[2.2.2]octane moiety, occupying 30.3% of hits. They were 30 
compounds (P58, P60, and P62~P89) shown in Appendix M. Compounds with 
1,4-DAP scaffold occupied 29.3% of hits. They were 29 compounds (P1, P4, 
P6~P9, P15, P21, P25, P26, P28, P33, P35, P39, P44~P47, P50, P52, P55~P57, 
P59, P61, M2, M3, M7 and M8) shown in Appendix M. Four representative 
compounds P60, P64, P82 and P88 (Figure 35) bearing Scaffold A were 
selected with the criterion of maximising structural diversity at R and Ar groups 
in Scaffold A, purchased from Enamine Ltd, and tested by in vitro radioligand 
displacement assay at A2A receptor (Note: The basic principle of radioligand 
displacement assay will be discussed in Section 4.3.). Unfortunately, these four 
compounds did not show binding at A2A receptor at 30~100 µM. Since the goal 
was to identify compounds that bind both A2A and D2 receptors, these four 
compounds were not proceeded to be tested against D2 receptor. These four 
compounds can be found in PubChem, ZINC (Irwin et al., 2012), and 
ChemSpider (Pence and Williams, 2010). However, their biological annotations 
were not available in these databases, which may suggest that 1-aza-4-
 CHAPTER 3  
83 
 
azoniabicyclo[2.2.2]octane was unlikely to be a binding moiety to biological 
targets. Even though these four compounds exhibited binding affinities to either 
A2A or D2 or both receptors in vitro, the quaternary ammonium cation would 
hinder permeability across a biological membrane, be it the gastrointestinal (GI) 
barrier or the blood-brain barrier (BBB), making them unsuitable for further 
development. In fact, the impact of lipophilicity on BBB permeability was 
studied as early as late 19th century, and recently, scientists in Amgen gave the 
suggested range of CLogP = 2~5 for increased brain penetration (Hitchcock and 
Pennington, 2006). It is obvious that the lipophilicity criteria for brain 
penetration (CLogP = 2~5) is more stringent than that for oral absorption 
(CLogP ≤ 5) proposed by Lipinski. The basics of BBB, along with other 
structural properties required for optimal brain exposure, will be further 
discussed in Chapter 6. As shown in Table 6, the CLogP of P60, P64, P82 and 
P88 were within the range of Lipinski’s RO5 but outside the preferred limit 
given by Amgen scientists. This implies that if the CLogP guideline given by 
Amgen scientists had been used to filter the 99 hits that were obtained after RO5 
filtering, the 30 compounds containing Scaffold A would not have existed in 
the final hits, which in turn, would have made 1,4-DAP the largest scaffold out 












Figure 34. Two largest scaffold classes identified by SVM models. 


























Figure 35. Four compounds with Scaffold A purchased from Enamine Ltd. 
 
Table 6. Known Structural Properties of Four Purchased Compounds 
Bearing Scaffold A 




P60 8717454 07613192 310.805 -2.42 1 5 0 
P64 8717456 07613194 290.343 -3.19 1 6 0 
P82 8717251 07612989 301.370 -3.47 1 6 0 
P88 8717208 07612946 331.465 -2.44 1 5 0 
aCID: PubChem Compound Identifier. bData from ZINC. cxLogP is an atom-
additive method for the calculation of LogP (Wang et al., 1997). 
 
From the viewpoint of SVM, which is a binary classification, P60, P64, P82 and 
P88 were experimentally confirmed to be four false positives out of SVM 
model. As mentioned earlier, the average false positive rate of the six SVM 
models in screening either reported A2A antagonists or reported D2 agonists was 
about 1% (i.e. the average of 1.5% and 0.64%). False positive rate is defined as 
the percentage of true negatives predicted as positives, and can be formulated 
as FP/(FP + TN) where FP denotes false positive and TN denotes true negative. 
Suppose that the number of true inactives in PubChem and MDDR is 10 million 
which is expected to be so in view of the much wider distribution of inactives 
in chemical space than that of actives for a given biological target, 1% false 
positive rate implies that the number of false positives is about 100,000. That is 
to say, as long as the number of false positives in hits is less than 100,000, the 
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false positive rate of the model can be maintained within 1%. Therefore, it is 
definitely possible that in the 172 hits identified by six SVM models, the number 
of true positives (TP) is less than that of false positives. This limitation, which 
results in the largest scaffold identified being the inactive, can be overcame 
either by continually refining SVM models towards a lower false positive rate 
and a higher yield, or by screening target-focused compound libraries (Harris et 
al., 2011). The failure of Scaffold A to bind A2A receptor in vitro turned my 
eyes to 1,4-DAP which also occupied a fairly large portion of SVM hits. As 
shown in Section 3.2.3.3, the substructure 1,4-DAP is likely to be a binder at 
D2 receptor whilst its role in binding A2A receptor has not been documented. In 
a sense, the result that a number of compounds bearing 1,4-DAP passed SVM 
models built on A2A antagonists suggests that there is a likelihood for A2A 
receptor to tolerate or accommodate 1,4-DAP, and therefore the effect of 1,4-
DAP on A2A receptor merits further investigation.   
 
3.3    Tanimoto Similarity  
The compounds collected from literature were used not only for building SVM 
models and outwardly screening databases (Section 3.2.3.5), but they were also 
inwardly examined by Tanimoto similarity (Section 3.3). 
 
3.3.1    Introduction  
Unlike substructure searching that relies on comparing many biologically active 
compounds for the purpose of identifying common features, similarity 
searching focuses on the specification of a whole compound (Willett et al., 
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1998). A given compound is characterised by its molecular descriptors, which 
are used to compare with those of another compound. The resulting numerical 
measure could be either similarity coefficient (with maximum value for two 
identical objects) or distance coefficient (with a value of 0 for two identical 
objects) to quantify the degree of resemblance. Similarity is the opposite of 
distance which is defined as 1 minus similarity. Tanimoto coefficient (Tc), or 
Jaccard coefficient, is the most widely used similarity coefficient in 
cheminformatics and is illustrated in Table 7. Imagine that there are two 
compounds, compound A (Cpd A) and compound B (Cpd B), and both are 
represented by 15 molecular descriptors. The binary bits 0 and 1 represent the 
absence and presence of that molecular feature, respectively. The number of bits 
“on” in compound A is 6. The number of bits “on” in compound B is 8. There 
are 2 molecular features (red colour in Table 7) shared by both compounds. The 
Tc for this pair of compounds is the number of bits in both compounds divided 
by the number of bits in either compound (i.e. 2/(6 + 8 – 2) = 0.17) (Figure 36, 
left). The Tc value ranges from zero to unity, with higher value indicating higher 
similarity between this pair of compounds. The Tc value of 0 indicates these 
two compounds have no descriptor in common. The Tc value of 1 does not 
guarantee the two compounds are identical but only indicates they have identical 
descriptors. When the intersection of a pair of compounds increases, which 
means these two compounds have more molecular features in common, the Tc 
value increases (Figure 36, right).    
Table 7. Compounds A and B Represented by Molecular Fingerprint 
cpd A 0 0 1 0 0 1 1 0 1 0 0 1 0 0 1 
cpd B 1 1 0 1 1 1 0 1 1 0 1 0 0 0 0 
A ∩ B 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 
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Figure 36. The Tanimoto similarity for object A and object B is calculated by 
the intersection divided by union. (Left) The calculation of Tc for the case in 
Table 7. (Right) More molecular features in common result in a higher Tc value.   
 
3.3.2    Methods 
The similarity for a pair of compounds was computed by the Tanimoto 
coefficient sim(i,j) (Willett et al., 1998). 
sim(i,j) = ∑ ݔௗ௜ݔௗ௝௟ௗୀଵ ⧸∑ ሺݔௗ௜ሻଶ ൅	௟ௗୀଵ ∑ ൫ݔௗ௝൯ଶ െ	∑ ݔௗ௜ݔௗ௝௟ௗୀଵ 	௟ௗୀଵ ሻ          (5) 
where l is the number of molecular descriptors. A compound i is considered to 
be similar to compound j if the corresponding sim(i,j) value is greater than the 
cutoff value. The cutoff values for molecular similarity analysis are typically in 
the range of 0.8 to 0.9 (Bostrom et al., 2006). A stricter cutoff value of 0.9 was 
used in the thesis. 
 
3.3.3    Results and discussion 
The preliminary inward examination of collected compounds did not show a 
compound that existed in A2A as well as D2 collections, so molecular similarity 
studies between A2A and D2 collections were pursued in order to find out the 
highly similar, but not identical, pairs of compounds. Instead of analysing the 
molecular similarity within either A2A or D2 collections to build 
pharmacophores for each receptor, one compound from each collection was 
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picked to form a pair. In any pair, one was a collected A2A antagonist, and the 
other one was a collected D2 agonist. It was hoped that by computing similarity 
of all pairs followed by ranking each pair in decreasing order of the computed 
similarities would shed light on which substructural fragments were common to 
both collections. In contrast to SVM models, which required cutoffs for binary 
classification, Tanimoto similarity analyses utilised the entire data sets 
irrespective of the biological potency.  
A Tanimoto similarity using two-dimensional fingerprints (Willett, 2006) was 
carried out on the basis of  1986 collected A2A antagonists (i.e. 1,595 confirmed 
actives, 96 confirmed inactives, 295 compounds from MDDR) and 778 
collected D2 agonists (i.e. 569 confirmed actives, 39 confirmed inactives, 170 
compounds from MDDR). A total of 1,545,108 (i.e. 1,986 × 778 = 1,545,108) 
pairs of compounds were therefore generated. Each pair is composed of an A2A 
antagonist and a D2 agonist. The degree of structural similarity between an A2A 
antagonist and a D2 agonist was calculated and shown by Tc. It was identified 
that 570 pairs had Tc = 0.80~0.88, and three pairs had Tc > 0.9 that is shown in 
Figure 37. The Tc values were 0.91 between 16a and 17, 0.927 between 16b 
and 17, and 0.926 between 16c and 17. Structural analysis of these three pairs 
with highest Tc values out of ~1.5 million pairs revealed the common indole 
(shown in blue) and pyrimidine (shown in red) groups at the two terminal ends 
of a molecule. Although the middle part of the molecule, which was shown as 
the green area, was not identical, it can be categorised as an alkyl/cycloalkyl 
attached to a nitrogen-containing basic moiety. Compounds 16a-c were 
discovered as novel ligands of A2A receptor by structure-based virtual screening, 
and 16a was confirmed as an A2A antagonist (Carlsson et al., 2010). The SAR 
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study based on scaffold 16 was done for six analogues. Comparison of 16b with 
16c indicated that the two methyl groups on pyrimidine contributed 15-fold 
binding affinity at A2A receptor. Either substitution with methoxy group at the 
indole C6 position or replacement of indole with other aryl groups, such as 
thiophene and anisole, did not affect A2A binding affinity, suggesting that the 
NH group on the indole ring may not form hydrogen bonds with nearby 
residues. In a predicted A2A receptor model in complex with 16a, the guanidine 
was predicted to form hydrogen bonds with Asn253 in transmembrane helix 6 
and Glu169 in extracellular loop 2, and one nitrogen atom on the pyrimidine 
forms a hydrogen bond with Asn253 (Carlsson et al., 2010). Compound 17 was 
developed in a programme directed towards the identification of novel D2 partial 
agonists (Wustrow et al., 1997). The SAR study for derivatives of 17 showed 
that increasing the number of carbon atoms in the middle linker from zero to 
one to two improve D2 binding affinity, and that the trans stereoisomer showed 
greater affinity than the cis stereoisomer. In addition, the piperazine-pyrimidine 
in 17 was replaced by piperazine-pyridine (Ki = 50 nM) and tetrahydropyridine-
phenyl (Ki = 8.7 nM), both of which showed higher D2 affinity than 17. 
Compound 17 belongs to N-arylpiperazine class of compound, and it is expected 
that the nitrogen atom attached to the middle linker forms a salt bridge with 
Asp114 in TM3 of D2 receptor, as mentioned in Section 3.1.3.2. It seemed that 
indole and pyrimidine rings contributed to binding affinities not only with A2A 
receptor but also with D2 receptor, and that by building SARs for the middle 
“alkyl—basic” linker against the two receptor (e.g. the effects of the alkyl chain 
length, the acyclic or cyclic alkyl groups, the different basic centres, on binding 
affinities with two receptors) it might be possible to identify a novel compound 
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with dual-acting activities. It is of particular note that two different 
substructures, guanidine (in 16a-c) and piperazine (in 17), attached to the 
pyrimidine ring. Compounds 16a-c were tested only at A2A but not D2 receptors, 
and likewise, compound 17 was tested only at D2 but not A2A receptors. There 
are therefore two straightforward approaches that could be explored for the 
identification of dual-acting ligands, namely testing 16a-c at D2 receptor and 
testing 17 at A2A receptor. Should either testing show activity to a certain extent, 
the number of common substructures between A2A and D2 ligands would 
increase—from [indole + pyrimidine] to either [indole + guanidine + 
pyrimidine] or [indole + piperazine + pyrimidine]. Instead of doing experiments 
to address these queries, I resorted to SVM results for direction. In Appendix 
M, compounds 16a-c or their analogues were not found, suggesting that the 
guanidine-pyrimidine substructure may not be tolerated by D2 receptor. In 
contrast, the piperazine-pyrimidine substructure was found in P1, P8, P47, M2 
and M3, which were part of 29 compounds bearing 1,4-DAP. Under such 
guidance from SVM results, the probability of the guanidine-pyrimidine 
substructure showing activity at D2 receptor was expected to be lower than that 
of the piperazine-pyrimidine substructure showing activity at A2A receptor. 
Hence, the higher probable substructures [indole + piperazine + pyrimidine] 
was regarded a rewarding pursuit. 














16a R1=F, R2=R3=Me (Ki = 0.2 uM)
16b R1=H, R2=R3=Me (Ki  = 0.4 uM)










(J. Med. Chem. 2010, 53, 3748-3755) (J. Med. Chem. 1997, 40, 250-259)
A2A ligand D2 ligand
Figure 37. The three pairs of reported compounds with Tc > 0.9. 
 
At this stage, it is worth summarising how SVM models and Tanimoto 
similarity analysis contributed to the discovery of the substructures [indole + 
piperazine + pyrimidine]. Whilst the largest scaffold (Scaffold A) of the 99 hits 
identified by SVM models was experimentally confirmed to be inactive at A2A 
receptor, the second largest scaffold (1,4-DAP) with only one short of the 
number of Scaffold A warranted consideration. The distribution of scaffolds in 
the 99 hits facilitated the selection from two possibilities generated by similarity 
analysis. Without the inputs from SVM models, it would have been necessary 
to experimentally measure binding of 16a-c at D2 receptor and 17 at A2A 
receptor, a situation that would entail in-house synthesis of 16a-c and 17. In 
addition, if the computation works had stopped at SVM models without 
proceeding to similarity analysis, the indole group would not have been revealed 
as a potentially important moiety for binding two receptors. Collectively, it was 
the combination of SVM models and similarity analysis that gave a potential 
starting point for the identification of dual-acting ligands at A2A and D2 receptors 
(Figure 38).    








































Figure 38. The flowchart for SVM models, virtual screening, and similarity 
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3.4    Chapter Conclusion 
In summary, two computational methods—support vector machine (SVM) 
models, and Tanimoto similarity analysis—were adopted to analyse collected 
A2A antagonists and D2 agonists from literature and MDDR database. Screening 
of compound collections from literature enabled the identification of the 1,4-
DAP substructure, which was a known privileged moiety accommodated by 
several aminergic GPCRs (including D2 receptor) and a potentially tolerable 
fragment for A2A receptor (Sections 3.2.3.1~3.2.3.3). The collected compounds 
underwent (i) binary classification by SVM models, which were subsequently 
used for screening millions of compounds in two databases (Sections 3.2.3.4 
and 3.2.3.5), as well as (ii) examinations by molecular similarity (Section 3.3). 
Scaffold A, the largest scaffold identified by SVM models, showed no binding 
in A2A radioligand binding studies. This led me to focus on second largest 
scaffold, 1,4-DAP. Subsequent Tanimoto similarity analysis not only specified 
that piperazine is the likely aromatic group of 1,4-DAP, but also revealed indole 
group as an additional moiety important for binding both A2A and D2 receptors. 
Analyses of collected compounds by SVM models and molecular similarity  
culminated in a possible starting point for synthesis—compounds with the 








CHAPTER 4    DESIGN, SYNTHESIS, AND A2A 
RECEPTOR BINDING STUDIES OF INDOLYL 
PIPERAZINYLPYRIMIDINES 
 
Dr. Ma Xiaohua in Professor Chen Yu Zong’s lab (Department of Pharmacy, 
National University of Singapore) performed cluster analysis of collected 
compounds. Radioligand binding assays for adenosine receptor subtypes were 
done through the collaboration with Professor Karl-Norbert Klotz (Institut für 
Pharmakologie und Toxikologie, Universität Würzburg, Germany). X-ray 
diffraction analysis of compound 70 was done by Tan Geok Kheng with the 
assistance of Dr. Ang Wee Han (Department of Chemistry, National University 
of Singapore). High-resolution mass spectrometry (HRMS) analysis of final 
compounds for biological assays was done by Wong Lai Kwai (Department of 
Chemistry, National University of Singapore). Dr. Priyankar Paira is 
appreciated for his advice on chemical synthesis.   
 
4.1    Design Rationale 
Similarity analysis described in Section 3.3 dealt with similarity between one 
A2A antagonist selected from the pool of the A2A collection and one D2 agonist 
selected from the pool of the D2 collection, but it did not group the two sets of 
compounds, A2A antagonists and D2 agonists, according to their respective 
computed similarity ranges. One major advantage of grouping all collected 
compounds by their molecular features is that it can give clues about the 
likelihood of a compound acting as both A2A antagonist and D2 agonist. The 
extremity would be all collected A2A antagonists are grouped in one side and all 
collected D2 agonists are grouped in another side, meaning that in the realm of 
known ligands there is no possibility to have a compound that binds A2A and 




objects into different groups (called clusters) so that objects in one cluster are 
more similar to each other than to the objects in another cluster. In the thesis, 
all collected compounds were represented by molecular descriptors given in 
Table 2, so compounds in the same cluster should have similar structural 
properties. Because compounds in a given cluster have similar structural 
properties, if one known A2A antagonist and one known D2 agonist are grouped 
in the same cluster, that A2A antagonist (D2 agonist) is likely to have structural 
motifs that are important in D2 (A2A) activity. The methods for clustering data 
include hierarchical and non-hierarchical approaches (Barnard and Downs, 
1992). Hierarchical clustering generates a classification in which there is a 
hierarchy ranging from each datum in an individual cluster to all data in one 
cluster. Non-hierarchical clustering is to partition the data into a number of non-
overlapping groups. Hierarchical clustering can be either agglomerative (small 
clusters merged into larger clusters) or divisive (larger clusters split into smaller 
clusters). An explanation of hierarchical agglomerative clustering (HAC) is 
shown in Figure 39. Suppose there are five compounds (A, B, C, D and E), each 
with their distinct molecular features. Initially, each compound is assigned a 
cluster, so there are five clusters in the beginning. The number of possible pairs 
is 5 × (5 – 1)/2 = 10 (i.e. A-B, A-C, A-D, A-E, B-C, B-D, B-E, C-D, C-E and 
D-E). Out of these 10 pairs, the pair with highest similarity (i.e. A-D) is merged 
into a new cluster AD, making the number of total clusters from five to four. 
The similarities between AD and each of the original clusters (i.e. B, C and E) 
are re-computed, and the cluster with highest similarity (i.e. C) to AD is merged 
with AD to become ADC. Such merging process based on similarity is repeated 
until all five compounds are grouped into one single cluster ADCBE. The y-
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axis in the dendrogram indicates the distance, which is 1 minus similarity 
(Section 3.3). Larger distance at which two clusters merge indicates less 
similarity between these two clusters. This also implies that the closer the two 
compounds are placed in the x-axis of the dendrogram, the more similar of these 
two compounds. This concept is important and useful in the endeavour to 
identify dual-acting ligands targeting A2A and D2 receptors because the shortest 
x-axis distance between a known A2A antagonist and a known D2 agonist 
provides an opportunity to achieve the aim of the thesis. 
 
 
Figure 39. Hierarchical agglomerative clustering. (Left) Compounds A~E are 
distributed in chemical space according to their molecular features. (Right) The 
dendrogram representing a hierarchy of clusters based on their molecular 
similarities. 
 
To better appreciate the potential of the collected data sets towards the goal of 
the thesis, hierarchical clustering of collected A2A antagonists and D2 agonists 
was conducted. The dendrogram obtained from 98 descriptors (Table 2) is 
shown in Figure 40. Most A2A antagonists (shown in green colour) appeared at 
the lower right of the dendrogram, whereas most D2 agonists (shown in blue 
colour) distributed at the upper left of the dendrogram, suggesting that reported 
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A2A antagonists as a whole and D2 agonists as a whole had remote similarity. 
Generally, high similarity means Tc > 0.85, intermediate similarity means 0.7 
< Tc ≤ 0.85, and remote similarity means 0.57 < Tc ≤ 0.7 (Zhang et al., 2015). 
Such remote similarity indicated the ligand-binding pocket of A2A receptor is 
distinct from that of D2 receptor, accounting for the difficulty in identifying a 
ligand that can bind both receptor. Despite such a challenge, there were still few 
reported A2A antagonists clustered in the region of D2 agonists (some green 
fragments in the upper left region), and few reported D2 agonists clustered in 
the region of A2A antagonists (some blue fragments in lower right region). As 
mentioned earlier, the closeness in the x-axis of the dendrogram signifies the 
structural resemblance. Since compounds with similar structures have similar 
properties, which is the principle widely held by the community (Maggiora et 
al., 2014), it was no surprise that such structural similarity existed within 
reported A2A antagonists as shown in the continuous green colour in the lower 
left of the dendrogram, and within reported D2 agonists as shown in the 
continuous blue colour in the upper right of the dendrogram. What was 
interesting and relevant to the goal of the thesis was the green and blue areas 
adjacent to each other, and therefore ten representative clusters with such 
adjoining green-blue property were selected for analysis. Each cluster contained 
some A2A antagonists and some D2 agonists. Compounds in each cluster are 
listed in Appendix N. Common substructures shared by A2A antagonists and D2 
agonists were observed in clusters 1, 2, 3, 8 and 9, but not in clusters 4, 5, 6, 7 
and 10. Compounds grouped in the same cluster could be very structurally 
dissimilar, as shown in the case of clusters 4, 5, 6, 7 and 10, so it was necessary 
to look at the chemical structures of compounds after cluster analysis. This was 
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attributed to the fact that clustering is descriptor-dependent. Compounds 
grouped in the same cluster only implies higher percentage of identical 
descriptors for each object in that particular cluster, but not necessarily 
guarantee higher structural similarity. In fact, it was well documented that 
different molecular descriptors affect the results of similarity calculations 
(Dimova et al., 2013). The common substructures benzimidazole, indole-
pyrimidine, quinoline, benzofuran and pyrimidine were identified in clusters 1, 
2, 3, 8 and 9, respectively. Notably, cluster 2 (Figures 41 and 42) corresponds 
to the best similarity results shown in Figure 37, and the SARs of compounds 
therein were summarised in Section 3.3.3. 
Figure 40. Clustering dendrogram of the collected compounds. A2A antagonists 
are shown in green, and D2 agonists are shown in blue. The main portion of A2A 
antagonists was distributed below the red dashed line, whereas the main portion 
of D2 agonists was distributed above the red dashed line. 
 

































































































Figure 41. Compounds in cluster 2. Three A2A antagonists (in green) and one 




Figure 42. The magnified area where compounds in cluster 2 are located in the 
clustering dendrogram. 
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The result that the hierarchical clustering analysis showed five clusters (i.e. 
cluster 1, cluster 2, cluster 3, cluster 8, and cluster 9), in each of which a 
common substructure can be found in both A2A antagonists and D2 agonists, 
prompted us to focus on compounds in these five clusters. In Chapter 3, indole, 
piperazine and pyrimidine groups were identified by combining SVM models 
and similarity analysis to be the substructures that may have the binding 
capacity at both A2A and D2 receptors. Herein, the hierarchical clustering 
analysis led to the identification of three other potential substructures that may 
bind the two receptors, namely benzimidazole (from cluster 1), quinoline (from 
cluster 3), and benzofuran (from cluster 8). Together, there were a total of six 
potentially relevant substructures identified from SVM models, similarity 
analysis, and hierarchical clustering analysis. The design of dual-targeting 
ligands at A2A and D2 receptors was thus based on these six substructures. Since     
five of the six substructures (i.e. except piperazine) were already among clusters 
1, 2, 3, 8 and 9, these five clusters together with the piperazine group were 
considered. A total of 47 synthetically feasible compounds 18-64 on the basis 
of these five clusters integrated with piperazine were designed (Figures 43–47). 
The design relied on the common substructures observed in both A2A 
antagonists and D2 agonists within the same cluster, and on the piperazine 
suggested by the results from SVM models and similarity analysis. According 
to synthetically feasible procedures (Maggiora et al., 2014), the piperazine ring 
was only included in the design based on clusters 1, 2, 3 and 9. With these six 
substructures as the molecular skeletons, a variety of linkers with different 
lengths, substituents, and functional groups were appended to the skeletons. 















































































































Figure 43. Eighteen compounds (18-35) designed from cluster 1. The common 
substructure benzimidazole (red squares) in this cluster and piperazine (blue 
squares) were included in the design. The basic core is either 2-(piperazin-1-
yl)benzimidazole (18-19, and 21-35) or 4-(piperazin-1-yl)benzimidazole (20) 





























































































Figure 44. Fifteen compounds (36-50) designed from cluster 2. The common 
substructures indole and pyrimidine (red squares) in this cluster, as well as 
piperazine (blue squares) were included in the design. An indole and a 
pyrimidine are at the terminal ends of a compound. 
 






























51 52 53 54 55
Figure 45. Five compounds (51-55) designed from cluster 3. The common 
substructure quinoline (red squares) in this cluster and piperazine (blue squares) 
were included in the design. The basic core is either 2-methyl-8-(piperazin-1-





































56 57 58 59
60 61 62
Figure 46. Seven compounds (56-62) designed from cluster 8. The common 
substructure benzofuran (red squares) in this cluster was included in the design. 
The benzofuran is at one end of a compound. The other end is either imidazole 
(58 and 62), 4,5-dihydro-imidazole (56, 57, 59 and 60) or benzimidazole (61).  
 
 



















Figure 47. Two compounds (63 and 64) designed from cluster 9. The common 
substructure pyrimidine (red squares) in this cluster and piperazine (blue 
squares) were included in the design. The basic cores are a pyrimidine and a N-
(p-methoxyphenyl)piperazine at the ends of a compound. 
 
Subsequently, in order to further prioritise these 47 compounds, filtering by six 
SVM models generated in Section 3.2.3.5 and by Tanimoto similarity with the 
cutoff value Tc ≥ 0.85 was performed. Four criteria (i.e. three SVM models and 
Tc ≥ 0.85) were used to evaluate each of these 47 compounds for each receptor. 
This was to ensure that selected compounds for future synthesis obeyed 
maximal numbers of criteria suggested by all three computational tools that 
have been used, namely SVM models, Tanimoto similarity, and hierarchical 
clustering. Ten (20, 36-38, 40, 41, 44-46, and 48) out of these 47 compounds 
were in compliance with at least one A2A and one D2 computed criteria (Table 
8), and the rest 37 compounds failed to pass any criterion. Compound 20 passed 
one A2A (SVM) and two D2 (SVM and similarity) criteria. Compounds 36-38, 
40, 41, 44, 45 and 48 passed one A2A (similarity) and one D2 (similarity) criteria. 
Compound 46 passed one A2A (similarity) and one D2 (SVM) criteria. Because 
these 10 compounds were the result of clustering analysis followed by SVM 
and similarity screening, they were expected to be most probable candidates for 
synthesis. It was noted that these ten candidates only covered clusters 1 and 2, 
but not clusters 3, 8 and 9, although they were designed from all these five 
clusters. This suggests that SVM and similarity screening weeded out 
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compounds contained in clusters 3, 8 and 9, which may have lower probability 
to be dual-acting ligands. In addition, nine (36-38, 40, 41, 44-46, and 48) of 
these ten compounds belonged to cluster 2, suggesting that compounds in 
cluster 2 have the highest likelihood to be dual-acting ligands. These nine 
compounds can be structurally divided into three scaffolds: (i) [indole + 
piperazine + pyrimidine] (IPP) (compounds 36-38, 40, 41, 44 and 45), (ii) 
[indole + 1,4-dihydropyrazine + pyrimidine] (IDP) (compound 46), and (iii) 
[indole + guanidine + pyrimidine] (IGP) (compound 48). Clearly, a large 
percentage (7 out of 9) of these nine compounds belonged to the scaffold IPP, 
suggesting that, among the nine compounds in cluster 2, there is a higher 
probability for the scaffold IPP than the rest two scaffolds to be the dual-acting 
ligands. This was in line with the results shown in Figure 38. Such a weeding-
out analysis was that ten compounds were reduced to nine compounds by 
choosing cluster 2 and discarding cluster 1 (i.e. 20), followed by that the 
remaining nine compounds were reduced to seven compounds by choosing the 
main scaffold and discarding the rest two scaffolds (i.e. 46 and 48). An 
alternative weeding-out analysis that can also bring the focus on IPP was to 
check whether each scaffold possessed the features that were identified in 
previous SVM models (Section 3.2.3.5) and similarity analysis (Section 
3.3.3)—only the scaffold IPP met both requirements (Table 9). The best result 
from starting with hierarchical clustering followed by the manual design and 
filtering with SVM models and similarity was consistent with the discovery 
(Figure 38) via the combination of SVM models and similarity. This 
consistency gave an assurance that compounds with the scaffold IPP should be 
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synthesised and tested at A2A and D2 receptors. The overall decision-making 
process for the subsequent chemical synthesis was charted in Figure 48. 
 
Table 8. Ten Compounds Compliant with at Least One Criterion of Each 
Receptor      
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Table 8. (Continued) Ten Compounds Compliant with at Least One 
Criterion of Each Receptor           
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Table 8. (Continued) Ten Compounds Compliant with at Least One 
Criterion of Each Receptor           
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Table 8. (Continued) Ten Compounds Compliant with at Least One 
Criterion of Each Receptor           































a[benzimidazole + piperazine + pyrimidine]. b[indole + piperazine + 
pyrimidine]. c[indole + 1,4-dihydropyrazine + pyrimidine]. d[indole + guanidine 
+ pyrimidine].  
 
Table 9. Weeding-Out Analysis of Ten Compounds Obtained from 
Clustering 
scaffold 1,4-DAPa? Tc > 0.9b? 
BPP (compound 20) Yes No 
IPP (compounds 36-38, 
40, 41, 44 and 45) 
Yes Yes 
IDP (compound 46) No Yes 
IGP (compound 48) No Yes 
aContributed by SVM models in Section 3.2.3.5. bContributed by similarity 
analysis in Section 3.3.3. 















































active at A2A and D2 receptors
Figure 48. Three computational tools, SVM models, Tanimoto similarity 
analysis, and hierarchical clustering analysis, are used to analyse collected 
compounds, screen databases, and identify potential scaffolds. The activities of 
the IPP scaffold to A2A and D2 receptors will be shown in Sections 4.2~4.4 and 
Chapter 5. 
 
4.2    IPP 
4.2.1    Chemical considerations    
The designed compounds with IPP scaffold were synthesised (Scheme 1). The 
mixture of urea 65 and 2,4-pentanedione under an acidic condition resulted in 
the formation of 4,6-dimethylpyrimidin-2-ol hydrochloride (66) in 78% yield. 
Following this, treating 66 with phosphorus oxychloride gave 2-chloro-4,6-
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dimethylpyrimidine 67 in 91% yield (Vlad and Horvath, 2002). For the sake of 
minimising the formation of 2‐[4‐(4,6‐dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]‐
4,6‐dimethylpyrimidine, five equivalents of piperazine were used for coupling 
with 67 in a basic condition. With 4,6-dimethyl-2-(piperazin-1-yl)pyrimidine 
(68) in hand, four indole-3-acids (i.e. indole-3-carboxylic acid, 2-methylindole-
3-acetic acid, indole-3-propionic acid, and indole-3-butyric acid) were selected 
for 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)-mediated amide 
formation to generate 69-72 with different lengths of linker. To study the effect 
of the carbonyl group of 69-72 on biological activities, reduction by lithium 
aluminum hydride (LiAlH4) was performed on 69-72 to give compounds 69a-
72a. Mechanisms of each step in Scheme 1 are proposed (Figure 49). The 
structural determination of 70 in the solid state was carried out by X-ray 
diffraction (Figure 50). The crystal was obtained by dissolving 70 in boiling 
EtOAc/MeOH (1:3) followed by slow solvent evaporation and filtration. The 
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aReagents and conditions: (i) 2,4-pentanedione, 37% HCl, EtOH, reflux, 24 h, 
78%; (ii) POCl3, reflux, 10 h, 91%; (iii) piperazine, K2CO3, H2O, 45~50 oC, 4.5 
h, 93%; (iv) indole-3-acid, EDC.HCl, EtOAc, DMF, 23 → 50 oC, 4~4.5 h, 
















































































































































































































Figure 50. X-ray crystal structure of compound 70.  
 
4.2.2    Experimental methods 
General. Reactions were consistently monitored by thin layer chromatography 
(TLC) on silica gel (precoated 60 F254 Merck plate) and carried out under a 
nitrogen atmosphere. All chemicals are commercial products from Sigma 
Aldrich or Alfa Aesar. Column chromatography was performed using silica gel 
60 (Merck, 70–230 mesh). Compounds were dissolved in HPLC-grade MeOH 
for accurate mass analysis using ESI time-of-flight (TOF) ionisation mode. 1H 
and 13C NMR spectra were determined in deuterated chloroform (CDCl3) or 
deuterated dimethylsulfoxide (DMSO-d6) using Bruker DPX Ultrashield NMR 
(400 MHz) spectrometer, with chemical shifts given in parts per million (δ) 
downfield relative to the central peak of the solvents, and J values (coupling 
constants) were given in Hz. The following abbreviations were used: s = singlet, 
d = doublet, t = triplet, m = multiplet, br = broad, td = triplet of doublets. High-
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performance liquid chromatography (HPLC) analysis was carried out for 
compounds used in biological assays. For HPLC (1): Hewlett-Packard series 
1050 HPLC system equipped with a HP-1050 quaternary pump, a degasser, 
diode array detector, a HP-1100 autosampler, and a LiChrosorb reversed phase 
C18 (5 μm) column (4.6 × 250 mm) with solvents being CH3CN/H2O. For 
HPLC (2) and HPLC (3): Agilent HPLC 1200 series instrument on a Zorbax 
SB-C18, 4.6 mm × 250 mm, 5 μm column with solvents being CH3CN/H2O 
(0.1% v/v CF3COOH) and MeOH/H2O (0.1% v/v CF3COOH) for HPLC (2) and 
HPLC (3), respectively. All HPLC samples were prepared by dissolving them 
in HPLC-grade MeOH. The analysis was performed at 30 °C, and the ultraviolet 
detection was made at wavelength 254 nm. The separations were carried out 
using gradient elution. The HPLC methods are as follows. HPLC (1): injection 
volume 5 μL, stop time 20 min, flow rate 1 mL/min, a gradient of 35 → 100% 
CH3CN for the 0–17 min period and back to CH3CN/H2O (3:7) at 20 min. HPLC 
(2): injection volume 20 µL, stop time 15 min, flow rate 0.5 mL/min, a gradient 
of 5 → 95% CH3CN for the 0–12 min period and back to CH3CN/H2O (5:95) 
at 15 min. HPLC (3): injection volume 20 µL, stop time 15 min, flow rate 0.5 
mL/min, a gradient of 5 → 95% MeOH for the 0–12 min period and back to 
MeOH/H2O (5:95) at 15 min. The purities of all the tested compounds were > 
95% measured by the peak area of the product divided by that of the total peak 
areas. 
The NMR spectra of compounds 66-72 and 69a-72a are listed in Appendix P. 
The HPLC chromatograms of compounds 69-72 and 69a-72a are listed in 
Appendix Q. 
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4,6‐Dimethylpyrimidin‐2‐ol hydrochloride (66). To a suspension of urea 
(1000 mg, 16.65 mmol) in EtOH (10 mL) were added 2,4-pentanedione (1885 
µL, 18.32 mmol) and concentrated hydrochloric acid (2775 µL, 33.3 mmol), 
and the resulting clear, colourless solution was stirred and refluxed under N2 for 
24 h. The mixture was cooled to 23 oC and filtered. The filter cake was washed 
with EtOH, Et2O, and dried in the vacuum oven to afford compound 66 (2096 
mg, 78% yield) as an off-white crystalline solid. 1H NMR (400 MHz, DMSO-
d6) δ 6.72 (s, 1H), 2.47 (s, 6H). 
2‐Chloro‐4,6‐dimethylpyrimidine (67). The mixture of compound 66 (1998 
mg, 12.44 mmol) and phosphorus oxychloride (20 mL) was refluxed for 10 h. 
The remaining phosphorus oxychloride was evaporated to get a brown oil in the 
flask. The mixture was cooled in an ice bath, and concentrated aqueous KOH 
solution was added dropwise cautiously with stirring, until the litmus paper 
showed pH value is approximately 8. Diethyl ether (30 mL) was added, and the 
mixture was stirred for 2.5 h. The water layer was extracted with Et2O (3 × 30 
mL) and EtOAc (3 × 30 mL). The organic layers were combined, washed with 
brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. 
The resulting yellow liquid was put in an ice bath under vacuum to afford 
compound 67 (1606 mg, 91% yield) as a yellow crystal. 1H NMR (400 MHz, 
DMSO-d6) δ 7.33 (s, 1H), 2.42 (s, 6H).  
4,6‐Dimethyl‐2‐(piperazin‐1‐yl)pyrimidine (68). Into a 250mL round-bottom 
flask were charged K2CO3 (3849 mg, 27.85 mmol), piperazine (10903 mg, 
126.58 mmol), and H2O (180 mL). The mixture was heated at 45–50 oC until it 
became a clear solution. Compound 67 (3610 mg, 25.32 mmol) was divided into 
four portions, and each portion was added into the mixture in a one-hour 
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interval. After the addition of all amounts of compound 67, the reaction mixture 
was cooled to 23 oC and stirred for overnight. The white precipitate was filtered, 
and the filtrate was collected. The filtrate was extracted with EtOAc (3 × 225 
mL). Organic layers were collected, washed with brine, dried over Na2SO4, 
filtered, and concentrated under reduced pressure to give compound 68 (4536 
mg, 93% yield) as a white crystal. 1H NMR (400 MHz, DMSO-d6) δ 6.36 (s, 
1H), 3.62 (t, J = 5.2 Hz, 4H), 2.69 (t, J = 5.2 Hz, 4H), 2.20 (s, 6H).  
3‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐1H‐indole (69). 
To a suspension of indole-3-carboxylic acid (520 mg, 3.23 mmol) and EDC.HCl 
(643 mg, 3.35 mmol) were added EtOAc (30 mL) and two drops of DMF, and 
the mixture was stirred for 1 h at 23 oC followed by the addition of compound 
68 (414 mg, 2.15 mmol). The reaction was heated at 50 oC for 3 h, and solvents 
were evaporated to dryness under high vacuum. Water was added, sonicated, 
and filtered. The filter cake was washed with hexanes/EtOAc (3:1) and further 
purified by crystallisation from MeOH/Et2O/EtOAc to provide compound 69 
(360 mg, 50% yield) as a white crystal. 1H NMR (400 MHz, DMSO-d6) δ 11.61 
(br s, 1H), 7.74–7.72 (m, 2H), 7.45 (d, J = 8 Hz, 1H), 7.16 (td, J = 7.2, 1.2 Hz, 
1H), 7.10 (td, J = 7.2, 1.2 Hz, 1H), 6.44 (s, 1H), 3.82–3.80 (m, 4H), 3.71–3.69 
(m, 4H), 2.24 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 166.8 (2 × C), 165.7, 
161.1, 135.7, 128.1, 126.1, 121.9, 120.3, 120.2, 111.9, 109.6, 109.1, 43.5 (2 × 
CH2), 40.1–38.9 (2 × CH2), 23.7 (2 × CH3). HRMS-ESI (m/z) [M + H]+ calcd 
for C19H22N5O, 336.1819; found, 336.1824 (Δ = -1.6 ppm). [M + Na]+ calcd for 
C19H21N5NaO, 358.1638; found, 358.1639 (Δ = -0.2 ppm). HPLC (1): t = 5.6 
min, 96.7% purity. HPLC (3): t = 15.5 min, 98.3% purity. 




yl)ethan‐1‐one (70). To a suspension of 2-methylindole-3-acetic acid (1515 
mg, 8.00 mmol) and EDC.HCl (1579 mg, 8.24 mmol) were added EtOAc (90 
mL) and six drops of DMF, and the mixture was stirred for 70 min at 23 oC 
followed by the addition of compound 68 (1026 mg, 5.34 mmol). The reaction 
was heated at 45 oC for 3 h, and solvents were evaporated to dryness under high 
vacuum. Water was added, sonicated, and filtered. The filter cake was purified 
by crystallisation from MeOH/EtOAc (3:1) to provide compound 70 (1130 mg, 
58% yield) as a light brown crystal. 1H NMR (400 MHz, DMSO-d6) δ 10.80 (br 
s, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 7.6 Hz, 1H), 6.97 (td, J = 7.2, 1.2 
Hz, 1H), 6.90 (td, J = 7.2, 1.2 Hz, 1H), 6.41 (s, 1H), 3.74 (s, 2H), 3.62–3.61 (m, 
2H), 3.52–3.49 (m, 6H), 2.34 (s, 3H), 2.20 (s, 6H). 13C NMR (100 MHz, 
DMSO-d6) δ 169.6, 166.8 (2 × C), 160.8, 135.1, 132.6, 128.2, 120.0, 118.2, 
117.8, 110.3, 109.1, 104.0, 45.2, 43.3, 43.2, 41.2, 30.0, 23.6 (2 × CH3), 11.5. 
HRMS-ESI (m/z) [M + H]+ calcd for C21H26N5O, 364.2132; found, 364.2123 
(Δ = 2.4 ppm). [M + Na]+ calcd for C21H25N5NaO, 386.1951; found, 386.1940 
(Δ = 3.0 ppm). HPLC (1): t = 9.8 min, 99.9% purity. HPLC (3): t = 15.6 min, 
99.6% purity. 
1‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]‐3‐(1H‐indol‐3‐
yl)propan‐1‐one (71). To a suspension of indole-3-propionic acid (518 mg, 
2.74 mmol) and EDC.HCl (540 mg, 2.82 mmol) were added EtOAc (30 mL) 
and two drops of DMF, and the mixture was stirred for 1.5 h at 23 oC followed 
by the addition of compound 68 (352 mg, 1.83 mmol). The reaction was heated 
at 50 oC for 3 h, and solvents were evaporated to dryness under high vacuum. 
Water was added, sonicated, and filtered. The filter cake was purified by 
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crystallisation from MeOH/EtOAc (1:1) to provide compound 71 (491 mg, 74% 
yield) as a transparent crystal. 1H NMR (400 MHz, DMSO-d6) δ 10.76 (br s, 
1H), 7.53 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 2.0 Hz, 1H), 
7.06 (td, J = 8.0, 0.8 Hz, 1H), 6.97 (td, J = 8.0, 0.8 Hz, 1H), 6.42 (s, 1H), 3.67– 
3.64 (m, 2H), 3.62–3.60 (m, 2H), 3.53–3.50 (m, 2H), 3.46–3.44 (m, 2H), 2.95 
(t, J = 7.2 Hz, 2H), 2.71 (t, J = 7.2 Hz, 2H), 2.22 (s, 6H). 13C NMR (100 MHz, 
DMSO-d6) δ 170.8, 166.8 (2 × C), 160.8, 136.2, 127.1, 122.5, 120.9, 118.3, 
118.2, 113.8, 111.3, 109.1, 44.8, 43.4, 43.1, 40.9, 33.4, 23.7 (2 × CH3), 20.6. 
HRMS-ESI (m/z) [M + H]+ calcd for C21H26N5O, 364.2132; found, 364.2131 
(Δ = 0.2 ppm). [M + Na]+ calcd for C21H25N5NaO, 386.1951; found, 386.1949 
(Δ = 0.5 ppm). HPLC (1): t = 10.2 min, 98.4% purity. HPLC (3): t = 15.6 min, 
98.4% purity. 
1‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]‐4‐(1H‐indol‐3‐yl)butan‐
1‐one (72). To a suspension of indole-3-butyric acid (509 mg, 2.50 mmol) and 
EDC.HCl (508 mg, 2.65 mmol) were added EtOAc (30 mL) and two drops of 
DMF, and the mixture was stirred for 70 min at 23 oC followed by the addition 
of compound 68 (317 mg, 1.65 mmol). The reaction was heated at 45–50 oC for 
3 h, and solvents were evaporated to dryness under high vacuum. Water was 
added, sonicated, and filtered. The filter cake was purified by crystallisation 
from MeOH/EtOAc (2:1) to provide compound 72 (411 mg, 66% yield) as an 
off-white crystal. 1H NMR (400 MHz, DMSO-d6) δ 10.75 (br s, 1H), 7.52 (d, J 
= 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 2.4 Hz, 1H), 7.05 (td, J = 
8.0, 0.8 Hz, 1H), 6.96 (td, J = 8.0, 0.8 Hz, 1H), 6.43 (s, 1H), 3.70–3.67 (m, 4H), 
3.53–3.50 (m, 2H), 3.46–3.44 (m, 2H), 2.72 (t, J = 7.2 Hz, 2H), 2.41 (t, J = 7.2 
Hz, 2H), 2.23 (s, 6H), 1.89 (quintet, J = 7.2 Hz, 2H). 13C NMR (100 MHz, 
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DMSO-d6) δ 170.8, 166.8 (2 × C), 160.1, 136.3, 127.2, 122.3, 120.8, 118.3, 
118.1, 114.2, 111.3, 109.1, 44.7, 43.5, 43.1, 40.9, 32.1, 25.6, 24.3, 23.7 (2 × 
CH3). HRMS-ESI (m/z) [M + H]+ calcd for C22H28N5O, 378.2288; found, 
378.2295 (Δ = -1.8 ppm). [M + Na]+ calcd for C22H27N5NaO, 400.2108; found, 
400.2110 (Δ = -0.7 ppm). HPLC (1): t = 11.3 min, 99.7% purity. HPLC (3): t = 
16.3 min, 99.1% purity. 
3‐{[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]methyl}‐1H‐indole (69a). 
To a slurry of LiAlH4 (5 small spoons) in anhydrous THF (30 mL) at 0 oC was 
added dropwise by syringe the solution of compound 69 (535 mg, 1.59 mmol) 
in anhydrous THF (60 mL), and the mixture was warmed to 23 oC with stirring 
for 21.5 h. At 0 oC, the following sequence of dropwise addition was performed 
with continuous stirring: H2O (2.7 mL), 15% aqueous NaOH (2.7 mL), 15% 
aqueous NaOH (3 mL), H2O (3 mL). The white sticky part was removed by 
filtration, and the filtrate was concentrated under reduced pressure. Purification 
by flash chromatography (1:3 → 1:1 EtOAc/hexanes) provided compound 69a 
(391 mg, 76% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 10.93 
(br s, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 2.4 
Hz, 1H), 7.07 (td, J = 6.8, 1.2 Hz, 1H), 6.98 (td, J = 6.8, 1.2 Hz, 1H), 6.36 (s, 
1H), 3.71–3.68 (m, 4H), 3.65 (s, 2H), 2.43–2.40 (m, 4H), 2.20 (s, 6H). 13C NMR 
(100 MHz, DMSO-d6) δ 166.6 (2 × C), 161.1, 136.3, 127.7, 124.7, 121.0, 119.0, 
118.5, 111.4, 110.6, 108.6, 53.2, 52.5 (2 × CH2), 43.4 (2 × CH2), 23.7 (2 × CH3). 
HRMS-ESI (m/z) [M + H]+ calcd for C19H24N5, 322.2026; found, 322.2029 (Δ 
= -1.0 ppm). [M + Na]+ calcd for C19H23N5Na, 344.1846; found, 344.1845 (Δ = 
0.3 ppm). HPLC (1): t = 8.5 min, 100% purity. HPLC (3): t = 14.6 min, 97% 
purity. 




indole (70a). To a slurry of LiAlH4 (5 small spoons) in anhydrous THF (30 mL) 
at 0 oC was added dropwise by syringe the solution of compound 70 (600 mg, 
1.65 mmol) in anhydrous THF (35 mL), and the mixture was warmed to 23 oC 
with stirring for 4 h. At 0 oC, the following sequence of dropwise addition was 
performed with continuous stirring: H2O (6 mL), 15% aqueous NaOH (6 mL). 
The white sticky part was removed by filtration, and the filtrate was 
concentrated under reduced pressure. Purification by flash chromatography 
(25% → 60% EtOAc/hexanes) provided compound 70a (546 mg, 95% yield) 
as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 10.67 (br s, 1H), 7.39 (d, J 
= 7.6 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 6.96 (td, J = 7.2, 1.2 Hz, 1H), 6.91 (td, 
J = 7.2, 1.2 Hz, 1H), 6.39 (s, 1H), 3.74–3.72 (m, 4H), 2.83–2.79 (m, 2H), 2.46– 
2.44 (m, 6H), 2.32 (s, 3H), 2.22 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 
166.6 (2 × C), 161.2, 135.1, 131.6, 128.2, 119.8, 118.0, 117.3, 110.3, 108.7, 
108.2, 59.1, 52.7 (2 × CH2), 43.4 (2 × CH2), 23.7 (2 × CH3), 21.5, 11.2. HRMS-
ESI (m/z) [M + H]+ calcd for C21H28N5, 350.2339; found, 350.2345 (Δ = -1.6 
ppm). [M + Na]+ calcd for C21H27N5Na, 372.2159; found, 372.2166 (Δ = -2.0 
ppm). HPLC (2): t = 9.0 min, 96.7% purity. HPLC (3): t = 14.5 min, 96.3% 
purity. 
3‐{3‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]propyl}‐1H‐indole 
(71a). To a slurry of LiAlH4 (5 small spoons) in anhydrous THF (30 mL) at 0 
oC was added dropwise by syringe the solution of compound 71 (752 mg, 2.07 
mmol) in anhydrous THF (35 mL), and the mixture was warmed to 23 oC with 
stirring for 4 h. At 0 oC, the following sequence of dropwise addition was 
performed with continuous stirring: H2O (6 mL), 15% aqueous NaOH (6 mL). 
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The white sticky part was removed by filtration, and the filtrate was 
concentrated under reduced pressure. Purification by flash chromatography 
(25% → 50% EtOAc/hexanes) provided compound 71a (700 mg, 97% yield) 
as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.74 (br s, 1H), 7.51 (d, J 
= 7.6 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 7.11 (d, J = 2 Hz, 1H), 7.05 (td, J = 7.2, 
1.2 Hz, 1H), 6.96 (td, J = 7.2, 1.2 Hz, 1H), 6.38 (s, 1H), 3.71–3.69 (m, 4H), 
2.73–2.69 (m, 2H), 2.40–2.34 (m, 6H), 2.21 (s, 6H), 1.83 (quintet, J = 7.6 Hz, 
2H). 13C NMR (100 MHz, DMSO-d6) δ 166.6 (2 × C), 161.2, 136.3, 127.2, 
122.2, 120.8, 118.3, 118.1, 114.4, 111.3, 108.7, 57.8, 52.8 (2 × CH2), 43.3 (2 × 
CH2), 27.2, 23.7 (2 × CH3), 22.5. HRMS-ESI (m/z) [M + H]+ calcd for 
C21H28N5, 350.2339; found, 350.2346 (Δ = -1.9 ppm). [M + Na]+ calcd for 
C21H27N5Na, 372.2159; found, 372.2166 (Δ = -2.0 ppm). HPLC (2): t = 9.0 min, 
100% purity. HPLC (3): t = 14.4 min, 96.2% purity. 
3‐{4‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]butyl}‐1H‐indole 
(72a). To a slurry of LiAlH4 (5 small spoons) in anhydrous THF (30 mL) at 0 
oC was added dropwise by syringe the solution of compound 72 (545 mg, 1.44 
mmol) in anhydrous THF (20 mL), and the mixture was warmed to 23 oC with 
stirring for 4 h. At 0 oC, the following sequence of dropwise addition was 
performed with continuous stirring: H2O (6 mL), 15% aqueous NaOH (6 mL). 
The white sticky part was removed by filtration, and the filtrate was 
concentrated under reduced pressure. Purification by flash chromatography 
(25% → 40% EtOAc/hexanes) provided compound 72a (510 mg, 97% yield) 
as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.72 (br s, 1H), 7.50 (d, J 
= 7.6 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 7.05 (td, J = 
6.8, 0.8 Hz, 1H), 6.95 (td, J = 6.8, 0.8 Hz, 1H), 6.38 (s, 1H), 3.69–3.66 (m, 4H), 
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2.70 (t, J = 7.2 Hz, 2H), 2.37–2.31 (m, 6H), 2.21 (s, 6H), 1.67 (quintet, J = 7.6 
Hz, 2H), 1.52 (quintet, J = 7.6 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 166.6 
(2 × C), 161.2, 136.3, 127.2, 122.1, 120.7, 118.3, 118.0, 114.6, 111.3, 108.7, 
57.8, 52.7 (2 × CH2), 43.3 (2 × CH2), 27.7, 26.2, 24.5, 23.7 (2 × CH3). HRMS-
ESI (m/z) [M + H]+ calcd for C22H30N5, 364.2496; found, 364.2497 (Δ = -0.4 
ppm). [M + Na]+ calcd for C22H29N5Na, 386.2315; found, 386.2318 (Δ = -0.8 
ppm). HPLC (2): t = 9.3 min, 100% purity. HPLC (3): t = 14.7 min, 98.5% 
purity. 
Solid-State Structural Determination. X-ray diffraction data were collected 
with a Bruker AXS SMART APEX diffractometer using MoKα radiation at 
223(2) K with the SMART suite of programs. Data were processed and 
corrected for Lorentz and polarisation effects using SAINT software, and for 
absorption effects using the SADABS software. Structural solution and 
refinement were then carried out using the SHELXTL suite of programs. The 
structure was determined by Direct Methods. Non-hydrogen atoms were located  
using difference maps and were given anisotropic displacement parameters in 
the final refinement. All H atoms were put at calculated positions using the 
riding model.  
Radioligand Competition Binding Assays for Adenosine Receptors. The 
basics of radioligand competition is given in Appendix R. A two-step procedure 
was employed to prepare a membrane for radioligand binding from cells stably 
transfected with the human adenosine receptor subtypes (hA1, hA2A, hA2B and 
hA3 expressed on CHO cells) (Klotz et al., 1998). First, using the low-speed 
step (1,000g for 4 min), the cell fragments and nuclei were removed, and then 
crude membrane fraction from the supernatant was sedimented at 100,000g for 
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30 min. Subsequently, the membrane pellet was resuspended in the specific 
buffer, frozen in liquid nitrogen, and stored at –80 oC. However, one step 
centrifugation method was used for the measurement of the adenylyl cyclase 
activity, in which the homogenate was sedimented for about 30 min at 54,000g. 
Finally, the obtained crude membrane pellet was resuspended in 50 mM 
Tris/HCl, pH 7.4 and used for the adenylyl cyclase assay immediately. 
Binding Assays of Human Cloned A1, A2A, A3 Adenosine Receptors. In 
accordance with the procedures described previously (Klotz et al., 1985; Lohse 
et al., 1987), competition binding experiments for adenosine A1 receptor were 
carried out for 3 h at 25 oC in 200 μL of buffer containing 1 nM [3H]-CCPA, 
0.2 U/mL adenosine deaminase, 20 μL of diluted membranes (50 μg of 
protein/assay) in 50 mM Tris/HCl, pH 7.4 and tested compounds in different 
concentrations. Non-specific binding was determined using theophylline 1 mM. 
In a similar manner, binding of [3H]-NECA to CHO cells transfected with the 
human recombinant A2A adenosine receptors was performed. A mixture of the 
protein with a concentration of 50 μg/assay in buffer, 30 nM [3H]-NECA and 
tested compound in different concentrations were incubated for 3 h at 25 oC. 
Non-specific binding was determined using N6-R-phenylisopropyl adenosine 
(R-PIA) 100 μM (De Lean et al., 1982). Additionally, binding of [3H]HEMADO 
to CHO cells transfected with the human recombinant A3 adenosine receptors 
was carried out as described earlier (Klotz et al., 2007). The competition 
experiment was carried out for 3 h at 25 oC in the buffer solution containing 10 
nM [3H]HEMADO, 20 μg membrane protein in 50 mM Tris-HCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 10 mM MgCl2, pH 8.25 and tested 
compound in different concentrations. Non-specific binding was determined 
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using R-PIA 100 μM. Filtration of assay mixture was carried out to separate 
bound and un-bound radioactivity, through Whatman GF/B glass-fiber filters 
using a MicroMate 196 Cell Harvester (Packard Instrument Company). The 
filter bound radioactivity was calculated on Top Count (efficiency of 57%) with 
Micro-Scint 20. Lastly, the Bio-Rad method (Bradford, 1976) using bovine 
albumin as a reference standard was employed to measure the protein 
concentration. 
Adenylyl Cyclase Activity Assay for A2B Receptor. The potency of the 
compounds at hA2B receptor (expressed in CHO cells) was determined in 
adenylyl cyclase experiments. All these experiments were performed as 
described previously with minor modifications (Klotz et al., 1985; Klotz et al., 
1998). Membranes transfected with the hA2B receptor were incubated with 100 
nM NECA, 150,000 cpm of [α-32P]ATP, and tested compounds in different 
concentrations for 20 min in the incubation mixture without ethylene glycol 
tetraacetic acid (EGTA) and NaCl. The IC50 values for concentration-dependent 
inhibition of NECA-mediated adenylyl cyclase activity caused by tested 
compounds were calculated. 
Data Analysis. A non-linear curve fitting method in the SCT-FIT program was 
used to calculate the 50% inhibition of binding of [3H]-NECA (IC50) produced 
by the different concentrations of tested compounds (in triplicate), as described 
previously (De Lean et al., 1982). The dissociation constant (Ki) values were 
calculated from IC50 by the Cheng and Prusoff equation (Cheng and Prusoff, 
1973). A non-linear regression analysis using the equation for sigmoidal 
concentration-response curve was applied to calculate the IC50 values of 
adenylyl cyclase activity assay.  
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4.2.3    Results and discussion 
Compounds 69-72 and 69a-72a were tested in competition binding experiments 
at human adenosine A1, A2A, A2B and A3 receptors expressed in Chinese hamster 
ovary (CHO) cells (Table 10). The absence of a carbonyl group between indole 
and piperazine rings led to derivatives (compound 69a: hA2A AR Ki > 30 µM; 
compound 70a: hA2A AR Ki = 34.4 µM) displaying decreased affinity at A2A 
receptor, in comparison with the corresponding compounds (compound 69: 
hA2A AR Ki = 11.2 µM; compound 70: hA2A AR Ki = 8.71 µM) with a carbonyl 
group therein. This demonstrated the importance of the carbonyl group in 
binding hA2A receptor. In light of the A2A crystal structures in complex with 
antagonists (Figure 51), it was assumed that the carbonyl group of 69 and 70 
acted as the hydrogen bond acceptor with Asn253 of A2A receptor.  
In addition, whilst compounds 69 and 70 exhibited affinity for hA2A receptor, 
further extending the length of the middle linker to three or four carbon atoms 
resulted in a complete loss of A2A affinity (i.e. compounds 71 and 72: hA2A AR 
Ki > 100 µM). This finding provided a clue that the carbon number of the linker 
may need to be limited within two for A2A binding activity.  
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Figure 51. The X-ray crystal structures of A2A receptor in complex with 
ZM241385 (blue sticks) and caffeine (yellow sticks) shows that both 
compounds locate in the same ligand-binding pocket. Hydrogen bonds are 
marked with red dashed lines (Dore et al., 2011) (reprinted with permission).   
 
4.3    Indole C4~C7 Positions of IPP 
4.3.1    Chemical considerations 
In the series of compounds containing IPP scaffold shown in Table 10, 
compounds 69 and 70 were identified to be hA2A receptor binders with Ki of 
8.71~11.2 µM and selectivity ratio > 9 over hA1 and hA3 subtypes. The next 
series of compounds was designed on the basis of the information obtained from 
Table 10, that is, (i) the introduction of a carbonyl group between indole and 
piperazine rings, and (ii) limiting the linker length within two carbons. In 
addition, at that time, it was hypothesised that the hydrogen and methyl group 
at the indole C2 position, as shown in 69 and 70 respectively, did not make 
much difference in affinity for hA2A receptor. Studies on the substitution at the 
indole C4, C5, C6 and C7 positions were therefore conducted. Synthesis of 
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derivatives 73-83 was accomplished by EDC-mediated coupling (Figure 49) 




















aReagents and conditions: (i) indole-3-acid, EDC.HCl, EtOAc, DMF, 23 → 55 
oC, 4.5~17 h, 43~69%. 
 
4.3.2    Experimental methods 
The general synthetic methods and radioligand binding procedures can be found 
under Section 4.2.2. The NMR spectra of compounds 73-83 are listed in 
Appendix S. The HPLC chromatograms of compounds 73-83 are listed in 
Appendix T. 
3‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐4‐methoxy‐1H‐
indole (73). To a brown suspension of 4-methoxyindole-3-carboxylic acid (247 
mg, 1.29 mmol) and EDC.HCl (261 mg, 1.36 mmol) were added EtOAc (20 
mL) and two drops of DMF, and the mixture was stirred for 1.5 h at 23 oC 
followed by the addition of compound 68 (167 mg, 0.87 mmol). The reaction 
was heated at 45–50 oC for 3 h, and solvents were evaporated to dryness under 
high vacuum. Water was added, sonicated, and filtered. The filter cake was 
purified by crystallisation from MeOH/EtOAc (1:1) to provide compound 73 
(219 mg, 69% yield) as a brown powder. 1H NMR (400 MHz, DMSO-d6) δ 
 CHAPTER 4   
129 
 
11.40 (br s, 1H), 7.37 (d, J = 1.2 Hz, 1H), 7.09–7.02 (m, 2H), 6.55 (d, J = 7.2 
Hz, 1H), 6.42 (s, 1H), 3.80–3.68 (2 × br s, 11H), 2.22 (s, 6H). 13C NMR (100 
MHz, DMSO-d6) δ 166.8 (2 × C), 166.3, 161.1, 152.8, 136.9, 124.1, 122.8, 
115.0, 110.4, 109.1, 105.1, 100.1, 55.1, 43.1 (2 × CH2), 40.1–38.9 (2 × CH2),   
23.7 (2 × CH3). HRMS-ESI (m/z) [M + H]+ calcd for C20H24N5O2, 366.1925; 
found, 366.1925 (Δ = -0.2 ppm). [M + Na]+ calcd for C20H23N5NaO2, 388.1744; 
found, 388.1739 (Δ = 1.3 ppm). HPLC (1): t = 8.7 min, 99.2% purity. HPLC 
(3): t = 15.4 min, 99.3% purity. 
1‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]‐2‐(5‐methoxy‐1H‐indol‐
3‐yl)ethan‐1‐one (74). To a suspension of 5-methoxyindole-3-acetic acid (306 
mg, 1.49 mmol) and EDC.HCl (313 mg, 1.63 mmol) were added EtOAc (25 
mL) and two drops of DMF, and the mixture was stirred for 100 min at 23 oC 
followed by the addition of compound 68 (193 mg, 1.01 mmol). The reaction 
was heated at 50 oC for 3 h, and solvents were evaporated to dryness under high 
vacuum. Water was added, sonicated, and filtered. The filter cake was purified 
by crystallisation from MeOH/EtOAc (1:1) to provide compound 74 (222 mg, 
58% yield) as a transparent colourless crystal. 1H NMR (400 MHz, DMSO-d6) 
δ 10.74 (br s, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 2.4 Hz, 1H), 7.08 (d, J 
= 2.4 Hz, 1H), 6.72 (dd, J = 8.8, 2.4 Hz, 1H), 6.41 (s, 1H), 3.78 (s, 2H), 3.74 (s, 
3H), 3.66–3.64 (m, 2H), 3.56–3.52 (m, 6H), 2.21 (s, 6H). 13C NMR (100 MHz, 
DMSO-d6) δ 169.6, 166.8 (2 × C), 161.1, 153.1, 131.3, 127.5, 124.2, 112.0, 
111.2, 109.2, 107.8, 100.7, 55.4, 45.4, 43.4, 43.1, 41.1, 30.9, 23.7 (2 × CH3). 
HRMS-ESI (m/z) [M + H]+ calcd for C21H26N5O2, 380.2081; found, 380.2078 
(Δ = 0.8 ppm). [M + Na]+ calcd for C21H25N5NaO2, 402.1900; found, 402.1890 
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(Δ = 2.5 ppm). HPLC (1): t = 8.5 min, 96.4% purity. HPLC (3): t = 14.8 min, 
98.8% purity. 
2‐(5‐Bromo‐1H‐indol‐3‐yl)‐1‐[4‐(4,6‐dimethylpyrimidin‐2‐yl)piperazin‐1‐
yl]ethan‐1‐one (75). To a suspension of 5-bromoindole-3-acetic acid (250 mg, 
0.98 mmol) and EDC.HCl (199 mg, 1.04 mmol) were added EtOAc (25 mL) 
and two drops of DMF, and the mixture was stirred for 1 h at 23 oC followed by 
the addition of compound 68 (125 mg, 0.65 mmol). The reaction was heated at 
50–55 oC for 3.5 h, and solvents were evaporated to dryness under high vacuum. 
Water was added, sonicated, and filtered. The filter cake was purified by 
crystallisation from MeOH/EtOAc (1:1) to provide compound 75 (128 mg, 46% 
yield) as a white shiny crystal. 1H NMR (400 MHz, DMSO-d6) δ 11.12 (br s, 
1H), 7.76 (d, J = 1.6 Hz, 1H), 7.33–7.30 (m, 2H), 7.17 (dd, J = 8.4, 2.0 Hz, 1H), 
6.42 (s, 1H), 3.81 (s, 2H), 3.67–3.65 (m, 2H), 3.60 (s, 4H), 3.53–3.51 (m, 2H), 
2.22 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 169.2, 166.8 (2 × C), 161.0, 
134.9, 129.1, 125.4, 123.5, 121.2, 113.4, 111.1, 109.1, 108.0, 45.3, 43.4, 43.1, 
41.1, 30.5, 23.7 (2 × CH3). HRMS-ESI (m/z) [M + H]+ calcd for C20H23BrN5O, 
428.1080; found, 428.1083 (Δ = -0.5 ppm). [M + Na]+ calcd for 
C20H22BrN5NaO, 450.0900; found, 450.0899 (Δ = 0.3 ppm). HPLC (1): t = 11.7 
min, 97.4% purity. HPLC (3): t = 16.4 min, 99.0% purity.  
3‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐5‐methoxy‐1H‐
indole (76). To a suspension of 5-methoxyindole-3-carboxylic acid (338 mg, 
1.77 mmol) and EDC.HCl (381 mg, 1.99 mmol) were added EtOAc (20 mL) 
and two drops of DMF, and the mixture was stirred for 75 min at 23 oC followed 
by the addition of compound 68 (229 mg, 1.19 mmol). The reaction was heated 
at 50 oC for 4.5 h, and solvents were evaporated to dryness under high vacuum. 
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Water was added, sonicated, and filtered to provide compound 76 (206 mg, 47% 
yield) as a light yellow shiny transparent crystal. 1H NMR (400 MHz, DMSO-
d6) δ 11.50 (br s, 1H), 7.68 (s, 1H), 7.33 (d, J = 8.8 Hz, 1H), 7.21 (d, J = 2.4 Hz, 
1H), 6.80 (dd, J = 8.8, 2.4 Hz, 1H), 6.44 (s, 1H), 3.83–3.80 (m, 4H), 3.76 (s, 
3H), 3.71–3.69 (m, 4H), 2.24 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 166.8 
(2 × C), 165.9, 161.1, 154.3, 130.7, 128.5, 126.8, 112.7, 112.3, 109.3, 109.1, 
101.8, 55.3, 43.6 (2 × CH2), 40.1–38.9 (2 × CH2), 23.7 (2 × CH3). HRMS-ESI 
(m/z) [M + H]+ calcd for C20H24N5O2, 366.1925; found, 366.1930 (Δ = -1.4 
ppm). [M + Na]+ calcd for C20H23N5NaO2, 388.1744; found, 388.1742 (Δ = 0.4 
ppm). HPLC (1): t = 8.4 min, 99.6% purity. HPLC (3): t = 15.2 min, 99.0% 
purity. 
2‐(5‐Bromo‐7‐fluoro‐2‐methyl‐1H‐indol‐3‐yl)‐1‐[4‐(4,6-
dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]ethan‐1‐one (77). To a suspension of 
(5-bromo-7-fluoro-2-methyl-1H-indol-3-yl)acetic acid (240 mg, 0.84 mmol) 
and EDC.HCl (232 mg, 1.21 mmol) were added EtOAc (20 mL) and two drops 
of DMF, and the mixture was stirred for 1 h at 23 oC followed by the addition 
of compound 68 (108 mg, 0.56 mmol). The reaction was heated at 50 oC for 4 
h, and solvents were evaporated to dryness under high vacuum. Water was 
added, sonicated, and filtered. The filter cake was purified by crystallisation 
from MeOH/EtOAc (9:1) to provide compound 77 (130 mg, 50% yield) as a 
dark brown crystal. 1H NMR (400 MHz, DMSO-d6) δ 11.53 (br s, 1H), 7.48 (d, 
J = 1.2 Hz, 1H), 7.04 (dd, J = 10.4, 1.2 Hz, 1H), 6.43 (s, 1H), 3.75 (s, 2H), 3.66– 
3.64 (m, 2H), 3.61–3.59 (m, 2H), 3.55–3.53 (m, 4H), 2.34 (s, 3H), 2.25 (s, 6H). 
13C NMR (100 MHz, DMSO-d6) δ 169.5, 167.3 (2 × C), 161.4, 148.5 (d, J = 
245.7 Hz, C-F), 136.5, 133.8 (d, J = 7.3 Hz), 122.1 (d, J = 13.2 Hz, F-C-C-NH), 
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117.3 (d, J = 2.9 Hz), 109.8 (d, J = 8.0 Hz), 109.6, 108.7 (d, J = 20.4 Hz, F-C-
C-H), 105.9 (d, J = 2.2 Hz), 45.5, 43.8, 43.6, 41.7, 29.7, 24.1 (2 × CH3), 11.9. 
HRMS-ESI (m/z) [M + H]+ calcd for C21H24BrFN5O, 460.1143; found, 
460.1132 (Δ = 2.3 ppm). [M + Na]+ calcd for C21H23BrFN5NaO, 482.0962; 
found, 482.0950 (Δ = 2.5 ppm). HPLC (1): t = 13.3 min, 95.9% purity. HPLC 
(3): t = 17.2 min, 96.5% purity. 
1‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]‐2‐(5‐fluoro‐2‐methyl‐
1H‐indol‐3‐yl)ethan‐1‐one (78). To a suspension of (5-fluoro-2-methyl-1H-
indol-3-yl)acetic acid (243 mg, 1.17 mmol) and EDC.HCl (245 mg, 1.28 mmol) 
were added EtOAc (20 mL) and two drops of DMF, and the mixture was stirred 
for 1 h at 23 oC followed by the addition of compound 68 (152 mg, 0.79 mmol). 
The reaction was heated at 50 oC for 4 h, and solvents were evaporated to 
dryness under high vacuum. Water was added, sonicated, and filtered. The filter 
cake was purified by crystallisation from MeOH/EtOAc (6:5) to provide 
compound 78 (133 mg, 44% yield) as a transparent colourless crystal. 1H NMR 
(400 MHz, DMSO-d6) δ 10.92 (br s, 1H), 7.22–7.19 (m, 2H), 6.79 (td, J = 9.2, 
2.4 Hz, 1H), 6.41 (s, 1H), 3.73 (s, 2H), 3.63–3.62 (m, 2H), 3.52 (s, 6H), 2.33 (s, 
3H), 2.21 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 169.4, 166.8 (2 × C), 
161.0, 156.7 (d, J = 228.9 Hz, C-F), 135.0, 131.7, 128.6 (d, J = 10.2 Hz), 111.1 
(d, J = 9.5 Hz), 109.1, 107.7 (d, J = 25.6 Hz, F-C-C-H), 104.5 (d, J = 4.3 Hz), 
102.7 (d, J = 23.3 Hz, F-C-C-H), 45.2, 43.3, 43.2, 41.2, 29.7, 23.7 (2 × CH3), 
11.6. HRMS-ESI (m/z) [M + H]+ calcd for C21H25FN5O, 382.2038; found, 
382.2042 (Δ = -1.2 ppm). [M + Na]+ calcd for C21H24FN5NaO, 404.1857; found, 
404.1852 (Δ = 1.2 ppm). HPLC (1): t = 10.1 min, 99.7% purity. HPLC (3): t = 
15.8 min, 98.7% purity. 




yl)ethan‐1‐one (79). To a suspension of 5-fluoro-1H-indole-3-acetic acid (328 
mg, 1.70 mmol) and EDC.HCl (345 mg, 1.80 mmol) were added EtOAc (20 
mL) and two drops of DMF, and the mixture was stirred for 2.5 h at 23 oC 
followed by the addition of compound 68 (218 mg, 1.14 mmol). The reaction 
was heated at 45–50 oC for 3 h, and solvents were evaporated to dryness under 
high vacuum. Water was added, sonicated, and filtered. The filter cake was 
purified by crystallisation from MeOH/EtOAc (2:1) to provide compound 79 
(237 mg, 57% yield) as a white shiny crystal. 1H NMR (400 MHz, DMSO-d6) 
δ 11.01 (br s, 1H), 7.35–7.30 (m, 3H), 6.91 (td, J = 9.2, 2.4 Hz, 1H), 6.42 (s, 
1H), 3.79 (s, 2H), 3.66–3.64 (m, 2H), 3.58 (s, 4H), 3.53–3.51 (m, 2H), 2.21 (s, 
6H). 13C NMR (100 MHz, DMSO-d6) δ 169.3 (2 × C), 166.8, 161.1, 156.7 (d, J 
= 229.6 Hz, C-F), 132.8, 127.5 (d, J = 10.2 Hz), 125.8, 112.3 (d, J = 9.5 Hz), 
109.21 (d, J = 25.6 Hz, F-C-C-H), 109.18, 108.4 (d, J = 4.4 Hz), 103.5 (d, J = 
23.3 Hz, F-C-C-H), 45.4, 43.5, 43.1, 41.1, 30.7, 23.7 (2 × CH3). HRMS-ESI 
(m/z) [M + H]+ calcd for C20H23FN5O, 368.1881; found, 368.1889 (Δ = -2.2 
ppm). [M + Na]+ calcd for C20H22FN5NaO, 390.1701; found, 390.1696 (Δ = 1.2 
ppm). HPLC (1): t = 9.6 min, 99.4% purity. HPLC (3): t = 15.5 min, 99.0% 
purity. 
5‐Chloro‐3‐[4‐(4,6‐dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐1H‐
indole (80). To a suspension of 5-chloroindole-3-carboxylic acid (248 mg, 1.27 
mmol) and EDC.HCl (269 mg, 1.40 mmol) were added EtOAc (20 mL) and two 
drops of DMF, and the mixture was stirred for 1 h at 23 oC followed by the 
addition of compound 68 (165 mg, 0.86 mmol). The reaction was heated at 45– 
50 oC for 16 h, and solvents were evaporated to dryness under high vacuum. 
 CHAPTER 4   
134 
 
Water was added, sonicated, and filtered. The filter cake was purified by 
crystallisation from MeOH/EtOAc (1:1) to provide compound 80 (137 mg, 43% 
yield) as a pink crystal. 1H NMR (400 MHz, DMSO-d6) δ 11.83 (br s, 1H), 7.83 
(s, 1H), 7.76 (dd, J = 2.0, 0.4 Hz, 1H), 7.47 (dd, J = 8.8, 0.4 Hz, 1H), 7.17 (dd, 
J = 8.4, 2.0 Hz, 1H), 6.44 (s, 1H), 3.82–3.80 (m, 4H), 3.73–3.70 (m, 4H), 2.24 
(s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 167.3 (2 × C), 165.5, 161.6, 134.7, 
130.0, 128.1, 125.4, 122.5, 120.1, 114.0, 109.61, 109.57, 43.9 (2 × CH2), 40.6– 
39.3 (2 × CH2), 24.2 (2 × CH3). HRMS-ESI (m/z) [M + H]+ calcd for 
C19H21ClN5O, 370.1429; found, 370.1433 (Δ = -0.9 ppm). [M + Na]+ calcd for 
C19H20ClN5NaO, 392.1249; found, 392.1245 (Δ = 0.9 ppm). HPLC (1): t = 10.9 
min, 99.1% purity. HPLC (3): t = 16.6 min, 98.1% purity. 
1‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]‐2‐(6‐fluoro‐1H‐indol‐3‐
yl)ethan‐1‐one (81). To a suspension of 6-fluoroindole-3-acetic acid (244 mg, 
1.27 mmol) and EDC.HCl (265 mg, 1.38 mmol) were added EtOAc (20 mL) 
and two drops of DMF, and the mixture was stirred for 70 min at 23 oC followed 
by the addition of compound 68 (165 mg, 0.86 mmol). The reaction was heated 
at 50 oC for 4.5 h, and solvents were evaporated to dryness under high vacuum. 
Water was added, sonicated, and filtered. The filter cake was purified by 
crystallisation from MeOH/EtOAc (8:5) to provide compound 81 (179 mg, 57% 
yield) as a light brown, clear crystal. 1H NMR (400 MHz, DMSO-d6) δ 10.97 
(br s, 1H), 7.56 (dd, J = 8.8, 5.6 Hz, 1H), 7.24 (d, J = 2.0 Hz, 1H), 7.11 (dd, J = 
10.0, 2.4 Hz, 1H), 6.86–6.81 (m, 1H), 6.42 (s, 1H), 3.81 (s, 2H), 3.66–3.63 (m, 
2H), 3.58 (s, 4H), 3.53–3.50 (m, 2H), 2.21 (s, 6H). 13C NMR (100 MHz, 
DMSO-d6) δ 169.8, 167.2 (2 × C), 161.5, 159.3 (d, J = 232.6 Hz, C-F), 136.4 
(d, J = 12.4 Hz), 124.6 (d, J = 3.7 Hz), 124.5, 120.3 (d, J = 10.2 Hz), 109.6, 
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108.9, 107.3 (d, J = 24.1 Hz, F-C-C-NH), 97.7 (d, J = 24.8 Hz, F-C-C-NH), 
45.8, 43.9, 43.6, 41.6, 31.2, 24.1 (2 × CH3). HRMS-ESI (m/z) [M + H]+ calcd 
for C20H23FN5O, 368.1881; found, 368.1879 (Δ = 0.6 ppm). [M + Na]+ calcd 
for C20H22FN5NaO, 390.1701; found, 390.1689 (Δ = 2.9 ppm). HPLC (1): t = 
9.6 min, 99.8% purity. HPLC (3): t = 15.6 min, 99.0% purity. 
3‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐7‐methoxy‐1H‐
indole (82). To a suspension of 7-methoxy-1H-indole-3-carboxylic acid (292 
mg, 1.53 mmol) and EDC.HCl (309 mg, 1.61 mmol) were added EtOAc (20 
mL) and two drops of DMF, and the mixture was stirred for 1 h at 23 oC 
followed by the addition of compound 68 (198 mg, 1.03 mmol). The reaction 
was heated at 50 oC for 3.5 h, and solvents were evaporated to dryness under 
high vacuum. Water was added, sonicated, and filtered to provide compound 82 
(215 mg, 57% yield) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ 
11.75 (br s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 7.29 (d, J = 7.2 Hz, 1H), 7.02 (t, J = 
8.0 Hz, 1H), 6.73 (d, J = 7.6 Hz, 1H), 6.44 (s, 1H), 3.93 (s, 3H), 3.81–3.78 (m, 
4H), 3.69–3.66 (m, 4H), 2.24 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 166.8 
(2 × C), 165.8, 161.1, 146.3, 127.6, 127.4, 125.9, 120.9, 112.9, 110.3, 109.1, 
102.4, 55.3, 43.5 (2 × CH2), 40.1–38.9 (2 × CH2), 23.7 (2 × CH3). HRMS-ESI 
(m/z) [M + H]+ calcd for C20H24N5O2, 366.1925; found, 366.1920 (Δ = 1.2 ppm). 
[M + Na]+ calcd for C20H23N5NaO2, 388.1744; found, 388.1733 (Δ = 2.9 ppm). 
HPLC (1): t = 9.5 min, 99.8% purity. HPLC (3): t = 15.9 min, 99.3% purity. 
1‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazin‐1‐yl]‐2‐(1H‐indol‐3‐yl)ethan‐
1‐one (83). To a suspension of indole-3-acetic acid (672 mg, 3.84 mmol) and 
EDC.HCl (774 mg, 4.04 mmol) were added EtOAc (30 mL) and two drops of 
DMF, and the mixture was stirred for 3 h at 23 oC followed by the addition of 
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compound 68 (493 mg, 2.56 mmol). The reaction was heated at 50 oC for 3.5 h, 
and solvents were evaporated to dryness under high vacuum. Water was added, 
sonicated, and filtered. The filter cake was purified by crystallisation from 
EtOH/EtOAc (1:1) to provide compound 83 (414 mg, 46% yield) as a white 
crystal. 1H NMR (400 MHz, DMSO-d6) δ 10.90 (br s, 1H), 7.58 (d, J = 7.6 Hz, 
1H), 7.34 (d, J = 8.4 Hz, 1H), 7.24 (d, J = 2.0 Hz, 1H), 7.07 (td, J = 7.4, 0.8 Hz, 
1H), 6.97 (td, J = 7.4, 0.8 Hz, 1H), 6.41 (s, 1H), 3.81 (s, 2H), 3.66–3.63 (m, 
2H), 3.57 (s, 4H), 3.53–3.51 (m, 2H), 2.21 (s, 6H). 13C NMR (100 MHz, 
DMSO-d6) δ 169.4, 166.8 (2 × C), 161.0, 136.1, 127.1, 123.5, 121.1, 118.8, 
118.4, 111.3, 109.1, 108.1, 45.4, 43.4, 43.1, 41.1, 30.9, 23.7 (2 × CH3). HRMS-
ESI (m/z) [M + H]+ calcd for C20H24N5O, 350.1975; found, 350.1980 (Δ = -1.4 
ppm). [M + Na]+ calcd for C20H23N5NaO, 372.1795; found, 372.1794 (Δ = 0.2 
ppm). HPLC (1): t = 9.2 min, 97.5% purity. HPLC (3): t = 15.3 min, 99.2% 
purity. 
 
4.3.3    Results and discussion 
The binding affinity of compounds 73-83 at adenosine receptor subtypes is 
given in Table 11. The hydrogen atoms at the indole C4, C5, C6 and C7 
positions were replaced with substituent groups, including halogens and 
methoxy group, to study the effects on hA2A binding affinity. Compound 73 
represents C4-substituted indolyl analogue, compounds 74-80 represent C5-
substituted indolyl analogues, compound 81 represents C6-substituted indolyl 
analogue, and compound 82 represents C7-substituted indolyl analogue. In the 
first place, it was found that simply replacing the hydrogen (-H) at the indole 
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C4, C5, C6 and C7 positions with methoxy (-OCH3), bromine (-Br), fluorine (-
F) and chlorine (-Cl) did not significantly enhance the binding affinity at hA2A 
receptor compared to that displayed by compounds 69 and 70. At the indole C4 
position, the introduction of a methoxy group (compound 73: hA2A AR Ki = 18.8 
µM) did not produce an appreciable difference in hA2A binding from the 
corresponding derivative without methoxy substitution (i.e. compound 69: hA2A 
AR Ki = 11.2 µM). At the indole C-5 position, the effects of methoxy group, 
fluorine, chlorine and bromine substitution were studied. Similar to the indole 
C4 position, the introduction of a methoxy group at the indole C5 position 
generated compounds with comparable hA2A affinity to the corresponding ones 
with a hydrogen atom on the same position (i.e. 74 versus 83; 76 versus 69). 
There was also no noticeable variation in hA2A activity in reference to 
substitution with either fluorine (i.e. 78 versus 70; 79 versus 83) or chlorine (i.e. 
80 versus 69). However, the presence of bromine at the indole C5 position was 
detrimental for affinity at hA2A receptor (e.g. compound 75: hA2A AR Ki > 100 
µM in comparison with compound 83: hA2A AR Ki = 27.6 µM). In fact, halogen 
substitution can potentially have steric, electronic and lipophilic effects on the 
whole compound, thereby influencing biological activity of that compound. 
Steric effects of halogenation refer to the creation of constraints or imposing 
certain conformations so as to either favour or disfavour ligand-receptor 
interactions. This is due to the larger size of halogens than that of hydrogen 
(Table 12). It is therefore probable that bromine at the indole C5 position created 
a steric clash with adjacent residues and prevented the ligand from accessing to 
the ligand-binding pocket. The electronic effects of halogenation are based on 
the inductive electron-withdrawing property of halogens. Although halogens 
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with higher electronegativity, such as fluorine and chlorine, create dipole 
moment in C-X bond (X = halogen) and decrease the electron density of the 
indole ring, there was no apparent change in hA2A binding, excluding the 
electronic effect of bromine on the inactivity of 75 and 77. The contribution of 
a halogen to the lipophilicity of a compound can be described by Hansch’s π 
parameter (Table 12). The reduction of affinity by introducing bromine at the 
indole C5 position can then also be explained by the highly non-polar property 
of 75 and 77. Taken together, two possibilities account for the loss of affinity 
exhibited by 75 and 77: (i) the large size of bromine, and (ii) the non-polarity 
contributed by bromine. It was therefore speculated that the receptor 
environment near the indole C5 position is either a relatively small, or a 
relatively polar, or both, cavity. More analogues with different substituents at 
the indole C5 position need to be made to prove or disprove this speculation.  
At the indole C6 position, the introduction of fluorine did not show significant 
change in hA2A affinity (i.e. 81 versus 83). Surprisingly, methoxy group 
substitution at the indole C7 position led to a 3-fold improvement in hA2A 
affinity (i.e. compound 82: hA2A AR Ki = 3.63 µM versus compound 69: hA2A 
AR Ki = 11.2 µM). The enhanced binding observed in compound 82 could be 
attributed to either the oxygen atom of the methoxy substituent participating in 
hydrogen bonds as proton acceptor, or the methyl group of the methoxy 
substituent being stabilised by hydrophoblic interactions with neighbouring 
residues, or both. It was recently shown that methoxy substituent on 
methoxyindole isomers caused changes in the π-delocalization of the indole ring 
(Lopes Jesus and Redinha, 2014), so the increased affinity exhibited by 
compound 82 may also due to the alteration of interactions (e.g. hydrophobic, 
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electrostatic) associated with the indole ring. It will be an interesting future 
direction to explore the SAR at the indole C7 position for optimising hA2A 
affinity.  
Comparison of the hA2A binding affinity of 83 with that of 69 and 70 gave two 
pieces of information. First (comparing 83 with 69), a 2.5-fold reduction of 
affinity (i.e. compound 69: hA2A AR Ki = 11.2 µM versus compound 83: hA2A 
AR Ki = 27.6 µM) was observed when an methylene group was introduced 
between indole and carbonyl group of 69, implying that one carbon for the 
linker may be optimal for binding. Second (comparing 83 with 70), the 3.2-fold 
decrease in affinity (i.e. compound 70: hA2A AR Ki = 8.71 µM versus compound 
83: hA2A AR Ki = 27.6 µM) occurred in the absence of the methyl group at the 
indole C2 position, suggesting that that methyl group contributed binding to a 
certain extent. It can therefore be deduced that the slightly higher affinity shown 
by 70 than that shown by 69 was contributed by the additional methyl group of 
70, not by the extra methylene group of 70. To conclude the SARs shown in 
Tables 10 and 11, it seems that 2-methyl-7-methoxyindole linked to 68 by a 
carbonyl group is the best combination, making it attractive to synthesise 84 in 
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Table 12. The Size and Lipophilicity of Hydrogen and Halogensa 
atom van der Waals radii Hansch’s π parameter 
H 1.20 0.00 
F 1.47 0.14 
Cl 1.75 0.71 
Br 1.85 0.86 










comparison of 82 with 69
info from 
i) Table 10
ii) comparison of 83 with 69
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Figure 52. Proposed compound 84 for future synthesis. 
 
4.4    Indole C2 Positions of IPP     
4.4.1    Chemical considerations 
The revelation of the importance of the methyl group at the indole C2 position 
motivated us to put a phenyl group at the same position, leading to the synthesis 
of compound 90 (Scheme 3). Ethyl ester 86 was readily prepared from indole-
3-acetic acid 85 in the acidic condition using EtOH as the solvent (95% yield). 
N-bromosuccinimide, freshly recrystallised from water, was used to brominate 
compound 86 at the C2 position to yield bromoester 87 (59% yield), followed 
by protection of indole NH with butyloxycarbonyl (Boc) group (91% yield). 
The protected indolyl bromide 88 was coupled with phenylboronic acid using 
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Pd(PPh3)4 (15 mol%) as the catalyst, Na2CO3 as the base, dioxane/H2O (3:1) as 
the solvent, under traditional heating conditions of Suzuki reaction (Miyaura 
and Suzuki, 1995) to generate compound 89 in 69% yield. The catalytic cycle 
for Suzuki coupling is shown in Figure 53. The cycle is composed of three major 
steps: (i) oxidative addition, (ii) transmetalation, and (iii) reductive elimination. 
Oxidative addition of aryl bromide 88 to 
tetrakis(triphenylphosphine)palladium(0) complex affords a stable 
palladium(II) complex 88a. Transmetalation refers to the transfer of the phenyl 
group in phenylboronic acid to palladium in 88a, forming a new palladium(II) 
complex 88b. Transmetalation is generally facilitated by the presence of bases, 
such as Na2CO3 in the synthesis of 89, which are able to quaternise the boron 
atom so as to enhance the nucleophilicity of B–Ph. The final step, reductive 
elimination, reproduces tetrakis(triphenylphosphine)palladium(0) complex and 
forms the desired product 89. The subsequent acid-promoted Boc deprotection, 
saponification, and amide formation resulted in the target compound 90 with an 
overall yield of 64% (3 steps). At the moment of this writing, the binding 
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aReagents and conditions: (i) conc. H2SO4, EtOH, reflux, 23 h, 95%; (ii) NBS, 
CH2Cl2, dark, 0 oC, 2 h, 59%; (iii) (Boc)2O, Et3N, DMAP, CH2Cl2, 23 oC, 1 h, 
91%; (iv) PhB(OH)2, Pd(PPh3)4, Na2CO3, dioxane, H2O, 80 oC, 18 h, 69%; (v) 
TFA, CH2Cl2, 0 → 23 oC, 28 h; (vi) KOH, H2O, MeOH, EtOH, 23 oC, 19.5 h; 




















B(OH)2Ph OH (from Na2CO3)
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Figure 53. The catalytic cycle for synthesis of 89. 
 
An additional study at the indole C2 position was to link 68 to the indole C2 
position for understanding the differences between indole C2 and C3 extensions 
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in affinity at hA2A receptor. Since the importance of one carbonyl group 
between indole and piperazine has been shown for indole-3-substituted 
derivatives (summarised in Figure 52), indole-2-acids with one carbonyl group 


















aReagents and conditions: (i) indole-2-carboxylic acids, EDC.HCl, EtOAc, 
DMF, 23 → 40 oC, 7 h, 16~36%. 
 
4.4.2    Experimental methods 
The general synthetic methods and radioligand binding procedures can be found 
under Section 4.2.2. The NMR spectra of compounds 86-95 are listed in 
Appendix U. The HPLC chromatograms of compounds 90-95 are listed in 
Appendix V. 
Ethyl 2-(1H-indol-3-yl)acetate (86). To a clear solution of indole-3-acetic acid 
(1014 mg, 5.79 mmol) in EtOH (25 mL) was added dropwise concentrated 
H2SO4 (1 mL) at 23 oC, and the mixture was refluxed under N2 for 20 h. The 
TLC analysis showed that the starting material still existed in the reaction 
mixture, so another 1 mL of concentrated H2SO4 was added dropwise at 23 oC. 
The reaction was refluxed for another 3 h to consume the remaining starting 
materials. The resulting clear, light purple solution was cooled to 0 oC, and 
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saturated aqueous NaHCO3 was added dropwise until the pH value was 7. 
EtOAc was added, and the aqueous phase was extracted with EtOAc (3 × 30 
mL). The combined organic layers were washed with brine (50 mL), dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification by flash 
chromatography (hexanes → 10% EtOAc/hexanes) afforded compound 86 
(1117 mg, 95% yield) as a brown oil. 1H NMR (400 MHz, DMSO-d6) δ 10.93 
(br s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.35 (dt, J = 8.0, 0.8 Hz, 1H), 7.24 (d, J = 
2.4 Hz, 1H), 7.08 (td, J = 6.8, 1.2 Hz, 1H), 6.98 (td, J = 6.8, 1.2 Hz, 1H), 4.07 
(q, J = 7.2 Hz, 2H), 3.72 (s, 2H), 1.18 (t, J = 7.2 Hz, 3H).  
Ethyl 2-(2-bromo-1H-indol-3-yl)acetate (87). To a stirred, clear, light-
brownish solution of compound 86 (1114  mg, 5.49 mmol) in anhydrous CH2Cl2 
(20 mL) at 0 oC in the dark was added N-bromosuccinimide (976 mg, 5.49 
mmol; recrystallised from water), and the mixture was stirred at 0 oC for 2 h. 
The solvent was evaporated, and the resulting purple oil was subjected to 
purification by flash chromatography (hexanes → 7.5% EtOAc/hexanes) 
afforded compound 87 (912 mg, 59% yield) as a yellow oil. 1H NMR (400 MHz, 
DMSO-d6) δ 11.78 (br s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 
7.10 (t, J = 7.2 Hz, 1H), 7.02 (t, J = 7.2 Hz, 1H), 4.07 (q, J = 7.2 Hz, 2H), 3.69 
(s, 2H), 1.17 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 170.4, 136.0, 
127.2, 121.6, 119.3, 118.0, 110.7, 109.9, 107.2, 60.2, 30.3, 14.1.  
tert-Butyl 2-bromo-3-(2-ethoxy-2-oxoethyl)-1H-indole-1-carboxylate (88). 
To a stirred, clear yellow solution of compound 87 (884 mg, 3.14 mmol) and 
di-tert-butyl dicarbonate (917 mg, 4.08 mmol) in anhydrous CH2Cl2 at 23 oC 
(20 mL) were added triethylamine (1094 µL, 7.85 mmol) and 4-
(dimethylamino)pyridine (21 mg, 0.17 mmol), and the resulting yellow solution 
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was stirred at 23 oC for 1 h. Water was added, and the aqueous phase was 
extracted with CH2Cl2 (3 × 40 mL). The combined organic layers were washed 
with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Purification by flash chromatography (hexanes → 3% 
EtOAc/hexanes) afforded compound 88 (1093 mg, 91% yield) as a clear oil. 1H 
NMR (400 MHz, DMSO-d6) δ 7.99 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 7.6 Hz, 
1H), 7.34 (t, J = 7.2 Hz, 1H), 7.26 (t, J = 7.2 Hz, 1H), 4.09 (q, J = 7.2 Hz, 2H), 
3.80 (s, 2H), 1.65 (s, 9H), 1.18 (t, J = 7.2 Hz, 3H).   
tert-Butyl 3-(2-ethoxy-2-oxoethyl)-2-phenyl-1H-indole-1-carboxylate (89). 
Compound 88 (233 mg, 0.61 mmol), phenylboronic acid (113 mg, 0.92 mmol), 
and tetrakis(triphenylphosphine)palladium(0) (108 mg, 0.0915 mmol) were put 
in a two-neck round-bottom flask, and the mixture was evacuated/refilled with 
N2 gas. A solution of degassed Na2CO3 (5 mL, 2M aqueous solution) and 
dioxane (15 mL) was added to the mixture and heated at 80 oC under nitrogen 
for 18 h. The mixture was cooled to 23 oC and solids were removed by filtration 
through Celite. The filtrate was concentrated under reduced pressure and 
chromatographed on silica gel (eluent: hexanes → 2.5% EtOAc/hexanes) to 
give compound 89 (160 mg, 69% yield) as a white solid. 1H NMR (400 MHz, 
DMSO-d6) δ 8.13 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.51–7.42 (m, 
3H), 7.39–7.35 (m, 3H), 7.29 (t, J = 7.2 Hz, 1H), 4.04 (q, J = 7.2 Hz, 2H), 3.53 
(s, 2H), 1.18 (s, 9H), 1.14 (t, J = 7.2 Hz, 3H). 
1-[4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl]-2-(2-phenyl-1H-indol-3-
yl)ethan-1-one (90). To a colourless solution of compound 89 (45 mg, 0.12 
mmol) in CH2Cl2 (3 mL) at 0 oC was added trifluoroacetic acid (50 µL, 0.65 
mmol), and the mixture was stirred at 0 oC for 10 min before it was warmed to 
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23 oC. After 1 h, trifluoroacetic acid (50 µL) was added. After 4 h, 
trifluoroacetic acid (100 µL) was added. After 17 h, trifluoroacetic acid (100 
µL) was added. After 6 h, the TLC analysis showed the full consumption of 
compound 89, and the reaction mixture was cooled to 0 oC with slow stirring. 
Saturated aqueous NaHCO3 was added dropwise to the mixture until the pH 
value was approximately 8–9. The layers were separated, and the aqueous phase 
was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were 
washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure to obtain an off-white solid (32 mg; ESI-MS (m/z): 280.5 
[M+H]+, 278.0 [M-H]-) which was dissolved in MeOH (6 mL) and EtOH (3 
mL). The aqueous 0.1M KOH solution (6 mL) was added, and the resulting 
slightly turbid solution was stirred at 23 oC for 19.5 h (ESI-MS (m/z): 250.0 [M-
H]-). The reaction was cooled to 0 oC, and 1N aqueous HCl was added dropwise 
until the pH value was approximately 7. Solvents were removed under reduced 
pressure to give a white solid (29 mg, 0.12 mmol) which was mixed with 
EDC.HCl (30 mg, 0.16 mmol), EtOAc (12 mL), and four drops of DMF. The 
mixture was stirred for 2 h at 23 oC, and compound 68 (18 mg, 0.09 mmol) was 
added. The reaction was stirred at 50 oC for 3 h, and solvents were evaporated 
to dryness under high vacuum. Purification by flash chromatography (1:3 → 
1:2 EtOAc/hexanes) afforded compound 90 (33 mg, 64% yield over three steps) 
as a clear oil. 1H NMR (400 MHz, DMSO-d6) δ 11.27 (br s, 1H), 7.63–7.60 (m, 
2H), 7.53–7.50 (m, 3H), 7.41–7.36 (m, 2H), 7.10 (td, J = 7.6, 1.2 Hz, 1H), 6.99 
(td, J = 7.6, 1.2 Hz, 1H), 6.43 (s, 1H), 3.92 (s, 2H), 3.64–3.63 (m, 2H), 3.53– 
3.50 (m, 6H), 2.22 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 169.3, 166.7 (2 
× C), 160.9, 135.9, 135.3, 132.6, 128.9, 128.7 (2 × CH), 127.9 (2 × CH), 127.5, 
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121.5, 118.9, 118.7, 111.1, 109.1, 105.8, 45.0, 43.3, 43.2, 41.3, 29.9, 23.7 (2 × 
CH3). ESI-MS (m/z): 426.7 [M+H]+, 424.8 [M-H]-. HPLC (2): t = 12.9 min, 
97.0% purity.          
2‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐1H‐indole (91). 
To a suspension of indole-2-carboxylic acid (500 mg, 3.10 mmol) and EDC.HCl 
(713 mg, 3.72 mmol) were added EtOAc (30 mL) and two drops of DMF, and 
the mixture was stirred for 1 h at 23 oC followed by the addition of compound 
68 (596 mg, 3.10 mmol). The reaction was heated at 40 oC for 6 h, and solvents 
were evaporated to dryness under high vacuum. Water was added, sonicated, 
and filtered. The filter cake was purified by crystallisation from MeOH/EtOAc 
to provide compound 91 (241 mg, 23% yield) as a clear crystal. 1H NMR (400 
MHz, DMSO-d6) δ 11.60 (br s, 1H), 7.62 (dd, J = 8.0, 0.4 Hz, 1H), 7.43 (dd, J 
= 8.0, 0.4 Hz, 1H), 7.21–7.17 (m, 1H), 7.07–7.03 (m, 1H), 6.86 (dd, J = 2.0, 0.8 
Hz, 1H), 6.46 (s, 1H), 3.84 (br s, 8H), 2.25 (s, 6H). 13C NMR (100 MHz, 
DMSO-d6) δ 166.9 (2 × C), 162.2, 161.0, 136.0, 129.8, 126.9, 123.3, 121.4, 
119.8, 112.1, 109.2, 104.3, 43.4 (2 × CH2), 40.1–38.9 (2 × CH2), 23.7 (2 × CH3). 
HRMS-ESI (m/z) [M + H]+ calcd for C19H22N5O, 336.1819; found, 336.1821 
(Δ = -0.8 ppm). [M + Na]+ calcd for C19H21N5NaO, 358.1638; found, 358.1634 
(Δ = 1.1 ppm). HPLC (1): t = 11.3 min, 95.0% purity. HPLC (3): t = 16.5 min, 
99.3% purity.  
2‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐5‐fluoro‐1H‐
indole (92). To a suspension of 5-fluoroindole-2-carboxylic acid (100 mg, 0.56 
mmol) and EDC.HCl (130 mg, 0.67 mmol) were added EtOAc (16 mL) and two 
drops of DMF, and the mixture was stirred for 1 h at 23 oC followed by the 
addition of compound 68 (107 mg, 0.56 mmol). The reaction was heated at 40 
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oC for 6 h, and solvents were evaporated to dryness under high vacuum. Water 
was added, sonicated, and filtered. The filter cake was purified by crystallisation 
from EtOH/EtOAc to provide compound 92 (31 mg, 16% yield) as a white silky 
crystal. 1H NMR (400 MHz, DMSO-d6) δ 11.72 (br s, 1H), 7.43 (dd, J = 8.8, 
4.4 Hz, 1H), 7.37 (dd, J = 9.6, 2.4 Hz, 1H), 7.06 (td, J = 9.6, 2.4 Hz, 1H), 6.84 
(s, 1H), 6.46 (s, 1H), 3.84 (br s, 8H), 2.25 (s, 6H). 13C NMR (100 MHz, DMSO-
d6) δ 166.8 (2 × C), 161.9, 161.0, 157.1 (d, J = 231.1 Hz, C-F), 132.7, 131.6, 
126.9 (d, J = 10.2 Hz), 113.3 (d, J = 9.4 Hz), 111.9 (d, J = 26.2 Hz, F-C-C-H), 
109.2, 105.5 (d, J = 22.6 Hz, F-C-C-H), 104.2 (d, J = 5.1 Hz), 43.3 (2 × CH2), 
40.1–38.9 (2 × CH2), 23.7 (2 × CH3). HRMS-ESI (m/z) [M + H]+ calcd for 
C19H21FN5O, 354.1725; found, 354.1720 (Δ = 0.4 ppm). [M + Na]+ calcd for 
C19H20FN5NaO, 376.1544; found, 376.1537 (Δ = 0.7 ppm). HPLC (1): t = 11.7 
min, 98.0% purity. HPLC (3): t = 16.6 min, 99.7% purity.  
2‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐5‐methyl‐1H‐
indole (93). To a suspension of 5-methylindole-2-carboxylic acid (101 mg, 0.57 
mmol) and EDC.HCl (134 mg, 0.69 mmol) were added EtOAc (16 mL) and two 
drops of DMF, and the mixture was stirred for 1 h at 23 oC followed by the 
addition of compound 68 (113 mg, 0.57 mmol). The reaction was heated at 40 
oC for 6 h, and solvents were evaporated to dryness under high vacuum. Water 
was added, sonicated, and filtered. The filter cake was purified by crystallisation 
from MeOH/EtOAc to provide compound 93 (70 mg, 35% yield). 1H NMR (400 
MHz, DMSO-d6) δ 11.46 (br s, 1H), 7.38 (d, J = 0.8 Hz, 1H), 7.32 (d, J = 8.4 
Hz, 1H), 7.02 (dd, J = 8.4, 1.6 Hz, 1H), 6.76 (d, J = 1.6 Hz, 1H), 6.46 (s, 1H), 
3.84 (br s, 8H), 2.37 (s, 3H), 2.25 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 
167.3 (2 × C), 162.7, 161.5, 134.8, 130.2, 128.8, 127.6, 125.6, 121.1, 112.3, 
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109.7, 104.3, 43.8 (2 × CH2), 40.6–9.3 (2 × CH2), 24.2 (2 × CH3), 21.6. HRMS-
ESI (m/z) [M + H]+ calcd for C20H24N5O, 350.1975; found, 350.1970 (Δ = 1.5 
ppm). [M + Na]+ calcd for C20H23N5NaO, 372.1795; found, 372.1785 (Δ = 2.7 
ppm). HPLC (1): t = 13.1 min, 98.9% purity. HPLC (3): t = 17.1 min, 98.3% 
purity. 
2‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐5‐methoxy‐1H‐
indole (94). To a suspension of 5-methoxyindole-2-carboxylic acid (203 mg, 
1.06 mmol) and EDC.HCl (244 mg, 1.27 mmol) were added EtOAc (20 mL) 
and two drops of DMF, and the mixture was stirred for 1 h at 23 oC followed by 
the addition of compound 68 (203 mg, 1.06 mmol). The reaction was heated at 
40 oC for 6 h, and solvents were evaporated to dryness under high vacuum. 
Water was added, sonicated, and filtered. The filter cake was purified by 
crystallisation from MeOH/EtOAc to provide compound 94 (139 mg, 36% 
yield) as a shiny, colourless, clear crystal. 1H NMR (400 MHz, DMSO-d6) δ 
11.45 (br s, 1H), 7.32 (d, J = 8.8 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.85 (dd, J 
= 8.8, 2.4 Hz, 1H), 6.76 (d, J = 1.2 Hz, 1H), 6.46 (s, 1H), 3.83 (br s, 8H), 3.76 
(s, 3H), 2.25 (s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 166.9 (2 × C), 162.2, 
161.1, 153.8, 131.3, 130.2, 127.2, 114.4, 113.0, 109.2, 104.1, 102.0, 55.3, 43.3 
(2 × CH2), 40.1–38.9 (2 × CH2), 23.7 (2 × CH3). HRMS-ESI (m/z) [M + H]+ 
calcd for C20H24N5O2, 366.1925; found, 366.1925 (Δ = -0.1 ppm). [M + Na]+ 
calcd for C20H23N5NaO2, 388.1744; found, 388.1733 (Δ = 2.7 ppm). HPLC (1): 
t = 10.6 min, 97.2% purity. HPLC (3): t = 16.2 min, 99.2% purity.  
{2‐[4‐(4,6‐Dimethylpyrimidin‐2‐yl)piperazine‐1‐carbonyl]‐1H‐indol‐7‐
yl}azinic acid (95). To a suspension of 7-nitroindole-2-carboxylic acid (204 
mg, 0.99 mmol) and EDC.HCl (227 mg, 1.19 mmol) were added EtOAc (20 
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mL) and two drops of DMF, and the mixture was stirred for 1 h at 23 oC 
followed by the addition of compound 68 (190 mg, 0.99 mmol). The reaction 
was heated at 40 oC for 6 h, and solvents were evaporated to dryness under high 
vacuum. Water was added, sonicated, and filtered. The filter cake was purified 
by crystallisation from MeOH/EtOAc to provide compound 95 (137 mg, 36% 
yield) as a light yellow, ball-like solid. 1H NMR (400 MHz, DMSO-d6) δ 11.77 
(br s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 7.32 (t, J = 8.0 Hz, 
1H), 7.04 (d, J = 2.4 Hz, 1H), 6.46 (s, 1H), 3.84 (br s, 4H), 3.71 (br s, 4H), 2.24 
(s, 6H). 13C NMR (100 MHz, DMSO-d6) δ 166.8 (2 × C), 161.5, 161.0, 133.9, 
133.0, 131.1, 130.0, 128.1, 120.2, 119.7, 109.3, 104.5, 40.1–38.9 (4 × CH2), 
23.7 (2 × CH3). HRMS-ESI (m/z) [M + H]+ calcd for C19H21N6O3, 381.1670; 
found, 381.1662 (Δ = 1.9 ppm). [M + Na]+ calcd for C19H20N6NaO3, 403.1489; 
found, 403.1480 (Δ = 2.2 ppm). HPLC (x): t = 11.7 min, 97.3% purity. HPLC 
(3): t = 16.8 min, 99.0% purity.  
 
4.4.3    Results and discussion 
Except for compound 95, the instalment of 68 at the indole C2 position through 
a carbonyl linker rendered derivatives (91-94) inactive at hA2A receptor (Table 
13), suggesting that moiety 68 was not well-tolerated when it was extended from 
the indole C2 position. Notably, 7-nitro indolyl derivative 95 showed modest 
affinity (Ki = 29.7 µM) at hA2A receptor. A nitro group is a functional group that 
(i) can act as hydrogen bond acceptors, (ii) is electron-withdrawing, and (iii) is 
polar in that the nitrogen atom is positively charged and the two oxygen atoms 
share a negative charge. Hence, the structural basis of the affinity shown by 
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compound 95 could be either (i) that the oxygen atoms form hydrogen bonding 
with water or nearby residues, (ii) that the polarised π-system of the indole ring 
leads to changes in ligand-receptor interactions, or (iii) that the charges on the 
nitro group result in electrostatic interactions (e.g. charge-charge interaction, 
charge-dipole interaction) with neighbouring residues. Apparently, 7-
nitroindole-2-substituted 95 (the highest hA2A affinity in indole-2 series) is 
reminiscent of 7-methoxyindole-3-substituted 82 (the highest hA2A affinity in 
indole-3 series). Although it is tempting to assume that the methoxy group at 
the indole C7 position of 82 (Table 11) and the nitro group at the indole C7 
position of 95 (Table 13) share the same mechanism that the electronegative 
oxygen atoms of methoxy and nitro groups accept hydrogens from nearby 
residues, more analogues with various C7 substituents on the indole-2 and 
indole-3 need to be made and tested for better understand the relationships 
between IPP scaffold and affinity at hA2A receptor. In addition to its activity at 
hA2A, compound 95 showed affinity at hA1 with Ki = 4.8 µM, suggesting its 
potential for the development of novel hA1 ligands.     
From the perspective of drug safety, the enzymatic reduction of nitroaromatic 
compounds results in nitroso compounds, hydroxylamines, and nitro radical 
anions which often exert toxic effects on biological systems (Patterson and 
Wyllie, 2014). For this reason, one of the compound selection criteria at the 
early stage of a drug discovery programme for neglected parasitic diseases was 
to remove unwanted groups, such as the nitro group which was considered 
potentially mutagenic and unsuitable for development (Brenk et al., 2008). 
Thus, replacement of the nitro group in compound 95 with other substituents 























































































































































































































































































































































































































































































































































    
CHAPTER 4 
 CHAPTER 4   
154 
 
4.5    Chapter Conclusion 
Under guidance of SVM models (Section 3.2.3.5), Tanimoto similarity (Section 
3.3.3), and hierarchical clustering analysis (Section 4.1), the scaffold [indole + 
piperazine + pyrimidine] (IPP) was identified. Compounds containing IPP were 
subsequently synthesised for the purpose of proving or disproving 
computational results. Competition binding experiments confirmed the binding 
of IPP-containing compounds at hA2A receptor in the micromolar range, with 
most promising candidates being 69, 70 and 82 (Ki = 4~11 µM) (Tables 10 and 
11). Three important structural features of IPP-containing compounds in hA2A 
binding were extracted from preliminary structure-activity relationship (SAR) 
studies (Figure 54). 
(a) At the indole C2 position, the presence of methyl group confers better 
affinity than that of hydrogen. 
(b) The linker bridging indole C3 and piperazine nitrogen must have a 
carbonyl group. In addition, the length of that linker is limited to one or 
two carbon atoms.   
(c) At the indole C7 position, methoxy group improved affinity.  
Out of the SAR analysis, compound 84 is proposed for future synthesis (Figure 
52). In addition, phenyl substitution at the indole C2 position was carried out 
via the palladium-catalysed cross-coupling reaction (Scheme 3). The hA2A 
binding activity of compound 90 will shed light on the tolerability of hA2A 
receptor in steric bulkiness at the indole C2 position. Overall, IPP-containing 
compounds as hA2A receptor binders presented herein are unprecedented, and 
the SAR summary (Figure 54) has laid a foundation for future optimisation. 


















CHAPTER 5    FURTHER PHARMACOLOGICAL 
EVALUATION AND CHARACTERISATION OF 
COMPOUNDS 69 AND 70 
 
Dr. Sourabh Banerjee in Dr. Madhavan Nallani’s lab (Institute of Materials 
Research and Engineering, A*STAR) performed dopamine D2 receptor binding 
assay. Miss Wang Wei and Dr. Deron Herr (Department of Pharmacology, 
National University of Singapore) conducted cell-based functional assays. The 
Drug Development Unit at the National University of Singapore was 
acknowledged for physicochemical evaluation, pharmacokinetic profiling, 
preliminary toxicology screening, and intellectual property analyses. 
Drosophila experiments were done by Dr. Ng Chee Hoe (National 
Neuroscience Institute, Singapore) with advice from Prof. Lim Kah-Leong 
(National Neuroscience Institute, Singapore).   
 
5.1    Introduction 
The goal of this thesis is to discover new chemical entities that act as both 
adenosine A2A receptor antagonist and dopamine D2 receptor. By means of 
compound collection from literature, in-depth analysis of collected compounds, 
as well as iterative synthesis-testing cycles, indolyl piperazinylpyrimidines 
(IPPs) 69, 70 and 82 were identified to be novel binders at hA2A receptor in the 
micromolar range (Ki = 4~11 µM) (Figure 55). Whilst existing hA2A antagonists 
have reached nanomolar affinity (e.g. KW-6002, Ki = 12 nM, Figure 12; 
ZM241385, Ki = 1.6 nM, Figure A11), the newly identified IPPs had the 
scaffold distinct from all known hA2A antagonists. Thus IPPs are worth a 
thorough exploration in the following two directions (Figure 55). First, it is 
interesting to optimise hA2A affinity on the basis of the SAR information 




piperazinylpyrimidines to hA2A affinity. This direction is being pursued in our 
lab. Second, IPP was the most promising scaffold resulted from several rounds 
of computational filters (Figure 48). These filters covered not only A2A 
antagonism but also D2 agonism, ensuring that the ones which could survive to 
the end of the filtering process had the higher chance to simultaneously bind 
two receptors. The hA2A affinity displayed by 69, 70 and 82 merely validated 
our computational tools to a half extent (i.e. hA2A antagonism only). To fully 
appreciate the accuracy of computational analyses used for the thesis, it became 
indispensable to further test the synthesised IPPs at hD2 receptor. The second 
direction was pursued, and documented in Sections 5.3.1 (for hD2 binding) and 
5.3.2 (for hD2 function). Since compound 82 was identified at the later stage 
and did not show significant difference in hA2A binding affinity compared to 
compounds 69 and 70 identified at the earlier stage, compounds 69 and 70 were 
selected for dopamine D2 receptor binding studies.      
69 R1=H, R2=H, n=0 (hA2A Ki = 11.2 uM)
70 R1=CH3, R2=H, n=1 (hA2A Ki = 8.71 uM)












enhance affinity at hA2A
test affinity at hD2
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5.2    Materials and Methods 
Dopamine D2 Receptor Proteopolymersomes. Polymersomes (ABA and 
BD21) preparation, cloning and in vitro synthesis of dopamine D2 receptor, and 
purification of proteopolymersomes were performed following previously 
described procedures (May et al., 2013). For the replacement assay, ABA-
polymersomes were covalently attached to an amino-functionalised glass slide, 
which was then treated with isopropanol, ultrapure water, and a N2-stream. The 
slide was cut into small chips, and each chip was treated with the ethanolic 
solution of the mixture containing tetrazol(4-(2-phenyl-2H-tetrazol-5-
yl)benzoic acid, N-hydroxysuccinimide and N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimidehydrochloride, and then incubated for one hour. ABA with 
10% methacrylate was dispensed onto the polydimethylsiloxane (PDMS) 
stamps and incubated for one hour. The photoinducible 1,3-dipolar 
cycloaddition between the tetrazole and the methacrylate functional group on 
the polymersomes was induced by 15 min incubation under UV light (254 nm). 
The chips were incubated with a 30 μM BODIPY-NAPS solution in TMN 
buffer for 30 min in the dark at room temperature. For determination of 
fluorescence intensities, the free program ImageJ was used.  
Adenylyl Cyclase Inhibition. CHO cells transfected with D2R were cultured 
and then serum starved overnight. Cells were treated with various 
concentrations of ligands (25 µL of 10X solution), stimulated with forskolin 
(0.5 µM) and IBMX (0.5 mM), and incubated for 15 minutes. After lysis, cAMP 
content was determined by ELISA. 
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Immunocytochemistry. HEK 293 cells were obtained from American Type 
Culture Collection (ATCC). The cell lines were grown as monolayers in 
humidified incubators at 37 °C with 5% CO2. Cells were cultured in DMEM, 
25 mM D-glucose, 4mM L-glutamine, 1 U/mL penicillin, 1 µg/mL 
streptomycin, 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Cells 
were seeded onto coverslips coated with Type I collagen (Millipore, 10X 
dilution) and cultured overnight. Cells were transfected with 500 ng DNA 
plasmid of DRD2-V5 with 1 µL LFM and incubated overnight. Cells were 
incubated with ligands for 15 min and fixed with 4% paraformaldehyde for 30 
min. After fixation, cells were incubated with V5 antibody (Invitrogen, R960-
25, 1:1000 diluted) overnight at 4 °C, with Alexa Fluor® 594 goat anti-mouse 
(cat #AP192C, Millipore, Billerica, MA, USA). The coverslips were mounted 
using VECTASHIELD® Mounting Media. Images were acquired with 
microscope.  
TGF Alpha Shedding. HEK 293 cells were seeded per well in a 6-well plate in 
DMEM supplemented with 10% FBS, and cultured overnight. 200 ng D2R 
plasmid, 500 ng AP-TGFα plasmid, and 100 ng Gα protein were transfected in 
HEK 293 cells, and incubated overnight. Transfected cells were detached by 
treatment with 1 mL 0.05% Trypsin-EDTA, and stop with DMEM + 10% FBS. 
After centrifugation, the pellet was collected, resuspended in 4 mL autoclaved 
PBS, and left it at room temperature for 10 min to remove the basal level of 
TGFα shedding caused by trypnisation. After another round of pelleting and 
resuspending, cells were resuspended in 3.5 mL of Hank’s Balanced Salt 
Solution (HBSS), seeded into each well in triplicates, and incubated at 37 °C for 
30 min to let the cells attach to the plate. Ligands (10 µL) were added and into 
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appropriate well (10X diluted) and incubated at 37 °C for one hour. Plates were 
centrifuged at 190g for 5 min to separate the cells and condition media. 
Condition media (80 µL) were transferred into a new plate in the same 
arrangement. The solution containing 80 µL 2X AP were added into each well 
in both condition media plate and cell plate. After incubation at 37 °C for 15 
min, the basal absorbance at 405 nm for both plates was read. After another one-
hour incubation, the second reading at 405 nm for both plates was taken. TGFα 
release was calculated according to the previously published method (Inoue et 
al., 2012).  
Solubility Studies. The 10 µL stock solution of the ligand (10 mM in DMSO) 
was added to the universal aqueous buffer (pH 7.4), and the mixture was 
sonicated. 300 µL of the turbid mixture was transferred to the 3 wells of 
MultiScreen HTS- PCF filter plate (Millipore Corp., Ireland), and the plate was 
covered and incubated with gentle shaking (250 rpm, 24 h) at room temperature 
(22.5 ± 2.5 oC). After the period of incubation (24 h), the filter plate was placed 
on a vacuum manifold and the contents were filtered into a 96-well UV plate. 
After filtration, 200 µL of filtrate was transferred from each well to the PP vial. 
Absorbances of the solutions were quantified by HPLC-UV and read at 250 nm.  
Parallel Artificial Membrane Permeability Assay. 5 µL of the 1% 
lecithin/dodecane (w/v) was pipetted into the well of the donor plate. 300 µL of 
the ligand solution (1% in DMSO, v/v) was added to the well in the donor plate 
(with lecithin). 300 µL of 1X PBS buffer (containing 1% v/v DMSO) was added 
into the corresponding well in the acceptor plate. The donor/acceptor plate unit 
was covered, placed in an air-tight container and agitated in an incubator (250 
rpm, 6 h) at temperature of 30.0 oC (± 2.5 oC). The concentrations of the analyte 
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present in each sample were analysed by LCMS, and the values of effective 
permeability (Pe) were calculated according to previously published formula 
(Avdeef et al., 2007).  
Metabolism Studies. Phosphate buffer (100 mM, pH 7.4) containing 1 mM 
EDTA was prepared from 400 mM mono- and dibasic potassium phosphate 
stock solution. NADPH stock solutions (10 mM) in phosphate buffer were 
freshly prepared daily. Liver microsomal incubations were conducted in 
triplicate. Incubation mixtures consisted of 7.5 µL of 20 mg/mL FRLM and 
MRLM (final: 0.3 mg microsome protein/mL), 2.5 µL of 100 µM test 
compound in acetonitrile (final: 3 µM), and 440 µL of 0.1 M phosphate buffer 
(pH 7.4). The mixture was first shaken for 5 min for pre-incubation in a shaking 
water bath at 37 oC. Reaction was initiated by adding 50 µL of 10 mM NADPH 
to obtain a final concentration of 1 mM NADPH in the mixture. The total 
volume of the reaction mixture was 500 µL. For metabolic stability studies, 
aliquots of 50 µL of the incubation sample mixture were collected at 0, 5, 10, 
15, 30, and 45 min. After collection of samples, the reaction was terminated 
with 100 µL of chilled acetonitrile containing the internal standard (0.01 µM). 
The mixture was then centrifuged at 10,000g to remove the protein, and the 
supernatant was subsequently applied to LC-MS/MS analysis. Positive control 
(PC) were prepared as described above, except the test compound was replaced 
with the known P450 substrate (midazolam, 2 µM). The samples were assayed 
for the degradation of midazolam to evaluate the adequacy of the experimental 
conditions for drug metabolism study. Negative control samples were also 
prepared as described above but without NADPH. In the determination of the 
in vitro half-life (T1/2), the peak areas of test compound were converted to parent 
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remaining percentages, using the t = 0 peak area values as 100%. The remaining 
percentages of the test compound were plotted against the microsomal 
incubation time using Microsoft Excel. Data points were determined from the 
average of three measurements with standard deviations as the error bars. The 
in vitro T1/2 (in units of min) and CLint, in vitro (in units of µL/min/mg) were 
calculated according to previously published formulas (Lu et al., 2006). 
Statistical analysis of data was performed using Microsoft Excel. All data were 
presented as means ± standard deviation (SD).  
Mutagenicity Test. In vitro mutagenicity was performed using a modified 
Ames Test protocol according to manufacturer’s instructions (MolTox). S. 
typhimurium strains (TA 98 and TA100) were grown from bacterial discs in 
Oxoid # 2 nutrient broth at 37 °C in a shaking incubator (~150 rpm) for about 
10 h. The cultures were then measured for absorbance with a UV 
spectrophotometer at 660 nm and to be used at a density of approximately 1.0 
to 1.2 absorbance units. For compound treatment, the top agar was melted in a 
hot water bath or microwave oven and 2 mL volumes were aliquoted into culture 
tubes. The tubes of agar were then maintained at 45 °C for at least 30 to 45 min 
for temperature equilibration. 100 µL of test compounds at concentrations of 1 
mM were added to separate tubes containing top agar in duplicates. Additional 
tubes were set aside as negative (DMSO, methotrexate) and positive controls 
(4-NQO and 2-AA). 500 µL of S9 mix was introduced to each tube containing 
either controls or test compounds. The contents were immediately mixed and 
decanted onto Minimal Glucose (MG) Agar Plate and swirled to obtain an even 
distribution of plating mixture over the agar surface. After the agar was set, the 
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plates were then incubated at 37 oC for 48 h. Images of colonies were captured 
and counted with the aid of ImageJ software. 
Cytotoxicity Test. Immortalised hepatocyte and cardiomyocte cell lines, 
TAMH (TGF-α overexpressing mouse hepatocytes) and HL-1 were used 
respectively as models for in vitro toxicity study. Both cells were cultured in 
accordance with previously described methods (Claycomb et al., 1998; Wu et 
al., 1994). Briefly, TAMH line between passages 21-35 were grown in serum 
free DMEM/Ham’s F12 (Invitrogen, Carlsbad, CA) supplemented with 5 
µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenium (Collaborative 
Biomedical Products, 354351 Boston, MA), 100 nM dexamethasone, 10 mM 
nicotinamide and 0.1% v/v gentamicin (Invitrogen) and 0.12% sodium 
bicarbonate (Sigma 5671). For HL-1 cells, cell culture flasks were first coated 
with fibronectin/gelatin (25 µg of fibronectin in 2 mL of 0.02% gelatin in water 
per T25 flask (Sigma G1393 & F1141) overnight at 37 oC and the excess fluid 
aspirated thereafter. Cells were then maintained in Claycomb medium (Sigma 
51800C) supplemented with 10% FBS (Sigma F2442), 2 mM L-glutamine 
(Sigma), 10 µM norepinephrine, 100 U/ml penicillin, 100 µg/ml streptomycin 
and 1X non-essential amino acids. Medium was changed every 24 h. All 
cultures were maintained in a humidified incubator with 5% carbon 
dioxide/95% air at 37 oC and passaged at 70-90% confluence. TAMH cells were 
plated into 96-well plates at 12,000 cells per well whilst HL-1 at 15,000 cells 
per well and incubated overnight. The following day, test compounds were 
prepared from DMSO stock solutions and diluted down into working 
concentrations of 0.03 µM to 100 µM, keeping final DMSO concentration of 
0.5% v/v. Medium was aspirated and replaced with respective compound 
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concentrations and incubated for another 24 h at 37 oC (n = 6). Cell-Titer-Glo 
(Promega G7571) assay was performed according to manufacturer’s 
instructions. The cell-reagent mixture was then transferred to a solid white flat-
bottom 96-well plate (Greiner 655207) for luminescence reading. 
Luminescence was then recorded with an integration time of 0.25 second with 
a Tecan Infinite® M200 Microplate reader. Data are expressed as percentage of 
viable cells compared to DMSO-treated controls. Semi-log graphs were plotted 
using GraphPad Prism (La Jolla, CA, USA). 
Drosophila Models of PD. Fly lines for 24B-Gal4 (muscle-specific), ddc-Gal4 
(dopaminergic neuron-specific), elav-Gal4 (pan-neuronal), UAS-mito-GFP, 
and UAS-dAMPK-KA were purchased from Bloomington Drosophila Stock 
Center. The parkin-null mutant flies were kind gifts from J. Chung and K. S. 
Cho (Korea Advanced Institute of Science and Technology, Daejeon, Korea). 
To generate transgenic mutant LRRK2 G2019S, cDNA containing a myc-tag at 
the C terminus was inserted into pUAST plasmid and microinjected into 
Drosophila embryos (BestGene). Sequencing of cloned products was 
performed before they were microinjected into the embryos. Climbing assays 
were performed according to a previously described method (Ng et al., 2012). 
Briefly, 20 female adult flies from each group were randomly selected after 
being anaesthetised and placed in a vertical plastic column (length 25 cm; 
diameter 1.5 cm). Age-matched normal flies were used as controls. After a 2 h 
recovery period from CO2 exposure, flies were gently tapped to the bottom of 
the column, and the number of flies that reached the top of column at 1 min was 
counted. Results are presented as mean ± SEM of the scores obtained from three 
independent experiments. To study the effect of compounds, flies were fed with 
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cornmeal-agar medium supplemented with the DMSO solution of the 
compound immediately at posteclosion (for parkin-null flies) or at day 35 
onward (for LRRK2 mutant flies) for a period of 25 days. Immunohistochemical 
analysis of whole-mount adult fly brains were prepared according to published 
protocols (Whitworth et al., 2005) and stained with rabbit anti-TH (1:300, Pel-
Freez Biologicals) as primary antibody. The stained samples were viewed using 
an Olympus Fluoview Upright Confocal Microscope. DA neurons were 
quantified according to a published method (Whitworth et al., 2005). The size 
of mito-GFP puncta was measured using the ImageJ program and expressed as 
mean ± SD (n ≥ 10 DA neurons per experimental group). Statistical significance 
for all the quantitative data obtained were analysed using one-way ANOVA 
with Tukey’s test HSD post hoc test (*p < 0.05, **p < 0.01). 
 
5.3    Results and Discussion 
5.3.1    Proteopolymersomes for D2 receptor binding assay   
Unlike the conventional method of overexpressing dopamine D2 receptor in host 
cells like what radioligand competition experiments do (Figure A13), the in 
vitro synthesised D2 receptor incorporated into block copolymer vesicles was 
used to determine D2 receptor binding of compounds 69 and 70 (May et al., 
2013). This alternative method for ligand-binding studies of membrane proteins 
overcomes the limitations of (i) cellular toxicity exerted by the cell-based 
radioligand binding approach (Katzen et al., 2009), (ii) loss of functional 
integrity in the reconstitution of GPCRs into lipid-based systems (Velez-Ruiz 
and Sunahara, 2011), and (iii) fragility of lipid bilayers faced by cell-free 
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nanolipoprotein particles (Nath et al., 2007). Amphiphilic block copolymers, as 
one of the biological membrane mimics, have superior stability to phospholipid-
based membrane mimics (Srinivas et al., 2004), and they can self-assemble into 
vesicles, known as polymersomes (Discher et al., 1999). The polymersome-
based dopamine D2 receptor binding assay is depicted in Figure 56. 
Figure 56. (Left) Synthesis of proteopolymersomes was carried out by mixing 
dopamine D2 receptor DNA template and a given polymersome, followed by 
purification using centrifugal filtration. (Right) Confirmation of the insertion 
and proper receptor folding was assessed by using the unlabelled specific 
antibody, fluorescently labelled secondary antibody, and dansyl-dopamine 
(Modified from May et al., 2013) (reprinted with permission). 
 
Two polymers, PMOXA20-PDMS54-PMOXA20 (one of the ABA triblock 
copolymers) and PBd22-PEO13 (one of the BD21 diblock copolymers), were 
used to generate the respective polymersomes. The cloned dopamine D2 
receptor genes were mixed with the prepared polymersome to produce the 
desired proteopolymersome. The reaction mixtures were purified, and then 
Western blot was used to confirm the incorporation of 25% D2 receptor into the 
two polymersomes (Appendix W). The retentates after the purification were 
subjected to flow cytometry using antibodies to reconfirm the incorporation 
 CHAPTER 5   
167 
 
(Appendix X). The correct conformation of D2 receptor inserted in the 
polymersomes was ensured by using dansyl-dopamine in solution as well as 
onto the glass surface. Further, the replacement of dansyl-dopamine by 
unlabelled dopamine in a concentration-dependent manner demonstrated the 
ligand specificity of the D2 receptor inserted in the polymersome. 
This assay platform was used to evaluate whether compounds 69 and 70 can 
bind D2 receptor. Instead of dansyl-dopamine, boron-dipyrromethene N-(p-
aminophenethyl)spiperone (BODIPY-NAPS) was incubated with D2R-
functionalised polymersomes because spiperone was a selective D2-like 
antagonist with Ki of 0.06 nM for D2 receptor (Bakthavachalam et al., 1991). 
The mixture was then incubated with solutions containing eight different 
concentrations (ranging from 3 nM to 0.3 mM) compounds 69 and 70, and the 
measured fluorescence intensity against ligand concentration was plotted in 
Figures 57A and 57B, respectively. The dose-dependent reduction in 
fluorescence was observed for both compounds, indicating that the strong 
binding (Ki = 0.06 nM) of spiperone with D2 receptor can be competitively 
replaced by 69 and 70. To understand the potency context, the ability of (±)-2-
(N-phenethyl-N-propyl)amino-5-hydroxytetralin hydrochloride (i.e. (±)-
PPHT.HCl, a potent dopamine D2 receptor agonist with Ki of 13.3 nM 
determined by competition binding experiments with [3H]spiperone) 
(Bakthavachalam et al., 1991) to replace BODIPY-NAPS was measured (Figure 
57C), and the sigmoidal decrease in fluorescence with increasing concentration 
of  (±)-PPHT.HCl was exemplary of how a D2 agonist ought to act in the D2R-
functionalised polymersomes. The dose-response curves of 69 and 70 
resembled that of (±)-PPHT.HCl, and the EC50 values for these three 
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compounds were determined to be 22.5 µM, 40.2 µM, and 0.2 µM, respectively 
(Table 14). The 15-fold difference (0.2/0.0133 = 15) in potency of (±)-
PPHT.HCl in the radioligand binding assay (Ki = 0.0133 µM) and in the 
proteopolymersome assay (EC50 = 0.2 µM) was consistent with one case of 
kinase inhibitors in which the EC50 values were 4- to 20-fold above the Ki values 
(Knight and Shokat, 2005). This leads to a speculation that the Ki (D2R) values 
for 69 and 70 could be in the range of 1~3 µM (22.5/15 = 1.5; 40.2/15 = 2.7), 
although D2 radioligand binding experiments were not performed for 69 and 70. 
Treatment of denatured D2R-proteopolymersomes with PPHT.HCl was 
performed (Figure 57D) for comparison with Figure 57C, showing the necessity 
of proteopolymersomes’ integrity. Together with A2A radioligand binding data 
(Tables 10 and 14), compounds 69 and 70 were demonstrated to be binders at 
A2A and at D2 in the micromolar range. 
 




Figure 57. The dose-response curve of compound 69 (A), compound 70 (B), 
and (±)-PPHT.HCl (C) with D2R-proteopolymersomes using fluorescence 
polarisation (FP) competition assay with BODIPY-NAPS. The non-binding 
control (D) was achieved by denaturing the D2R-proteopolymersomes with 
heat, resulting in a curve that fluorescence intensity did not decrease much when 
the concentration of (±)-PPHT.HCl increased. 
 
 











N.A.d 0.0133b 0.2c 
69 11.2a N.D.e (could be 
1~3)f 
22.5c 
70 8.71a N.D.e (could be 
1~3)f 
40.2c 
aData from Table 10. bCompetition binding experiments were done using the 
radioligand [3H]spiperone to label D2 receptor (Bakthavachalam et al., 1991; 
Madras et al., 1990). cACM: artificial cell membrane; EC50: the concentration 
of an agonist that produces half-maximal response. Data are also shown in 
Figure 70. dN.A.: not available. eN.D.: not determined. fSee main texts for the 
speculation.     
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5.3.2    Cell-based functional assay for D2 receptor  
At this point in time, it has been shown that newly synthesised compounds 69 
and 70 not only bind at A2A receptor (Table 10) but also bind at D2 receptor 
(Figure 57). The next step was to evaluate whether these two compounds, after 
interacting with the two receptors, can give rise to changes in intracellular 
events so as to define their agonism or antagonism to respective receptors. As 
shown in Figure 58, the classical paradigm of D2R activation is mediated by 
heterotrimeric (i.e. α, β and γ subunits) Gi/o proteins, which is how “G protein”-
coupled receptors (GPCRs) are named. In the absence of the endogenous 
dopamine or agonists, Gα is bound to guanosine 5’-diphosphate (GDP) and 
Gβγ. Upon D2R activation, the conformational change of the receptor results in 
the GDP release, guanosine 5’-triphosphate (GTP) binding, and dissociation of 
Gα from Gβγ. The released Gα then interacts and inhibits adenylyl cyclase, 
leading to the decrease in the adenosine 3’,5’-cyclic monophosphate (cAMP) 
production. Thus, measuring the extent to which a compound inhibits cAMP 
accumulation has been one of the functional assays for D2R activation (Kuhhorn 
et al., 2011). To prevent uncontrolled stimulation of cells by agonists, several 
mechanisms of signal attenuation, including agonist removal from the 
extracellular fluid, receptor desensitisation, receptor endocytosis, and receptor 
down-regulation, are generally adopted by cells (Bohm et al., 1997). Among 
these mechanisms, desensitisation and endocytosis are relevant to this thesis. G 
protein-mediated signalling is turned off (or, desensitised) by a process that 
involves G protein-coupled receptor kinases (GRKs) and β-arrestins. Prolonged 
exposure to agonists leads to GRK-catalysed D2R phosphorylation at the 
carboxyl intracellular loops. It is noteworthy that GRKs only recognise and 
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phosphorylate agonist-bound receptors, and that receptor phosphorylation is the 
first step to receptor internalisation. This rationalises the use of D2R 
internalisation assay to evaluate D2R activation in the thesis. After 
phosphorylation, β-arrestins are recruited to bind the phosphorylated receptor. 
The binding of β-arrestins hinders G protein binding, thereby dampening G 
protein-mediated signalling (i.e desensitisation). Further, β-arrestins can 
continue to facilitate the endocytosis of the receptor via clathrin-coated pit, a 
process known as internalisation (Beaulieu and Gainetdinov, 2011). In a sense, 
the occurrence of signalling attenuation is indicative of the former existence of 
that signalling, so receptor internalisation assays have been used to investigate 
the agonistic function of a ligand. For instance, a study (Goggi et al., 2007) was 
performed for the direct visualisation of dopamine- and bromocriptine (a D2R 
agonist)-induced D2R internalisation using double antibody labelling followed 
by confocal microscopic imaging analysis. In that study, treatment of CHO cells 
with SKF38393 (a D1R agonist) failed to induce D2R internalisation, and an 
exposure to sulpiride (a D2R antagonist) prevented D2R internalisation. That is, 
D2R internalisation can only be induced by its agonist rather than antagonist, 
validating the use of D2R internalisation assay for D2R activation. In this thesis, 
the in vitro functional responses upon exposing 69 or 70 to cells expressing D2R 
were investigated by three experiments—cAMP reduction, receptor 
internalisation, and TGFα shedding (Note: TGFα shedding will be introduced 
at the later part of this Section.). Table 15 gives a summary of the three assays. 
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Figure 58. The simplified depiction of proteins involved when dopamine D2 
receptor is activated (Modified from Beaulieu and Gainetdinov, 2011) 
(reprinted with permission). 
 
Table 15. Dopamine D2 Receptor Activation Assays Used in the Thesis 
assay effector molecule cellular response 
cAMP reduction G protein signalling ↑ 
receptor internalisation β-arrestina signalling ↓  
TGFα shedding G protein signalling ↑ 
aIn addition to the classical view that β-arrestins mediate receptor 
desensitisation and internalisation, β-arrestins can act as signal transducers and 
regulate many other cellular processes, such as receptor translocation, 
exocytosis, kinase regulation, transcription regulation, chemotaxis, 
apoptotic/anti-apoptotic signaling, receptor transactivation, and protein 
synthesis. Such β-arrestin-mediated signalling is beyond the scope of the thesis, 
and interested readers are referred to two reviews published by Prof. Lefkowitz 
(Lefkowitz and Shenoy, 2005; Rajagopal et al., 2010).    
 
The first D2R activation assay used to characterise functional properties was the 
inhibition of cAMP accumulation. Chinese hamster ovary (CHO) cells were 
transfected with D2R, pre-treated with compound 70 and quinpirole, and 
stimulated with forskolin and 3-isobutyl-1-methylxanthine (IBMX). Quinpirole, 
a potent D2R agonist with a Ki of 4.8 nM (Seeman and Schaus, 1991), acted as 
the reference agent. The purpose of using forskolin (an activator of adenylyl 
cyclase) and IBMX (an inhibitor of phosphodiesterase) was identical, that is, to 
elevate basal levels of cAMP (Figure 59). As shown in Figure 60A, the control 
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refers to the high cAMP content resulted from the stimulation with 
forskolin/IBMX in the absence of either quinpirole or 70. Subsequently, 
different concentrations of either quinpirole or 70 were added to investigate 
whether, and if so, to which extent the added ligand can reverse the cAMP effect 
induced by forskolin/IBMX. The concentration-dependent decrease in cAMP 
accumulation when the D2R-expressing cells were treated with quinpirole 
suggests that quinpirole-induced D2R conformation caused the Gi protein to 
bind and inhibit adenylyl cyclase (Taussig et al., 1993). Activation with 
quinpirole at the concentration of 1 µM resulted in an 11% decrease (calculated 
by (103.97–92.63)/103.97 = 11%) in intracellular cAMP concentration with p-
value of 0.0232, and the result of 1 µM quinpirole was normalised relative to 
the control (Figure 60B). After normalisation, it became clear that the extent to 
which 1 µM of quinpirole inhibited the cAMP accumulation was the desired 
D2R agonistic behaviour expected of newly synthesised compounds, whereas 
the minus percentage of [cAMP] reduction in Figure 60B would indicate that 
the tested compound activates adenylyl cyclase. Three concentrations of 
compound 70 (1 µM, 10 µM and 100 µM) were evaluated, and their respective 
capability to inhibit cAMP accumulation was measured. There was no 
concentration-dependent response for compound 70 observed in this cAMP 
assay. The optimal inhibition occurred at 100 µM of 70 (p = 0.0232), which 
showed comparable potency to 100 nM of quinpirole. In Figure 60B, the y-axis 
values for all three concentrations of 70 were above zero, suggesting that 
compound 70 inhibited cAMP accumulation induced by forskolin/IBMX and 
therefore acted as a D2R agonist. The stability of D2R expression in CHO cells 
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can be improved, and then it will be interesting to determine the EC50 value of 







































Figure 59. The formation of cAMP, a second messenger regulating a myriad of 
physiological functions, is catalysed by adenylyl cyclase. The hydrolysis of 
cAMP is catalysed by phosphodiesterase. The accumulation of cAMP can be 
done by treatment with either forskolin that is a diterpene isolated from Coleus 
forskohlii and binds at a hydrophobic pocket of adenylyl cyclase (Pinto et al., 
2008), or IBMX that is an xanthine-derived inhibitor of phosphodiesterase 
(Wells et al., 1981). The inhibition of such accumulation can be realised by 











Figure 60. Inhibition of cAMP accumulation induced by compound 70 in 
comparison with the reference compound quinpirole (Q). The CHO cells were 
transfected with D2R, pre-treated with the indicated concentrations of quinpirole 
or compound 70, and activated with forskolin/IBMX. (A) The cAMP 
concentration (in the unit of picomole) measured by ELISA. (B) Normalisation 
to control (0%) and 1 µM of quinpirole (100%). *p<0.05. Error bars = standard 
error of the mean (SEM). 
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The second D2R activation assay used to characterise functional properties was 
receptor internalisation. The D2R DNA plasmid with the epitope tag V5, 
encoding a peptide composed of 14 amino acids (GKPIPNPLLGLDST), was 
transfected into Human Embryonic Kidney (HEK) 293 cells. Subsequently, the 
cells were incubated with mouse anti-V5 IgG, and then with Alexa Fluor® 594-
conjugated goat anti-mouse IgG (Figure 61, Left). V5 epitope was identified 
from the P and V proteins of simian virus 5 (SV5), and has been widely used as 
one of the protein tags. The mouse monoclonal antibody anti-V5 recognised the 
V5 sequence with high specificity. To stain the internalisation process, a red-
fluorescent dye Alexa Fluor® 594 conjugated to a polyclonal anti-mouse IgG 
was chosen for detection and illumination. Images were acquired by laser 
confocal microscope. As shown in Figure 61 (Right), V5-tagged-D2R-
expressing HEK 293 cells were treated with dopamine (DA; 300 nM), 69 (0.01 
µg/mL = 30 nM), 69 (0.1 µg/mL = 298 nM), 70 (0.01 µg/mL = 28 nM) and 70 
(0.1 µg/mL = 275 nM) for immunocytochemistry. Without any ligand 
treatment, many sharp lines outlining the plasma membrane were observed, 
suggesting that in the quiescent state D2R was largely localised on the plasma 
membrane (Figure 61, control). Consistent with previous studies (Bartlett et al., 
2005), dopamine caused the D2R internalisation to a large extent, as evidenced 
by the great loss of red edges and the appearance of a punctum in the cytoplasm. 
The extent of internalisation expected of newly synthesised compounds 69 and 
70 was therefore between that of control and that of dopamine. Gratifyingly, 
following exposure to 69 and 70, the diminished surface labelling in conjunction 
with punctate intracellular patterns were observed, demonstrating the ability of 
69 and 70 to promote the endocytosis of D2R. In light of results reported by 
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other laboratories (Kuhhorn et al., 2011), such translocation of D2R from the 
plasma membrane to the cytosol induced by 69 and 70 suggested that these two 
compounds acted as D2R agonists.  
 
Figure 61. (Left) The V5 
(GKPIPNPLLGLDST)-tagged D2 
receptor was specifically 
recognised by the primary antibody 
anti-V5, which was recognised by 
the secondary antibody anti-mouse. 
The fluorophore Alexa Fluor® 594 conjugated to the secondary antibody 
enabled the tracking of D2R internalisation. (Right) Ligand-induced D2R 
internalisation. V5-tagged D2R was normally abundant on the plasma 
membrane (control—negative control), but was internalised into intracellular 
vesicles after activation by dopamine (DA—positive  control), 69 or 70.  
 
Comparing cAMP assay with internalisation assay shows that higher 
concentrations of 70 were required to inhibit cAMP accumulation than to induce 
internalisation (Figure 60 versus 61). Whilst this discrepancy may be simply 
due to variation between experiment conditions, the following possibilities 
appear to be plausible. As mentioned earlier, the paradigmatic scheme for 
receptor desensitisation has been GRK-mediated phosphorylation, but one 
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recent study shows that protein kinase C (PKC)-mediated phosphorylation can 
also result in the attenuation of Gi protein coupling and eventually the D2R 
internalisation (Namkung and Sibley, 2004). PKC is one of the second 
messenger-activated protein kinases, and in the D2R case, PKC is activated by 
the second messenger cAMP. Therefore, the increase in the formation of PKC 
due to stimulation with 70 could enable the phosphorylation of both 70-bound 
and unbound D2R, leading to a number of D2R internalisation. Since both GRK-
mediated (GRKs 2, 3, 5 and 6) phosphorylation (Ito et al., 1999) and PKC-
mediated phosphorylation could contribute to D2R internalisation, lower 
concentrations of 70 was sufficient to elicit D2R internalisation (Kelly et al., 
2008), which was in contrast with the higher concentrations of 70 for the 
inhibition of cAMP accumulation. Alternatively, the lower ligand concentration 
required for D2R internalisation can be accounted for by either (i) “heterologous 
desensitisation”, or (ii) constitutive GRK-mediated phosphorylation. 
Specifically, heterologous desensitisation is a process whereby the activation of 
one GPCR causes the desensitisation of another GPCR, and one relevant 
example of such heterologous regulation is that activation of M1 muscarinic 
receptor by carbachol (an M1R agonist) leads to an increase in D2R 
phosphorylation (Namkung and Sibley, 2004). So, it could be that compound 
70 bound non-D2R receptors to activate these receptors, and the resultant second 
messenger-dependent kinases phosphorylated D2R. Moreover, the constitutive 
D2R endocytosis has been confirmed using fluorescence microscopy and 
surface biotinylation (Vickery and von Zastrow, 1999). So, there is a possibility 
that 70-induced PKC enhanced the basal D2R internalisation. Taken together, it 
could be these three characteristic regulatory mechanisms associated with 
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D2R—PKC phosphorylation, heterologous desensitisation, and constitutive 
activity—that resulted in the lesser amount of 70 required to induce 
internalisation compared to the inhibition of cAMP accumulation.          
The third D2R activation assay used to characterise functional properties was 
TGFα shedding. Similar to the conventional cAMP assay, TGFα shedding assay 
is to measure G protein-mediated signaling (Table 15). Ectodomain shedding 
occurs at many membrane-anchored proteins, such as cytokines, growth factors, 
and transmembrane receptors, leading to the cleavage and release of the 
extracellular domains (Peschon et al., 1998). The released domains, in turn, 
regulate the paracrine signalling of another cell in the distance (Massague and 
Pandiella, 1993), sequester soluble ligands (McDermott et al., 1999), or even 
activate receptors of their own (Brown et al., 2000). The proteolytic processing 
of membrane proteins is mediated by a family of metalloproteases known as 
ADAM which is also membrane-anchored (Blobel, 2005). The importance of 
ADAM-mediated ectodomain shedding is shown in the regulation of epidermal 
growth factor receptor (EGFR) signalling (Figure 62). It is documented that 
transactivation of EGFR-dependent signalling upon GPCR activation requires 
ADAM (Prenzel et al., 1999). Specifically, as depicted in Figure 62, the 
activation of M1 muscarinic acetylcholine receptor by carbachol (an M1R 
agonist) results in G protein-dependent intracellular signalling, and this 
signalling eventually phosphorylates the cytoplasmic region of ADAM (Inoue 
et al., 2011). The phosphorylation activates the metalloprotease activity of 
ADAM to cleave the precursor of heparin-binding EGF (HB-EGF) anchored on 
the cell membrane. The released extracellular HB-EGF interacts with 
membrane-anchored EGFR and triggers a different signalling from that induced 
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by carbachol stimulation. There are therefore triple membrane-passing events 
occurred for signals being transduced in GPCR-induced EGFR activation: (i) 
the signal transduced from outside to inside the cell mediated by GPCR, (ii) the 
signal transduced from inside to outside the cell mediated by ADAM, and (iii) 
the signal transduced from outside to inside the cell mediated by EGFR. This 
GPCR-ADAM-EGFR mechanism has been identified in a variety of GPCRs, 
and could be potentially targeted for therapeutic intervention (Paolillo and 
Schinelli, 2008). In the year 2011, a group of researchers in Tohoku University 
reported that upon activation of P2Y5 receptor with lysophosphatidic acid 
(LPA), the ADAM17 (also known as TACE)-mediated shedding of the 
precursor of transforming growth factor-α (TGFα) was elicited, the released 
TGFα activated EGFR, and the triggered signalling led to hair follicle 
development (Inoue et al., 2011). This group of researchers then extended the 
application of TGFα shedding to almost all GPCRs, and demonstrated the 
usefulness of this assay system in evaluating ligand functions, including 
agonism, inverse agonism, and antagonism (Inoue et al., 2012). This assay has 
the advantage of accuracy, cost-efficiency, high-throughput capacity, and 
availability of equipment. Therefore, we adopted this assay for evaluating 
compounds 69 and 70.       
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Figure 62. The model of GPCR-ADAM-EGFR crosstalk. The stimulation of 
GPCR results in activation of ADAM, leading to proteolytic cleavage of proHB-
EGF. The released mature EGF-like ligand activates EGFR and its downstream 
signalling events (Fischer et al., 2003). Reproduced with permission, from O.M. 
Fischer, S. Hart, A. Gschwind and A. Ullrich (2013) Biochemical Society 
Transactions, 31, 1203-1208. © the Biochemical Society. Link:  
http://www.biochemsoctrans.org/bst/031/1203/bst0311203.htm          
 
The principles of evaluating GPCR activation using TGFα is shown in Figure 
63. In this assay, HEK 293 cells were transfected with dopamine D2 receptor, 
alkaline phosphatase (AP)-tagged TGFα, and Gα protein. The transfected cells 
were seeded in a 96-well plate and treated with dopamine (as the positive 
control), 69 and 70. After incubation for 1 h, the conditioned media were 
separated from cells by centrifugation. Adding para-nitrophenylphosphate (p-
NPP) (an AP substrate) followed by measurement of absorbance at the 
wavelength of 405 nm gave the results shown in Figure 64. Dopamine (DA) 
was used in low concentrations (10 nM and 1 µM), and the obvious AP-TGFα 
release induced by DA treatment suggests that this TGFα shedding assay was 
working in the D2R system, and the effects of 69 and 70 were compared with 
 CHAPTER 5   
182 
 
that of DA. The percentage of AP-TGFα release stimulated by three 
concentrations (1 µM, 10 µM, 100 µM) of 69 and 70 were recorded. Whilst 
compound 69 at 1 µM and 10 µM showed marginal concentration-dependent 
responses, higher concentration (i.e. 100 µM) of 69 led to a significant reduction 
in the extent of AP-TGFα release. It is possible that compound 69 has non-
specific binding at receptors other than D2R, and in turn, induces additional 
intracellular signalling events. The crosstalk between D2R-mediated and non-
D2R-mediated signalling pathways could somehow prevent TACE from being 
activated by, for example, abolishing phosphorylation of TACE. In contrast, 
compound 70 showed a more marked dose-response relationships with the 
concentrations ranging from 1 µM to 100 µM, indicating that compound 70 was 
amenable to ectodomain shedding of AP-TGFα. In terms of AP-TGFα release, 
compound 70 at 100 µM gave a one-third response relative to that induced by 
dopamine at 10 nM. Since compound 70 showed concentration-dependent AP-
TGFα release, it would be interesting to determine EC50 value of 70. Overall, 
both 69 and 70 showed effects in the TGFα shedding assay in D2R-expressing 
cells, suggesting the capacity of the two compounds for activating D2R. Table 
16 summarises the three D2R activation assays used in the thesis. Since cAMP 
and TGFα assays are G protein-mediated, the justification provided previously 
for the lower ligand concentrations in the cAMP assay than in the internalisation 
assay may apply to the results of the TGFα assay. In summary, compound 70 
was shown to be a D2R agonist in the cAMP, internalisation and TGFα assays, 
and compound 69 was shown to be a D2R agonist in the internalisation and 
TGFα assays.                




Figure 63. The mechanism of TGFα shedding assay for assessing GPCR 
activation. If a ligand were to activate a GPCR, the resulting G protein-mediated 
signalling would lead to the activation of TNFα converting enzyme (TACE), 
also known as ADAM17. TACE, acting as a sheddase, proteolytically cleaves 
the membrane-anchored precursor of AP-tagged TGFα to a certain extent. The 
AP-tagged TGFα is released to the condition media, and the extent of AP-TGFα 
release is measured by the formation of para-nitrophenol (p-NP) catalysed by 
AP. (Inoue et al., 2012) (reprinted with permission).       
 
 
Figure 64. The TGFα shedding assay for compounds 69, 70 and dopamine 
(DA). 
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Table 16. Summary of Three D2R Activation Assays 
assay cell line ligands  
assessed
potency on D2R activation 







69: 30 nM, 298 nM 






69: marginal effects 
100 µM of 70 ~ 1/3 effect induced by 
10 nM of DA 
 
5.3.3    Drug-like properties  
The drug discovery approach adopted in the thesis is to start with two validated 
pharmacologically relevant receptors, namely adenosine A2A and dopamine D2 
receptors, followed by in vitro testing of ligand-receptor binding—a study of 
what the compounds do to the therapeutic targets. This approach often results 
in the quest for strongest receptor binding and high selectivity with a negligence 
of considering the journey of a drug from its site of administration to its site of 
action. It is very rare that a drug can be applied directly to the intended 
pharmacological targets for which it is designed, so more often than not a drug 
must first make a journey to its site of action via systemic circulation. Whilst 
the way for a drug to enter into systemic circulation can be many, such as 
through oral dosing (most common route of administration), injection into 
muscle, injection into subcutaneous tissue layers, rectal delivery, transdermal 
delivery, intranasal delivery, pulmonary delivery (Boussery et al., 2008), one 
common event before reaching systemic circulation is to permeate biological 
membranes. The process of a drug from its site of administration to systemic 
circulation is known as absorption, and after that, the movement of the drug 
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from one location to another (e.g. the intended tissue where therapeutic targets 
are located, the unintended site giving rise to adverse effects) via blood plasma 
refers to distribution. It is therefore the combination of the in vitro activity 
profiles and the performance at all biological barriers (Kerns and Di, 2008b) 
from the site of administration to the site of action that determine the in vivo 
exposure of a drug to the specific therapeutic targets.  
Take an orally administered drug for example. Suppose the drug has been shown 
good in vitro affinity and selectivity at a particular receptor or a subset of 
receptors. After it is taken orally, the first barrier is the dissolution rate of the 
drug in the acidic stomach environment (pH 1~3) because the drug must be 
dissolved in the aqueous physiological media prior to passing the capillaries for 
absorption. Generally, drugs have limited absorption in the stomach due to (i) 
low surface area of stomach, (ii) low blood flow around the stomach, and (iii) 
rapid gastric emptying. Subsequently, the drug goes to the small intestine 
(duodenum, jejunum, ileum) with pH 5~8, and the barriers here are the 
dissolution rate, solubility (in pH 5~8), and membrane permeability across the 
intestinal wall where most of the drug absorption occurs. Additional barriers in 
the intestine includes metabolic enzymes cytochrome P450 3A4 (CYP3A4), 
enzymatic hydrolysis (by peptidase, esterase, ribonuclease, phosphatase), and 
efflux transporter P-glycoprotein (P-gp). Overall, the barriers for a drug in the 
gastrointestinal (GI) tract include (i) dissolution rate, (ii) solubility, (iii) 
permeability, (iv) chemical instability, and (v) hydrolytic enzymes. After the 
drug enters into the bloodstream and before it distributes to the therapeutic 
target, barriers include (i) plasma protein binding, (ii) plasma enzyme 
hydrolysis, (iii) red blood cell binding, and (iv) blood-brain barrier (BBB), if 
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the intended target is located inside the brain. Concurrently, a portion of the 
drug is always eliminated from the body by biotransformation (i.e. xenobiotic 
metabolism taking place mainly in liver) and excretion (i.e. removal by kidney 
or bile), both of which also constitute barriers to effective in vivo drug 
concentrations at the therapeutic target. Taken together, after administration, the 
drug concentration in vivo increases upon absorption, and due to multiple 
biological barriers the concentration decreases with time as it is distributed to 
tissues, metabolised by enzymes, and eventually eliminated from the body 
(ADME) (Figure 64). Pharmacokinetics (PK) is the time-course study of drug 
concentrations in the body from absorption to elimination, and it is described as 
what the body does to the drug. Importantly, PK parameters, including volume 
of distribution (Vd), area under the curve (AUC), clearance (CL), half-life (T1/2) 
and bioavailability (F) are useful to assess the exposure of a drug (Kerns and 
Di, 2008g). For elaborate information on PK parameters, readers are referred to 
relevant textbooks (Rowland and Tozer, 2010; Shargel et al., 2012). PK of a 
drug is important because, despite good in vitro activity (e.g. affinity, 
selectivity), its delivery to the intended therapeutic targets in vivo could 
potentially be attenuated by all the aforementioned biological barriers, resulting 
in reduced in vivo exposure. Thus, in addition to establish structure-activity 
relationship (SAR) for achieving strong target binding, exploring structure-
property relationship (SPR) to ensure high performance at every biological 
barrier is equally important and serves as a complement to SAR for the purpose 
of maximising drug efficacy (Di et al., 2009). That is, modifications of chemical 
structures can be used not only for enhancing binding affinity at the intended 
targets but also for improving the drug exposure to the intended targets.  




Figure 64. Schematic representation of drug absorption, distribution and 
elimination. Despite being “active” in in vitro assays on affinity, the drug needs 
to reach its site of action to exert its pharmacological effects. Thus, 
pharmacokinetics precedes pharmacodynamics. Upon administration, multiple 
barriers exist until the drug reaches the site of action, and each of these barriers 
can reduce the rate and extent of progressing to the target.  
 
According to Christopher A. Lipinski, “drug-like” compounds refer to those that 
have “sufficiently acceptable” ADME and toxicity (ADME-Tox) properties to 
survive Phase 1 clinical trials (Lipinski, 2000). By this definition, it is clear that 
drug-likeness includes both inherent activity at the target and sufficient 
exposure. Notably, drug-like properties have been in some ways more linked to 
properties influencing ADME-Tox since Lipinski’s publications. It is 
documented that poor ADME-Tox properties contribute 50% of reasons for 
drug attrition (van de Waterbeemd and Gifford, 2003), and that those drug-like 
properties which have the most impact on drug discovery and development are 
solubility, permeability, metabolism, and transporter effects (Di et al., 2009). In 
the thesis, the following assays were therefore performed in vitro for 
compounds 69 and 70: (i) solubility (Section 5.3.3.1), (ii) permeability (Section 
5.3.3.1), (iii) metabolism (Section 5.3.3.2), and (iv) toxicity (Section 5.3.3.3) 
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assays. Measuring these physicochemical (i.e. solubility, permeability), 
biochemical (i.e. metabolism), and toxicological properties not only reveals 
clues to how drug-like 69 and 70 are (Kerns and Di, 2008a) but also guides 
prediction and structural modification (van De Waterbeemd et al., 2001) 
towards optimal in vivo exposure.   
 
5.3.3.1    Solubility and permeability assays        
The importance of aqueous solubility and intestinal permeability can be 
illustrated by Biopharmaceutics Classification System (BCS) introduced by 
Gordon L. Amidon in 1995 (Amidon et al., 1995). BCS states that solubility and 
permeability are key parameters dictating drug absorption, and divides drugs 
into four classes—(i) Class I (high solubility-high permeability drugs), (ii) Class 
II (low solubility-high permeability drugs), (iii) Class III (high solubility-low 
permeability drugs), and (iv) Class IV (low solubility-low permeability drugs). 
According to BCS, a highly soluble drug refers to the highest dose strength of 
a drug is soluble in ≤ 250 mL of aqueous media over a pH range of 1.0–7.5, and 
a highly permeable drug means the extent of absorption ≥ 90% of administered 
dose. In 2000, the BCS guidance was accepted and published by Food and Drug 
Administration (FDA) as a standard to allow a waiver for Class I drugs (highly 
soluble and highly permeable) of in vivo bioavailability/bioequivalence testing. 
In 2006, such waiver was extended to Class III (highly soluble but with low 
permeability) supported by World Health Organization (WHO) (Shah and 
Amidon, 2014). BCS classification is not only useful for predicting oral 
absorption, a later analysis demonstrated its usefulness in predicting routes of 
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elimination: in general, (i) Class I and Class II drugs are prone to be 
metabolized, and (ii) Class III and Class IV drugs are primarily eliminated by 
kidney or bile (Wu and Benet, 2005), warranting the investigation of solubility 
and permeability of compounds 69 and 70.  
Kinetic solubility was determined by pre-dissolving compounds in DMSO as a 
10 mM stock solution followed by the addition into the aqueous buffer solution. 
The turbid mixture was transferred to MultiScreen filter plates (Millipore), 
incubated for a fixed period of time (i.e. 3 h and 24 h), and filtered. The UV 
absorbance (at 250 nm) of the filtrate was measured using a UV plate reader. 
According to Beer’s law, the concentration of the compound is proportional to 
the UV absorbance, and the results are presented in Table 17. The solubility of 
compound 69 was 9.07 ± 0.11 µg/mL (27.03 ± 0.32 µM) at 3 h and 4.58 ± 0.10 
µg/mL (13.67 ± 0.31 µM) at 24 h. The solubility of compound 70 was 2.75 ± 
0.05 µg/mL (7.55 ± 0.14 µM) at 3 h and 1.41 ± 0.01 µg/mL (3.89 ± 0.03 µM) 
at 24 h. The minimum solubility required of a compound depends on its 
permeability and dose. Specifically, for drugs with higher permeability and 
higher potency (i.e. lower dose to produce the pharmacological effects), lower 
solubility is sufficient for them to achieve complete oral absorption. On the 
contrary, drugs with lower permeability and lower potency (i.e. needing a higher 
dose to produce the pharmacological effects), higher solubility is necessary for 
them to achieve complete oral absorption. In short, solubility, permeability and 
dose of a drug are intercorrelated (Lipinski, 2000). Due to the fact that doses are 
generally not defined at the drug discovery stage but at the drug development 
stage, a solubility guideline for oral absorption is suggested for drug discovery 
teams: < 10 µg/mL (low solubility), 10~60 µg/mL (moderate solubility), > 60 
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µg/mL (high solubility) (Kerns and Di, 2008c). Both 69 and 70 exhibited low 
aqueous solubility at ambient temperature in pH 7.4, and the decrease in 
solubility was observed as the incubation time increased from 3 h to 24 h. In 
addition to the comparison of solubility results with the aforementioned 
guideline that is mainly for absorption at the gastrointestinal (GI) tract, it would 
be helpful to examine the solubility profiling of marketed CNS drugs 
(Alelyunas et al., 2010) since 69 and 70 were meant to treat PD, a CNS disorder. 
A group of researchers in AstraZeneca measured the solubility of 98 marketed 
CNS drugs, and the results showed that (i) 84% of the CNS drugs have solubility 
> 100 µM, (ii)  7% of the CNS drugs have solubility < 10 µM, and (iii) the CNS 
drugs with solubility < 10 µM are either out of the current market or having 
liabilities. In light of these results, there seems an association between low 
solubility and attrition in CNS drugs. Thus, the poorly water-soluble compounds 
69 and 70 (solubility in the range of 4~27 µM) can pose a high risk if they are 
further advanced and developed without performing any solubility 
improvement.  
Zoom-in analysis of individual solubility shows the slightly better solubility of 
69 than that of 70, which can be accounted for by structural properties of 69 and 
70 (Table 18). For a drug solute to pass into an aqueous solution, the following 
steps are required: (i) the solute molecule removed from the crystal lattice, a 
process requiring to break solute-solute interactions; (ii) a void created in the 
solvent; (iii) the solute molecule inserted into the solvent, creating solute-
solvent interactions. Solubilisation is energetically favourable if the energy 
released from solute-solvent interactions in step (iii) is larger than that used for 
destroying solute-solute interactions in step (i) as well as solvent-solvent 
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interactions (which is usually negligible) in step (ii). The two primary 
determinants of drug solubility in aqueous media are therefore associated with 
steps (i) and (iii). This implies that, for a series of analogous compounds such 
as 69 and 70, solubility is lower for those with stronger intermolecular attraction 
(which can be generally indicated by higher melting point and higher molecular 
weight) and weaker water affinity (which can be indicated by higher 
partition/distribution coefficient). Thus, the higher CLogP, CLogD and MW of 
70 (Table 18) resulted in its lower solubility. The structural properties shown in 
Table 18 can not only explain the slight difference in solubility of 69 and 70, 
but can also underpin the tactics for improving solubility, which will be 
proposed in Chapter 6 (Walker, 2014; Williams et al., 2013).  
 
Table 17. The Aqueous Solubility and Permeability of Compounds 69 and 
70a 
 69 70 guidelineb 
solubility (µg/mL), 3 h 9.07 ± 0.11 2.75 ± 0.05 > 60 
solubility (µM), 3 h 27.03 ± 0.32 7.55 ± 0.14 > 100 
solubility (µg/mL), 24 h 4.58 ± 0.10 1.41 ± 0.01 > 60 
solubility (µM), 24 h 13.67 ± 0.31 3.89 ± 0.03 > 100 
PAMPA Pe (10-8 cm/s), 6 h 2.47 ± 0.09 52.02 ± 1.49 > 200 
PAMPA Pe (10-8 cm/s), 16 h 9.25 ± 0.33 54.93 ± 2.78 > 200 
aConditions in determining solubility: pH 7.4, temperature 22.5 ± 2.5 oC. 
Conditions in determining permeability: pH 7.4, temperature 30.0 ± 2.5 oC. 
PAMPA: parallel artificial membrane permeability assay. Pe: effective 
permeability. Data presented as mean ± SD (three determinations of test 





 CHAPTER 5   
192 
 






aCLogP: calculated partition coefficient. CLogD: calculated distribution 
coefficient at pH = 7.4. MW: molecular weight. TPSA: topological polar surface 
area (Ertl et al., 2000). HBD: number of hydrogen bond donors. pKa: negative 
base-10 logarithm of acid dissociation constant for the most basic centre. 
CLogP, CLogD, TPSA and pKa were calculated by MarvinSketch 15.1.5.0. 
 
In addition, permeability of compounds 69 and 70 was determined (Table 17). 
In the intestine, the membrane permeation is mainly mediated by four 
mechanisms, namely passive transcellular transport, paracellular permeation, 
carrier-mediated uptake, and carrier-mediate efflux (Figure 65). Passive 
transport is a diffusion process driven by concentration gradient resulting in the 
movement of drugs from one side of the lipid bilayer to the other side, and it is 
documented that 80~95% of marketed drugs are absorbed in the intestine via 
passive diffusion (Kerns et al., 2004). In paracellular permeation, small and 
polar drugs (e.g. salicylic acid, theophylline) pass membranes through loose 
junctions between cells. Carriers, also known as transporters, are 
transmembrane proteins that bind drug molecules, consume energy, and then 
move drug molecules into (by uptake transporters) or out of (by efflux 
transporter) a cell (Sugano et al., 2010). A non-cell-based permeability assay, 
known as parallel artificial membrane permeability assay (PAMPA), was 
developed in 1998 to specifically describe passive absorption process (Kansy et 
al., 1998). PAMPA has the advantages of increased throughput, reduced cost, 
 69 70 
CLogP 2.14 2.27 
CLogD 2.13 2.26 
MW 335.4 363.5 
TPSA 65.1 65.1 
HBD 1 1 
pKa 4.67 4.67 
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and rapid turnaround time, as well as its single mechanism of permeability (i.e. 
passive diffusion). The fact that the majority of drug molecules are absorbed by 
passive diffusion justifies the use of PAMPA for compounds 69 and 70. As 
shown in Figure 66, the test compound in DMSO was diluted with aqueous 
buffer and then placed in the donor well. To the acceptor well, with a porous 
filter at the bottom, was added phospholipid (i.e. lecithin) solubilised in the 
long-chain hydrocarbon (i.e. dodecane) that acted as the artificial membrane. 
The mixture was incubated for a period of time (6 h and 16 h), and samples were 
taken from both donor and acceptor wells. The concentrations of test compound 
in both wells were derived by LCMS analysis, and the derived concentrations 
were converted to effective permeability (Pe) (Kerns and Di, 2008h). At pH 7.4, 
the Pe values of 69 were 2.47 ± 0.09 (× 10-8 cm/s) at 6 h and 9.25 ± 0.33 (× 10-
8 cm/s) at 16 h. At pH 7.4, the Pe values of 70 were 52.02 ± 1.49 (× 10-8 cm/s) 
at 6 h and 54.93 ± 2.78 (× 10-8 cm/s) at 16 h (Table 17). A guideline for PAMPA 
with respect to Pe states that the compound with Pe > 2 (× 10-6 cm/s) is 
considered to have high absorption potential, the compound with Pe = 0.5~2 (× 
10-6 cm/s) is considered to have medium absorption potential, and the 
compound with Pe < 0.5 (× 10-6 cm/s) is considered to have low absorption 
potential (Avdeef et al., 2007). Accordingly, 69 and 70 were found to be poorly 
permeable. Compounds with low permeability are typically detrimental to their 
intestinal absorption (Lipinski et al., 1997), bioavailability (Kerns and Di, 
2008d), and cell-based activity (if the therapeutic target is inside the cell) (Kerns 
et al., 2004). For both 69 and 70, permeability increased as the incubation time 
increased from 6 h to 16 h. The determinants of permeability include 
lipophilicity of the compound (Avdeef et al., 2007), compound pKa/solution pH 
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(Kerns et al., 2004), molecular weight of the compound (Di et al., 2009), as well 
as polarity of the compound indicated by hydrogen bond donors/acceptors and 
polar surface area (Veber et al., 2002). Because the biological membrane is 
composed of nonpolar lipid bilayers, permeability is generally higher for 
compounds with higher lipophilicity, un-ionisable, smaller size, and reduced 
polarity. The higher permeability of 70 (Table 17) is therefore the consequence 
of its higher CLogP and CLogD (Table 18), which may outweigh the effect of 
molecular weight. Possible structural modifications to improve permeability 
will be proposed in Chapter 6.  
Figure 65. Four major mechanisms of intestinal membrane transport. A: passive 
transcellular transport, B: paracellular permeation, C: carrier-mediated uptake, 
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5.3.3.2    Metabolism assays 
Solubility and permeability are two major determinants of drug absorption 
(Lipinski et al., 1997). After a drug is absorbed and distributed to its target 
macromolecules through the blood, it is then cleared from the body. Drug 
clearance (or, drug elimination) is done by three mechanisms: (i) hepatic 
biotransformation (most prevalent), (ii) biliary excretion of unchanged drugs, 
and (iii) renal excretion of unchanged drugs (Obach, 2013). Hepatic 
biotransformation takes place mostly by the enzymes in the endoplasmic 
reticulum (ER), and is often a bi-phasic process whereby the drug first 
undergoes Phase I functionalisation reactions (e.g. oxidation catalysed by 
cytochrome P450 enzymes or flavin monooxygenases), followed by Phase II 
conjugation reactions (e.g. glucuronidation catalysed by uridine 5’-diphospho-
glucuronosyltransferases). Both Phase I and II reactions have a common goal—
generating more polar compounds to facilitate the excretion via bile or urine. 
Drug metabolism must be executed in optimal timing, that is, neither too quickly 
so as to ensure adequate drug efficacy, nor too late to minimise toxicity. At one 
end of the spectrum, when a drug is overly metabolised at the stage of first-pass 
intestinal metabolism or first-pass hepatic metabolism before reaching 
therapeutic targets, the low in vivo exposure may compromise drug efficacy. In 
this extreme case, the improvement in efficacy can be done by making 
analogues to block labile sites (Kerns and Di, 2008e, i). At the other extreme in 
which two drugs (e.g. drug A and drug B) are co-administered, the binding of 
drug A at a cytochrome P450 (CYP) isozyme results in the reduced binding of 
drug B at this particular isozyme, which in turn, leads to the reduced clearance 
of drug B. The higher concentration of drug B due to inhibited metabolism may 
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be toxic. A notable example is the co-administration of erythromycin (acting as 
drug A) and terfenadine (acting as drug B). Erythromycin inhibits the 
metabolism of terfenadine, and the accumulation of terfenadine results in 
cardiac arrhythmia. This results in the withdrawal of terfenadine from the 
market in February 1998. In this extreme case, structural modification for 
making analogues that decrease the binding at CYP isozymes can be done to 
reduce toxicity (Kerns and Di, 2008f). For the details regarding all enzymes that 
involve in drug metabolism, how enzymes catalyse metabolic reactions, and the 
possibility of generating toxic or active metabolites, readers may consult listed 
references (Macherey and Dansette, 2008; Obach, 2013; Testa, 2008).       
The in vitro metabolic stability of compounds 69 and 70 was evaluated by liver 
microsomes. Liver microsomes contain CYP isozymes, flavin 
monooxygenases, reductases, esterases, UDP-glucuronosyltransferases, amino 
acid conjugases, glutathione-S-transferases, and methyltransferases. The 
cofactor NADPH is needed because it is a high energy molecule and provides 
energy for reactions catalysed by enzymes contained in the microsome. Such in 
vitro microsomal assay is generally the first-line and most frequently used 
method to assess drug clearance by Phase I enzymes, primarily by CYP 
isozymes. This is because approximately 60% of marketed drugs are 
metabolised by CYP-mediated reactions (McGinnity et al., 2004). It is also 
worth noting that metabolic stability is quite species-dependent, so microsomes 
derived from rat, mouse, and human can have variable results (Di et al., 2003). 
Rat microsomes are commonly used in the early stage of drug discovery, and 
are therefore adopted for evaluating 69 and 70. To the mixture of a rat liver 
microsome (either male or female) and a test compound (either 69 or 70) was 
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added NADPH, and an aliquot of the incubation sample mixture was collected 
at six different time points (i.e. 0 min, 5 min, 10 min, 15 min, 30 min, 45 min). 
The collected samples were centrifuged, and the supernatant portions were 
subjected to LC-MS/MS analysis for the quantification of the remaining parent 
compounds. Midazolam, a known CYP substrate, was used as the positive 
control. As shown in Figure 67, the half-life (T1/2) of midazolam (ca. 3~4 min) 
was in agreement with that reported previously in a highly cited paper (Obach, 
1999) (times cited: 540, Web of Science, as at 7 April 2015), indicating that the 
experimental conditions used here were robust enough to describe the metabolic 
stability of 69 and 70. In this experiment, in vitro half-life (T1/2), which refers 
to the time required for the concentration of the test compound reduced by half, 
was used to determine in vitro intrinsic clearance (CLint, in vitro) values (Obach, 
1997). Lower half-life is correlated with higher clearance. Within 10 min, both 
69 and 70 were quickly metabolised with less than 30% remaining, suggesting 
that both compounds were metabolically unstable. The half-life values of 69 
and 70 were determined to be 4.4~5.2 min and 0.80~1.26 min, respectively. In 
general, compounds having short half-life in the in vitro metabolic stability 
assay tend to suffer from low oral bioavailability (Wring et al., 2002). A useful 
guideline for rat microsomal stability states that compounds with in vitro 
intrinsic clearance < 13.2 µL/min/mg are categorised as “low clearance”, and 
compounds with in vitro intrinsic clearance > 71.9 µL/min/mg are categorised 
as “high clearance” (Cyprotex, 2015). Clearly, compounds 69 and 70 fall into 
“high clearance” category, which may result in insufficient duration of action 
in vivo. In addition, after 5 min of incubation, the remaining percentage of 69 
(i.e. 40% and 72%) was still higher than that of midazolam (i.e. 28%), whereas 
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the remaining percentage of 70 (i.e. 1% and 7%) was extremely low, suggesting 
that 70 is more metabolically unstable than 69. Numerous studies have shown 
that there is a linear relationship between the lipophilicity of a compound and 
its binding affinity at CYP isozymes, that is, a more lipophilic compound 
required lower concentrations to saturate a given CYP isozyme (Lewis et al., 
2004; Lewis and Ito, 2008). Hence it appears likely that the higher in vitro 
intrinsic clearance of 70 (CLint, in vitro = 1864~3089 µL/min/mg) than that of 69 
(CLint, in vitro = 447~522 µL/min/mg) is the consequence of the higher CLogP and 
CLogD values of compared 70 (Table 18). Moreover, for both compounds, 
higher clearance in the male rat liver microsome (MRLM) than that in the female 
rat liver microsome (FRLM) can be explained by the fact that CYP3A and 
CYP2C are found only in MRLM. It is believed that MRLM could be more 
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Subsequently, LightSight Software (AB Sciex) was employed to identify 
possible metabolites of compounds 69 (Table 19 and Figure 68) and 70 (Table 
20 and Figure 70). After incubation, the LC-MS/MS analysis for the time 
window of 30 min led to the detection of the parent compound 69 (i.e. M19) 
and its 19 metabolites (i.e. M1–M18, M20), all of which were eluted before 20 
min (Table 19). These 19 metabolites can be classified into 5 groups: (i) MW 
gain of 32 (i.e. M1, M2, M5 and M7) due to dioxygenation of 69; (ii) MW gain 
of 14 (i.e. M3 and M4) due to either (ii-a) methylation of 69, or (ii-b) the 
conversion of CH2 to keto C(=O) of 69; (iii) MW gain of 16 (i.e. M6, M8, M11–
M15, M17 and M18) due to monooxygenation of 69; (iv) MW gain of 18 (i.e. 
M9 and M10) due to either (iv-a) the addition of OH and H of 69, (iv-b) 
hydrogenation and monooxygenation of 69, or (iv-c) demethylation and 
deoxygenation of 69; (v) MW loss of 2 (i.e. M16 and M20) due to 
dehydrogenation of 69. The amount of parent compound 69 (i.e. M19) was ca. 
8% of the total analyte after incubation with microsomes, and the 19 metabolites 
constituted the remaining ca. 92%, which was consistent with the metabolic 
instability of 69 shown in Figure 67. Of all the 19 metabolites, M8 (retention 
time: 14.03 min, m/z 352.1), which has the gain of mass shift 15.7 relative to 
the protonated parent compound 69 (m/z 336.4), was found to be the 
predominant metabolite of 69. This peak with m/z 352.1 was expected to be a 
protonated monooxygenation product of 69. The fragmentation patterns of M8 
and M19 (i.e. the protonated parent compound 69) are shown in Figure 68. 
Compound 69 displayed an MH+ ion at m/z 336.1, and three product ions at m/z 
193.1, m/z 150.1, and m/z 144.1. The prominent product ion at m/z 193.1 
corresponded to fragment F1, which was formed by amide hydrolysis of 69. 
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The product ion at m/z 144.1 was identified as the other product of amide 
hydrolysis, and corresponded to fragment F2. A moderate amount of product 
ion at m/z 150.1 was observed, and it corresponded to fragment F3. In the 
product ion spectrum of M8, the MH+ ion (m/z 352.0), which was 16 mass units 
higher than that of 69 (m/z 336.1), indicated an additional oxygen atom was 
incorporated into M8. The common product ion at m/z 144.1 observed in both 
parent 69 and M8 excluded the possibility that monooxygenation occurred in 
fragment F2. That is, monooxygenation must have occurred in fragment F1, 
and this surmise was supported by the presence of the product ion at m/z 209.1, 
corresponding to fragment F4, in highest abundance. The product ion at m/z 
166.1, corresponding to fragment F5, further narrowed down the possibilities 
of monooxygenation positions—fragment F3 was revealed to be the moiety 
where monooxygenation occurred.   
 
Table 19. Metabolites of Compound 69 Identified Using LightSight Software 
Sorted by Retention Time  
 




Figure 68. The product ion spectra of the parent compound 69 and its major 
metabolite 69-M8. The respective fragment ions are highlighted in yellow. The 
structure of 69-M8 was not confirmed. 
 
Reviewing buspirone metabolism may give clues to the exact position of mono-
oxidation on fragment F3. Buspirone (Figure 69), as mentioned in Appendix D 
(Figure A4), is an anxiolytic drug approved by FDA in 1986. A group of 
researchers in Bristol-Myers Squibb conducted an in vitro study using human 
liver microsomes to profile metabolites of buspirone and determine CYP 
isozymes responsible for these metabolic reactions (Zhu et al., 2005). They 
demonstrated that the primary metabolites of buspirone are 1-PP by N-
dealkylation, Bu N-oxide by N-oxidation, and 3’-OH-Bu, 5-OH-Bu and 6’-OH-
Bu by hydroxylation (Figure 69). It appears that CYP isozymes tend to perform 
aromatic oxidation (Meunier et al., 2004) at the C5 position of pyrimidine of 1-
PP moiety. This metabolic study on buspirone led to a hypothesis that mono-
oxidation also occurred at the C5 position of pyrimidine of fragment F3 (Figure 
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68). This hypothesis can be proven true only if the followings are met: (i) 69-
M8 is synthesised as the reference standard, (ii) the retention time of synthesised 
69-M8 is the same as that of M8 peak (i.e. 14.03 min), and (iii) the product ion 
spectrum of synthesised 69-M8 is the same as that of M8 peak (i.e. the top 















































Figure 69. The proposed buspirone metabolism in human liver microsomes.  
 
For compound 70, a total of 15 metabolites (Table 20) were detected. Unlike 
compound 69, the parent compound 70 did not exist in the metabolite mixtures, 
which was consistent with the observation in Figure 67 that compound 70 was 
more metabolically unstable than compound 69. These 15 metabolites can be 
classified into 5 groups: (i) MW gain of 48 (i.e. M1) due to trioxygenation of 
70; (ii) MW gain of 14 (i.e. M2–M5, M7–M9) due to either (ii-a) methylation 
of 70, or (ii-b) the conversion of CH2 to keto C(=O) of 70; (iii) MW gain of 32 
(i.e. M6, M10 and M11) due to dioxygenation of 70; (iv) MW gain of 16 (i.e. 
M13) due to monooxygenation of 70; (v) MW loss of 2 (i.e. M12, M14 and 
M15) due to dehydrogenation of 70. Of all the 15 metabolites, M11 (retention 
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time: 12.04 min, m/z 396.1), which has the gain of mass shift 31.6 relative to 
the calculated protonated parent compound 70 (m/z 364.5), was found to be the 
predominant metabolite of 70. The percentage (ca. 20%) of 70-M11 in the 
metabolite mixtures of 70 was approximately 20%, lower than that (ca. 50%) of 
69-M8 in the metabolite mixtures of 69. This peak with m/z 396.1 was expected 
to be a protonated dioxygenation product of 70. The fragmentation patterns of 
M11 are shown in Figure 70. The MH+ ion (m/z 396.1), which was 32 mass 
units higher than that of 70 (m/z 364.5), was in highest abundance, and indicated 
two additional oxygen atoms were incorporated into 70. The product ion at m/z 
144.1 corresponded to fragment F6, and the product ion at m/z 336.0 appeared 
to the product of di-demethylation of 70. One of the oxygenation positions is 
presumed to be at the 5 position of pyrimidine in the light of studies on 
buspirone metabolism (Figure 69), and the region of the other oxidation position 
can be deduced from the presence of other product ions. First, the presence of 
product ion at m/z 144.1 precluded the possibility of oxygenation on F6. Second, 
product ions at m/z 182.2 and 225.2, although the intensities are low, provided 
a clue that the other oxygenation should occur on fragment F8. A previous study 
using tandem mass spectrometry to analyse the mixture of SCH 66712, a 
compound containing piperazinylpyrimidine, and CYP2D6 (Nagy et al., 2011) 
led to a speculation that the specific site of the other oxidation is more likely to 
be the piperazine ring (the red circle on 70-M11 in Figure 70), not the 
pyrimidine ring. This speculation was supported by some other metabolic 
studies of piperazine-containing drugs (Kamel et al., 2010; Miraglia et al., 2010; 
Pellegatti et al., 2009). That said, similar to the discussion for compound 69 
(vide supra), reference standards are needed to confirm the speculation. Possible 
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metabolites informed by the analysis of Figure 70 include amine oxide 96 and 
hydroxylated 97 and 98 (Figure 71), and these three proposed compounds can 
be the reference standard to test the speculation.  
 
Table 20. Metabolites of Compound 70 Identified Using LightSight Software 
Sorted by Retention Time 
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Figure 70. The product ion spectrum of the major metabolite of 70. The 
respective fragment ions are highlighted in yellow. The structure of 70-M11 





























Figure 71. The proposed compounds 96-98. 
 
Taken together, synthesis of proposed 69-M8 is required to confirm the 
chemical structure of the major metabolite of 69 (i.e. M8 in Table 19), and 
synthesis of proposed 96-98 is also necessary to confirm the chemical structure 
of the major metabolite of 70 (i.e. M11 of Table 20). Future directions on the 
improvement of metabolic stability of 69 and 70 will be discussed in Chapter 6.  
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5.3.3.3    Toxicity assays 
Like what have been stated in Chapter 1, drug design and discovery projects 
should focus not only on enhancing the beneficial effects of drugs but also on 
reducing the potentially deleterious effects of drugs, which can arise from CYP 
inhibition (Zlokarnik et al., 2005), hERG blocking (Sanguinetti and Mitcheson, 
2005), formation of reactive metabolites (Kalgutkar et al., 2005), or induction 
of oxidative stress (Deavall et al., 2012). The study of drug toxicity focuses on 
these unintended effects, also known as side effects or adverse drug reactions, 
which lead to the disruption of normal physiological functions. Drug toxicity 
accounts for approximately 30% drug attrition (Kola and Landis, 2004), so early 
screening of toxicity can greatly minimise the risks of costs spent in the late 
stages of development as well as patients’ health after drugs get marketed. In 
the thesis, in vitro assays for mutagenicity and cytotoxicity were performed on 
compounds 69 and 70.  
Mutagens are substances capable of inducing transmissible damages to genetic 
materials, which may lead to cancer (Benigni and Bossa, 2011; Benigni et al., 
2013). One well-established method to investigate the mutagenic potential of a 
compound is bacterial reverse mutation assay, also known as Ames assay 
(Figure 72) (Mortelmans and Zeiger, 2000). The assay measures the extent to 
which a given compound can revert, regain or restore the gene function as the 
indicator of its mutagenicity. Specifically, the initial screening of histidine 
mutants (His–) of Salmonella typhimurium done by Bruce N. Ames in the 1970s 
led to the selection of some tester strains (e.g. TA98, TA100, TA1535, TA1537, 
TA1538) that are highly sensitive to various mutagens and can be reverted back 
to their wild types (His+) (Ames et al., 1973). The Salmonella typhimurium 
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strains with pre-existing mutations (His–) are unable to synthesise histidine (one 
of the growth requirements for these strains) and therefore could not form 
colonies in the agar plate. If the incubation of one such strain with a given 
chemical results in the formation of many colonies, it would suggest that the 
chemical induces back-mutation (His– → His+) and is therefore considered as a 
mutagen. But if the incubation does not result in many colonies but only few 
colonies comparable with those in the negative control, the observed colonies 
should be arising from spontaneous back-mutation but not from chemical 
treatment and therefore the chemical is considered as a non-mutagen.  
Figure 72. Diagram depicting Ames assay. The source of this figure is 
Genetics: Analysis and Principles (Robert J. Brooker, McGraw-Hill Education, 
copyright year 2012). The figure is reproduced with permission of McGraw-
Hill Education. 
 
A previous analysis of the mutagenicity database in National Toxicology 
Program (NTP) showed that using two Salmonella strains TA98 and TA100 
with and without metabolic activation systems was capable of detecting 89% of 
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the mutagens (Zeiger et al., 1985), and therefore these two strains were adopted 
for the thesis. As shown in Figure 73, two strains, TA98 and TA100, in the 
presence (+S9) and absence (–S9) of a metabolising system “S9 mix”, were 
used to assess the mutagenicity of compounds 69 and 70. “S9 mix” is a 
metabolic activation system consisting of the 9000g supernatant fraction of rat 
liver microsomes, NADP and cofactors. Exogenous “S9 mix” was used owing 
to the lack of CYP metabolising enzymes in Salmonella typhimurium. Agar 
plates +S9 and –S9 can be used to detect pro-mutagens for cases where the 
native chemical is not mutagenic but its metabolites are mutagens, and direct-
acting mutagens, respectively. The high number of His+ revertants induced by 
treatment with 4-nitroquinoline N-oxide (4-NQO) and 2-aminoanthracene (2-
AA), both of which are known mutagens and acted as diagnostic positive control 
chemicals, validated the reversion properties of each strain and the metabolising 
activity of  “S9 mix” system (Maron and Ames, 1983). The metabolic activation 
of 2-AA into mutagens by various CYP isozymes has been documented 
(Carriere et al., 1992), and this was the reason why 2-AA was used as the 
positive control chemical for TA98 +S9 (Figure 73B) and TA100 +S9 (Figure 
73D). 4-NQO was reported to be a DNA damaging agent in the cell-based assay 
with no added exogenous metabolic enzymes (Dahm and Hubscher, 2002), and 
hence it was used as the positive control chemical for TA98 –S9 (Figure 73A) 
and TA100 –S9 (Figure 73C). Methotrexate was previously confirmed to be 
negative in Ames assay (Matsuzaki et al., 2010), so it was used as the negative 
control for all four incubations (Figure 73A–D). DMSO was used as the solvent 
control (vehicle). The number of His+ revertants induced by compounds 69 and 
70 at two concentrations, 10 µM and 100 µM, was even lower than that induced 
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by methotrexate in each incubation, suggesting that these two compounds have 
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In addition to mutagenicity, drug-induced hepatotoxicity (Lee, 2003) and 
cardiac toxicity (Wallace et al., 2004) are also of primary concerns in drug 
safety assessment. Cell viability assays using transforming growth factor-alpha 
mouse hepatocyte (TAMH) and HL-1 cardiomyocyte were performed to assess 
the cytotoxic potential of compounds 69 and 70. TAMH lines were derived from 
the transgenic mice overexpressing transforming growth factor alpha (TGF-α) 
(Wu et al., 1994), and have been widely used as an in vitro model to estimate 
hepatotoxicity induced by acetaminophen (Pierce et al., 2002), 
tetrafluoroethylcysteine (Ho et al., 2005), flutamide (Coe et al., 2007), lapatinib, 
dexamethasone (Teo et al., 2012), and flupirtine (Lemmerhirt et al., 2015). 
TAMH lines were treated with compounds 69 and 70 in eight different 
concentrations (100 µM, 33.3 µM, 11.1 µM, 3.7 µM, 1.23 µM, 0.41 µM, 0.13 
µM, 0.045 µM), and the percentage of viable cells was plotted against the 
logarithm of ligand concentration (Figure 74B–C). Both compounds at the 
concentrations less than 30 µM were shown to be non-cytotoxic in TAMH lines. 
Acetaminophen at high doses is known to induce hepatotoxicity (James et al., 
2003), so it was used as the positive control (Figure 74A). In parallel, HL-1 
cardiac myocyte cell lines were capable of maintaining cardiac-specific 
phenotypes (Claycomb et al., 1998; White et al., 2004), and have been proven 
as useful in vitro models for studying various aspects of cardiac biology, 
including cardiac apoptosis (Kitta et al., 2001), cardiomyocyte cell cycle 
(Lanson et al., 2000), and cardiac gene promoter function (Dai et al., 2002). 
Recently, HL-1 cardiomyocytes were adopted by a group of researchers in the 
United States FDA to study doxorubicin-induced cardiotoxicity (Aryal et al., 
2014), and this became the basis for using doxorubicin as the positive control 
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(Figure 74D). Similar to the viability study using TAMH lines, there was no 
toxicity observed at ligand concentrations less than 30 µM in HL-1 cell (Figures 
74E–F). The decreased viability induced by 0.045 µM of compound 69 in HL-
1 cell (Figure 74E) appeared to be a false negative result. Taken together, 
compounds 69 and 70 have no mutagenicity up to 100 µM and no cytotoxicity 
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5.3.4    In vivo Drosophila models of Parkinson’s disease 
Although most PD cases occur in a sporadic manner, it has been gradually 
appreciated that PD can be inheritable since the identification of α-synuclein in 
PD families (Polymeropoulos et al., 1997). To date, six genes are believed to 
conclusively link to PD, that is, SNCA (or, α-synuclein), LRRK2, Parkin, 
PINK1, DJ-1, and ATP13A2. Of these six genes, mutations in Parkin and 
LRRK2 have been recognised to be the predominant causes for early- (Lucking 
et al., 2000) and late-onset (Kumari and Tan, 2009) hereditary PD cases, 
respectively. Since modelling the genetics of PD in mice has proven 
disappointing (Duty and Jenner, 2011), genetic models in multicellular model 
organisms, such as Drosophila, C. elegans, and zebrafish have been developed 
to provide insights into the molecular events associated with PD gene mutations. 
Of these genetic models, the Drosophila model gained most attentions because 
this organism contains highly conserved homologues of many human genes. It 
has been demonstrated that the premature loss of fly climbing ability was 
achieved by the transgenic Drosophila overexpressing mutant forms of α-
synuclein (Feany and Bender, 2000), and this climbing defect can be restored 
by L-DOPA administration (Pendleton et al., 2002). Particularly, Parkin (Cha 
et al., 2005) and LRRK2 (Liu et al., 2008) mutants in Drosophila models 
displayed a good degree of reproducibility in the brain DA neuron reduction, 
validating Drosophila models being superior to mice models in producing PD-
like phenotypes after PD-associated gene mutations. Importantly, 
pharmacological compounds can be mixed with food and readily delivered to 
the nervous system of flies, as they lack a well-defined BBB. In addition to the 
aforementioned advantages, the low cost, small size, short lifespan (about 2 
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months) and high-throughput capacity of Drosophila make this model attractive 
for drug testing in various diseases (Pandey and Nichols, 2011). Notably, the 
closest homologue of Drosophila adenosine receptor, DmAdoR, in human is 
hA2A receptor, so it gives confidence when using Drosophila model to assess 
A2A ligands such as compounds 69 and 70. Also, DmAdoR is mainly distributed 
in the brain of adult flies (Kucerova et al., 2012), but as mentioned earlier, BBB 
permeability of compounds cannot be evaluated using Drosophila model. 
Moreover, D2-like receptors (Hearn et al., 2002) have been shown to regulate 
locomotion in Drosophila (Draper et al., 2007). Due to the relevance of 
Drosophila to human A2A and D2 receptors, this in vivo system was used to test 
the efficacy of compounds 69 and 70. 
The high prevalence of G2019S mutant in LRRK2-associated PD cases has 
been well documented (Lesage et al., 2006; Ozelius et al., 2006), and 
importantly, studies have shown that expression of LRRK2-G2019S mutant in 
Drosophila caused more severe PD phenotypes, including locomotor 
dysfunction, loss of dopaminergic neurons, and early mortality, than expression 
of wild-type LRRK2 (Liu et al., 2008). Prior to evaluating compounds 69 and 
70 in the Drosophila model of PD, the effect of compound concentrations on 
fly viability was studied. At the ligand concentration of 500 µM, both 
compounds were lethal to G2019S flies (data not shown). Lower ligand 
concentrations were tried, and at 50 µM, whilst treatment with compound 70 
still resulted in toxicity, compound 69 was able to delay the G2019S fly 
mortality (Figure 75). Although compounds 69 and 70 did not show in vitro 
toxicity (Figures 73 and 74), the higher toxicity induced by 70 than that induced 
by 69 in Drosophila may suggest that 69 is safer than 70 in the in vivo setting. 
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In fact, “Drosophotoxicology” was coined to describe the use of Drosophila for 
screening neurotoxicity of chemicals, so it could be that 70 is more neurotoxic 
than 69 (Rand, 2010). Compound 69 at 50 µM was therefore selected for the 
subsequent climbing assay and quantification of dopaminergic (DA) neurons 
(Figure 76). 
Figure 75. Survival percentages of LRRK2 G2019S flies after 7 days, 10 days 
and 17 days of treatment with various concentrations (50 µM, 100 µM, 200 µM) 
of compound 69. 
 
In the climbing assay (Figures 76A and 76C), the flies were tapped to the bottom 
of the column, and the extent of their climbing to the top was measured. To 
quantify DA neurons (Figures 76B and 76D), brains of flies were dissected, 
immunostained with anti-tyrosine hydroxylase (anti-TH) antibody, and viewed 
by confocal microscopy. Initially, parkin-null (pk-/-) flies were used to evaluate 
compound 69 (Figures 76A and 76B). Remarkably, compound 69-treated 
parkin-null flies not only exhibited improvement in climbing scores compared 
with untreated mutant  flies (Figure 76A), but they also showed reduction of 
DA neuron loss in the PPL1 cluster (Figure 76B), which is the cluster used 
widely in parkin-null flies (Whitworth et al., 2005). Next, we examined whether 
compound 69 can likewise ameliorate LRRK2 G2019S-induced PD 
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phenotypes, and found that compound 69-treated LRRK2 G2019S flies also 
displayed improvement in climbing (in a concentration-dependent manner) 
(Figure 76C) as well as mitigation of DA neuron degeneration (Figure 76D). 
Together, these findings suggest that compound 69 acts as a suppressor of DA 
neuron dysfunction in two Drosophila genetic PD models—one  with transgene 
parkin-null which represents recessive PD, and one with transgene LRRK2 
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5.4    Chapter Conclusion 
In summary, in view of the hA2A binding affinity exhibited by compounds 69 
and 70, these two compounds were selected for further pharmacological 
evaluation. In the artificial cell membrane system, both compounds showed 
binding to dopamine D2 receptor with EC50 of 23–40 µM. Various functional 
assays for D2R activation were conducted: (i) Inhibition of cAMP accumulation 
in CHO cells was observed upon treatment of 70, with its concentration of 100 
µM showing comparable activity induced by 100 nM of quinpirole. (ii) D2R 
internalisation in HEK 293 cells was observed following treatment with 69 and 
70 at 30 nM. (iii) TGFα shedding in HEK 293 cells was observed upon 
treatment of 70, with its concentration of 100 µM resulting in an effect that was 
approximate one-third of what can be caused by treatment with 10 nM of 
dopamine. All these three experiments pointed to the D2R agonistic activity of 
69 and 70. Nevertheless, further characterisation showed that both compounds 
had poor aqueous solubility, permeability and metabolic stability, and structural 
properties (e.g. CLogP, CLogD, MW) that may account for these poor drug-like 
properties were discussed. There was no mutagenicity up to 100 µM, nor 
hepatotoxicity and cardiotoxicity up to 30 µM. Further in vivo testing of 
compound 69 in the Drosophila models of PD showed that treatment with 
compound 69 at 50 µM not only improved mutant-induced locomotor 
impairment but also mitigated DA degeneration in parkin-null as well as in 





CHAPTER 6    CONCLUSIONS AND FUTURE 
DIRECTIONS 
 
The lower birth rate and rising life expectancy has resulted in an increase in the 
percentage of elderly people. The world population aged 60 and above was 841 
million estimated in the year 2013, and it was projected to exceed two billion 
by the year 2050 (Chatterji et al., 2015). Concomitant with population ageing 
was the burden of diseases and public spending on healthcare. A study done in 
the year 2010 showed that 630,000 people in the United States had been 
diagnosed with Parkinson’s disease (PD), the most prevalent movement 
disorder in older people, and this had incurred 14.4 billion USD medical 
expenses (Kowal et al., 2013). Therefore, developing more effective treatments 
for PD is undoubtedly a rewarding endeavour. 
The study reported in this thesis integrated computational tools, synthetic 
organic chemistry, in vitro pharmacological and drug-like evaluations, as well 
as Drosophila PD models to address this unmet medical need. Inspired by the 
significant roles of hA2A and hD2 receptors in the pathogenesis of PD and the 
emerging appreciation that in most cases a drug exerts its action through 
interacting with multiple receptors, we selected these two relevant receptors and 
aimed at identifying new chemical entities (NCEs) able to antagonise hA2A and 
concurrently agonise hD2 receptor. There would be no point in spending more 
resources (e.g. time, costs, manpower) to target two receptors if the resulting 
compounds do not show more effectiveness than those that were designed and
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discovered by targeting either receptor alone. Hence, the challenges in the thesis 
are twofold: (i) whether compounds capable of binding these two receptors 
simultaneously and exerting respective functions (i.e. antagonism at hA2A 
receptor, agonism at hD2 receptor) could exist, and if so, (ii) whether the 
identified compounds can have higher efficacy and lower toxicity than either 
known hA2A antagonist or hD2 agonist administered alone. For the first 
challenge, it is worth mentioning that the initial aspiration was not to adopt 
reported binding moieties against the two receptors followed by integrating the 
two moieties via linked, fused or merged approaches, as shown in Figures 19 
and 20. Rather, the objective was to identify “drug-like” compounds (i.e. MW 
< 500) that had dual-acting properties at the two receptors. The quickest way to 
achieve this objective is to check whether there is a compound reported as an 
hA2A antagonist by one group of researchers and a hD2 agonist by a different 
group, and this strategy usually works in identifying multi-kinase inhibitors 
(Karaman et al., 2008) because of more conserved binding pockets amongst 
kinase family members as opposed to distinct receptor families to which 
adenosine and dopamine receptors belong. Investigation of approximately 2,000 
compounds published as at the year 2011 did not reveal any single chemical 
entity with such desired mechanisms of action, but uncovered the substructure 
1,4-disubstituted aromatic piperazine (1,4-DAP) commonly observed in some 
reported hA2A antagonists and hD2 agonists (Section 3.2.3.3). Analysis by 
support vector machine (SVM) and Tanimoto similarity led to the specification 
of aromatic ring in 1,4-DAP being pyrimidine, as well as the importance of 
indole ring on the molecule (Figure 38). Cluster analysis further strengthened 
confidence in selecting [indole + piperazine + pyrimidine] (IPP) for synthesis 
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(Figure 48). Gratifyingly, some of compounds containing IPP scaffold showed 
binding at hA2A in the micromolar range, and to our knowledge, there are no 
IPP-containing compounds reported as hA2A binders. Compounds 69/70, 
bearing IPP scaffold, were also confirmed to be hD2 binders (Section 5.3.1) and 
hD2 agonists (Section 5.3.2). The first challenge was therefore successfully 
tackled, except that the hA2A antagonism of IPP-containing compounds remains 
to be evaluated (Future Direction 1). 
For the second challenge, it is worth reviewing the only marketed A2A 
antagonist for PD treatment, KW-6002 (Figure 12), and four commonly 
prescribed dopamine agonists for PD treatment, rotigotine, pramipexole, 
apomorphine and ropinirole (Figure 25). KW-6002 has nanomolar binding 
affinity (Ki = 12 nM) at hA2A receptor, and all four dopamine agonists are also 
tight hD2 receptor binders with Ki = 4~32 nM. The advantage of 69/70 over 
KW-6002 may be the binding at hD2 receptor, and similarly, the advantage of 
69/70 over the four dopamine agonists may lie in the affinity at hA2A receptor. 
Whether 69/70, with micromolar ranges of affinity at hA2A and hD2, are equal 
to or even superior than KW-6002, rotigotine, pramipexole, apomorphine or 
ropinirole needs more studies. It will be interesting to use the same set of 
experimental conditions in the Drosophila model to compare the extents of 
motor improvement and neuroprotection induced by 69/70 as well as the 
aforementioned five PD drugs currently used in the clinics (Future Direction 
2). As one would expect, structural modifications of IPP-containing compounds 
towards optimal hA2A and hD2 binding should be done in parallel with 
advancing 69/70. The optimisation works will be guided by the structure-
activity relationship (SAR) studies (Figure 54) established in Chapter 4, and 
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may utilise antagonist-bound hA2A X-ray crystal structures (Congreve et al., 
2012; Dore et al., 2011; Jaakola et al., 2008; Liu et al., 2012) for molecular 
docking studies to understand how 69/70 interact with hA2A. Although agonist-
bound hD2 X-ray crystal structures are not available, several attempts at 
constructing active-state hD2 models are documented (Kling et al., 2014; 
Krogsgaard-Larsen et al., 2014; Malo et al., 2013) (Future Direction 3). If the 
optimisation can result in IPP-containing compounds with nanomolar binding 
affinity to both hA2A and hD2 receptors, the chance of these compounds for 
meeting the second challenge would definitely be higher than that of 69/70. 
The novelty of compounds 69/70 was confirmed by a prior art search carried 
out by Saturo Global (a professional knowledge solutions firm) facilitated by 
NUS Industry Liaison Office (ILO). The search was executed in databases such 
as PatBase, USPTO, EPO, CAplus and WIPO to identify the relevant patent 
references, yielding one relevant and eleven background patent references. The 
search was also performed on databases such as PubMed, Scirus, ScienceDirect, 
Google Scholar and Google to identify relevant non-patent references, yielding 
six non-patent references. Careful evaluation of all these eighteen relevant 
references showed that the works in this thesis did not correspond to any 
references regarding compound structures, procedures of compound 
preparation, and disease applications. A response to the prior art search report 
was subsequently drafted and sent to Saturo Global. The response turned out to 
be agreeable to the firm.       
Despite being novel, compounds 69/70 are plagued by low aqueous solubility, 
low permeability, as well as low metabolic stability, offering opportunities for 
improvement. Since the intended targets of 69/70 are located in dopaminergic 
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neurons in the midbrain (Figure 1), it is necessary to consider structural 
properties expected of a CNS drug for optimal brain exposure (Rankovic, 2015) 
before commencing the optimisation of drug-like properties. As described in 
Section 3.2.3.5, Lipinski’s rule of 5 (RO5) has been widely adopted as the 
guideline in the design of oral drugs, and it was used for filtering the hits 
identified by support vector machine (SVM) models. In general, the criteria for 
CNS drugs are more stringent than those for oral drugs (Kerns and Di, 2008) 
because CNS drugs are usually taken orally and need to cross both 
gastrointestinal (GI) barrier and blood-brain barrier (BBB). This justifies the 
use of RO5 in Chapter 3, since it is highly preferable that compounds discovered 
in the thesis are orally bioavailable and CNS penetrant.  
BBB is mainly composed of endothelial cells (ECs) connected by tight junctions 
(TJs), and serves as the barrier between blood capillaries and the brain 
parenchyma to impede the entry of foreign substances into the brain (Rubin and 
Staddon, 1999). BBB is such a selective barrier that 98% of small molecule 
drugs do not cross it (Pardridge, 2005). For small molecules to cross BBB, they 
must have low molecular weight (MW) and high lipid solubility. Of the six 
structural properties shown in Table 18, lipid solubility is influenced by CLogP, 
CLogD, TPSA, HBD and pKa. There are a number of BBB rules or guidelines 
summarised from the analysis of marketed CNS drugs (Ghose et al., 2012; 
Pajouhesh and Lenz, 2005; Wager et al., 2010), and all rules point to a common 
principle that, compared to non-CNS drugs, CNS drugs tend to have lower MW 
(Pardridge, 2005), higher LogP, lower PSA, fewer HBD (Mahar Doan et al., 
2002), and contain a basic amine (Kerns and Di, 2008) (Table 21). These rules 
provide strict cutoffs or ranges for individual structural properties and may be 
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of great utility for medicinal chemists in the optimisation of CNS drugs. 
Complying with cutoff values set in these recommendations during ligand 
design in the earlier phase and lead optimisation in the later phase not only 
increases the likelihood of BBB penetration but also leads to more favourable 
pharmacokinetic properties that a CNS drug normally has, since these 
recommendations are extracted from successful (i.e. marketed) CNS drugs. 
Comparison of Table 18 with Table 21 indicates that TPSA and HBD of 
compounds 69/70 are slightly higher than what are recommended in Table 21, 
suggesting that decreasing TPSA and HBD may improve brain exposure. It may 
not make sense to reduce HBD of 69/70 because the number is one and the NH 
of the indole might be necessary in receptor binding. Hence, according to Table 
21, reduction of TPSA becomes one of the goals in future optimisation. 
 
Table 21. Structural Properties Required of CNS Drugs 





Compounds with TPSA < 60 Å2 and most 
basic pKa < 8 have lower chance to be P-
glycoprotein (P-gp) substrates. 
 
 
analysis done by 






preferred ranges for increasing the 
probability of BBB permeability: CLogP 
= 2~4, CLogD (pH 7.4) = 2~4, MW < 
450, PSA < 70 Å2, HBD = 0~1  
 





drugs, 45  
non-CNS 
drugs 
What distinguishes CNS drugs and non-
CNS drugs is that the former have greater 
lipophilicity (mean value of CLogP = 
3.43; range value of CLogP = 0.16~6.59; 
mean value of CLogD = 2.08; range value 
of CLogD = –1.34~6.57), lower PSA 
(mean value = 40.5 Å2; range value = 
4.63~108), and fewer HBD (mean value = 
0.67; range value = 0~3). 
analysis done by 
GlaxoSmithKline 
(Mahar Doan et 
al., 2002) 
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Moreover, optimisation should also be done towards improvement in aqueous 
solubility, permeability and Phase I metabolic stability. The determinants of 
solubility and permeability were presented in Section 5.3.3.1 and listed in Table 
18. Changes in these structural property determinants by chemical modification 
lead to changes in solubility, permeability, and metabolic stability. An 
important thing one needs to bear in mind would be that holistic consideration 
is always executed so as not to overly benefit one drug-like property (e.g. 
solubility) but risk the other (e.g. permeability). Table 22 shows the consensus 
in the medicinal chemistry community with regard to structural modification 
strategies to improve various drug-like properties. To improve solubility, one 
may try to reduce lipophilicity (Lin and Lu, 1997), reduce MW (Misra et al., 
2004), add polar groups (Kim et al., 2004), add HBD (Xie et al., 2004), or 
introduce ionisable groups (Li et al., 2000). Approaches to improving general 
permeability include heightening lipophilicity (Quan et al., 2005), lowering 
MW (Palanki et al., 2000), reducing TPSA (Goodwin et al., 2001), and reducing 
HBD (Desai et al., 2012), all of which are included in what CNS drugs tend to 
display (vide supra). For a compound having good BBB permeability, 
additional criteria such as bearing an aliphatic basic amine, are recommended. 
Strategies to improve metabolic stability include reducing lipophilicity (Peglion 
et al., 2002), blocking metabolic site (Tandon et al., 2004), and replacing 
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Table 22. Changes in Structural Properties that can Improve Drug-Like 
Properties 
 lipophilicity MW TPSA HBD pKa/pH 
solubility ↓ ↓ ↑ ↑ ionisable group 
 
permeability ↑ ↓ ↓ ↓ 70% of CNS drugs 
contain an aliphatic 





↓  block metabolic sites 
 replace unstable groups
 
Ideally, all criteria listed in Tables 21 and 22 are to be met in future optimisation. 
However, in Table 22, some criteria in solubility and permeability are often 
opposed. For example, increasing lipophilicity will increase permeability but 
compromise solubility. To maximally but not completely meet the requirements 
listed in Tables 21 and 22, we propose the following as a recommendation for 
future optimisation. In view of the toxic effect of compound 70 in Drosophila, 
it is hypothesised that compound 69 has more translational value and may be 
prioritised over 70 in future optimisation. The structural properties of compound 
69 (Table 18) are listed in Figure 77. To improve solubility, one straightforward 
strategy is to remove two methyl groups on pyrimidine of compound 69, leading 
to the proposed compound 99 which has lower lipophilicity and lower MW than 
compound 69 to fulfil two requirements listed in Table 22 for enhancing 
solubility. Next, taking into account that 70% CNS drugs (e.g. buspirone, 
aripiprazole) contain an aliphatic basic amine and 1,4-DAP substructure of 99 
is to be maintained, a methylene group is proposed to be inserted in the amide 
group of 99, resulting in compound 100 which is expected to have better 
permeability. Subsequently, the discussion in Section 5.3.3.2 (Figure 68) shows 
that the most likely site of hydroxylation in compound 69 after incubation with 
 CHAPTER 6  
229 
 
microsomes is the C5 position of pyrimidine ring, so blocking that labile site 
becomes the strategy for improving metabolic stability. The frequently 
employed substituent is the fluorine atom, as testified by many successful 
examples (Bohm et al., 2004; Park et al., 2001), including buspirone (Tandon 
et al., 2004), so the introduction of a fluorine substituent to compound 100 
results in the proposed compound 101. The rationale behind fluorine 
substitution for enhancing metabolic stability is the following. First, the 
dissociation energy of C–F bond (105.4 kcal/mol) is higher than that of C–H 
(98.8 kcal/mol) (O'Hagan, 2008). The strength of C–F bond can be explained 
by the electrostatic interaction between Cδ+ and Fδ– instead of the electron 
sharing as a covalent bond (Wiberg and Rablen, 1993), and therefore it is more 
difficult for CYP enzymes to attack C–F bond than C–H bond. Second, due to 
its high electronegativity, fluorine can pull electrons away from the pyrimidine 
of compound 101, making the pyrimidine more electron poor. Since oxidation 
of pyrimidine requires loss of electrons, fluorine-containing 101 with lower 
electron density on its pyrimidine compared to compound 100 will be less 
susceptible to oxidation by CYP enzymes. Comparison of 101 with 69 in terms 
of structural properties reveal that the major differences are lipophilicity and 
pKa. According to Table 22, the lower lipophilicity of 101 than that of 69 may 
improve solubility and metabolic stability, and creation of a basic amine in 101 
may also improve permeability. Therefore, compound 101, which is presumed 
to have improved solubility, permeability and metabolic stability compared to 
compound 69, is worth trying for future optimisation.  
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Concurrently, it is noted that the estimated pKa of compound 101 is 5.56, 
implying that 101 would predominantly exist as the neutral species at 
physiological pH 7.4. A pKa distribution study done on 174 CNS drugs and 408 
non-CNS drugs (Manallack, 2008) shows that: (i) 83% of CNS drugs contain at 
least one basic centre, and (ii) the majority of CNS drugs contain basic amines 
with pKa above 7, which is a requirement for interacting with Asp in TM3 of 
most GPCRs (Section 3.1.3.2, Figure 24). In addition, as shown in Table 21, Eli 
Lilly recently analysed > 2,000 compounds and found that those compounds 
whose most basic pKa < 8 have lower chance to be the substrate of P-
glycoprotein (P-gp) (Desai et al., 2013), an active efflux transporter expressed 
in BBB endothelial cells (Hitchcock, 2012). It thus follows from combining the 
pKa distribution with Eli Lilly’s studies that the optimum pKa range for CNS 
drugs is 7~8. It appears that partially positive charge on the tertiary amine of a 
CNS drug favours the interactions with the carboxylate of Asp, resulting in the 
criterion of pKa > 7, and that increasing polarity confers higher likelihood of P-
gp efflux, resulting in the criterion of pKa < 8. In fact, the pKa values of many 
CNS drugs bearing 1,4-DAP substructure fall into the range of 7~8 (Figure 78). 
Hence, it is deemed essential to raise the pKa of compound 101 by increasing 
the basicity of the tertiary amine on the piperazine (i.e. the blue-coloured N of 
compound 101 in Figure 77). The electron lone pairs at this nitrogen atom are 
influenced by the electron-withdrawing ketone group that is two bonds away, 
so one of the ways to increase the basicity is to replace the ketone group with 
an electron-donating group. But one should never forget the essentiality of that 
oxygen atom of the carbonyl group in hA2A binding, as discussed in Section 
4.2.3 (Table 10), and this prompts a search for a replacement moiety that can 
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Figure 78. Selected CNS drugs with 1,4-DAP substructure. 
 
The terms “isosteric compounds” and “isosteres” were introduced by Irving 
Langmuir in 1919, and refer to compounds that have the same number of atoms 
and electrons and thus similar physical properties (e.g. viscosity, heat of 
formation) to one another (Langmuir, 1919). For example, N2 is an isostere of 
CO, and CO2 is an isostere of N2O. Langmuir’s concept of isosterism was 
subsequently applied to biological systems, leading to the concept of “bio-
isosteric replacement” proposed by Harris Friedman (Friedman, 1951). The 
current consensus of bioisosteres is largely shaped by Thornber: “Bioisosteres 
are groups or molecules which have chemical and physical similarities 
producing broadly similar biological properties.” (Thornber, 1979). Among the 
isosteres of the carbonyl group (Figure 79), the isostere that can not only donate 
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electrons but also retain the oxygen atom is oxetane, so compound 102 is 
proposed. Unlike cyclobutane, oxetane has a planar four-member ring (Luger 
and Buschmann, 1984) and is more stable than oxirane towards nucleophilic 
ring opening (Wolk et al., 2004). The oxetane ring is found in many natural 
products, such as Taxol®, oxetanocin A, bradyoxetin and oxetin. In fact, 
oxetanes as attractive structural motifs for drug discovery have been well 
documented (Burkhard et al., 2010; Wuitschik et al., 2010; Wuitschik et al., 
2008; Wuitschik et al., 2006). Structural comparison of propan-2-one with 3,3-
dimethyloxetane revealed the agreement in the orientation of oxygen lone pairs, 
the similarities in C–C–C bond angles, as well as the difference in the distance 
between the oxygen atom and main chain (Figure 79). How the steric bulk of 
oxetane in compound 102 and elimination of π-conjugation of the carbonyl 
group with indole ring seen in compound 101 will influence binding at hA2A 
and hD2 receptors requires further investigation. Upon replacement with 
oxetane, CLogP is estimated to go up from 1.97 to 2.38, which is higher than 
that of compound 69 (i.e. 2.14), suggesting the potential of better permeability 
than compound 69. Importantly, the increase in pKa to the desired range 7~8 
makes compound 102 partially charged in the physiological condition, thus 
lowering its CLogD to 1.84. This also implies that 102 should be more water 
soluble than 69. As mentioned earlier, lowering TPSA is one of the goals in 
future optimisation (Table 21), and the two methylenes of oxetane lower the 
TPSA from 65.1 to 57.3. Therefore, in addition to compound 101, compound 
102 (i.e. the oxetane version of 101) is also proposed as one candidate for future 
optimisation because of its promising structural properties (i.e. higher CLogP, 
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lower TPSA and higher pKa compared to compound 69). Taken together, 
Future Direction 4 is to synthesise and test compounds 99-102.    
Figure 79. Lists of carbonyl isosteres and structural comparison of propan-2-
one with 3,3-dimethyloxetane (Wuitschik, 2008) (reprinted with permission). 
 
In a nutshell, this project has allowed the identification of promising scaffolds 
binding at hA2A and hD2 receptors. Future optimisation in terms of synthesis, 
pharmacological characterisation and in vivo testing will provide more insights 
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Appendix C. Polypharmacology in Cancer Therapy 
Sunitinib, working by blocking proliferation and angiogenesis of cancer cells 
for the treatment of gastrointestinal stromal tumour (GIST) (Demetri et al., 
2006), advanced renal-cell carcinoma (RCC) (Motzer et al., 2007), and 
pancreatic neuroendocrine tumour (pNET) (Raymond et al., 2011), is probably 
the best case illustrating polypharmacology in cancer therapy. Blood vessels are 
composed of endothelial cells and are responsible for supplying nutrients and 
oxygen for proper cellular functions. In normal adults, new blood vessels are 
formed by sprouting from pre-existing ones, and this process is called 
angiogenesis or neovascularisation. The vasculature in adults is quiescent and 
represents the long-lived system with the turnover time in years, but only under 
circumstances such as female reproduction or wound healing is angiogenesis 
turned on through a complex multistep process, which in turn, leads to 
formation of new vessels in a transient manner (Hanahan and Folkman, 1996; 
Hanahan and Weinberg, 2000). By contrast, experiments have shown that 
implanted tumour cells persistently recruited new capillary blood vessels 
(Gimbrone et al., 1972), and once without access to vasculature, the tumour 
cells underwent either apoptosis (Parangi et al., 1996) or necrosis (Brem et al., 
1976), supporting that ongoing angiogenesis is essential for the growth and 
metastasis of tumour cells. The pivotal role of angiogenesis in cancer and the 
therapeutic opportunities based on its molecular mechanism were first proposed 
in 1971 by Judah Folkman (Folkman, 1971). He contended that the trigger of 
“angiogenic switch” from quiescence for a tumour phenotype is characterised 
by the increased production of positive angiogenic factors, including vascular 
endothelial growth factors (VEGFs) and platelet-derived growth factors 
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(PDGFs), as well as down-regulation of negative angiogenic factors, such as 
thrombospondin (Folkman, 1995). The VEGFs and PDGFs released by tumours 
attract endothelial cells and pericytes, respectively. Subsequently, VEGFs and 
PDGFs bind to the corresponding cell surface receptors which belong to the 
class of receptor tyrosine kinases (RTKs), and consequently, promote the 
growing of tumour blood vessels. RTKs are the cell surface receptors with 
protein tyrosine kinase activity, and their mechanism of activation is 
characterised by ligand-induced receptor oligomerisation which stabilises 
cytoplasmic domains and therefore triggers kinase function (Ullrich and 
Schlessinger, 1990). The binding of VEGF-A to VEGF receptor subtype 2 
(VEGFR-2) on the endothelial cell activates a cascade of intracellular signalling 
and eventually up-regulates the genes involved in the proliferation of 
endothelial cells (Shibuya and Claesson-Welsh, 2006). Additionally, the 
interaction of PDGF-B and PDGF receptor isoform β (PDGFR-β) on the 
pericyte was used in a study where it was proven that simultaneous targeting 
endothelial cells and pericytes induces tumour blood vessel regression and 
endothelial cell apoptosis (Erber et al., 2004).  
The anti-angiogenic therapy to treat cancer relies on the principle that impaired 
supplies of nutrient and oxygen lead to tumour starvation. Two approaches have 
been adopted—inhibition of growth factors, and inhibition of the RTKs of these 
growth factors. The former approach is best exemplified by the first-approved 
(by the US FDA in 2004) angiogenesis inhibitor, bevacizumab, which is a 
recombinant humanised monoclonal antibody which binds to all VEGF 
isoforms for the treatment of metastatic colorectal cancer, advanced non-
squamous non-small cell lung cancer (NSCLC), metastatic kidney cancer, and 
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glioblastoma either by itself or in combination with other chemotherapies 
(Ferrara et al., 2004). The latter approach will be illustrated by sunitinib which 
got US FDA approval for the treatment of GIST in 2006, advanced RCC in 
2006, and pNET in 2011. The discovery of sunitinib perfectly represents the 
paradigm of deliberate dual-targeting strategy in an attempt to increase 
inhibitory activities against both VEGFR-2 kinase and PDGFR-β kinase (Figure 
A1). Random screening of synthetic compounds using VEGFR-2 
autophosphorylation assay followed by analogues synthesis led to the 
identification of a series of 3-substituted indolin-2-ones (Sun et al., 1998), and 
among them, SU5416 exhibited potent and selective VEGFR-2 inhibition, 
displayed inhibition VEGF-driven mitogenesis of human umbilical vein 
endothelial cells (HUVECs), and prevented tumour growth in mouse models of 
cancer (Fong et al., 1999). However, in 2002, the analysis of efficacy and safety 
in the phase 3 study for SU5416 failed to achieve the defined trial endpoints. 
Unlike SU5416 which targets VEGFR-2 selectively, SU6668 was subsequently 
developed, and showed activities at three distinct members of RTK family, 
namely VEGFR-2, PDGFR-β, and fibroblast growth factor receptor-1 (FGFR-
1) (Sun et al., 1999), as well as suppressed angiogenesis in in vivo tumour 
xenograft experiments (Laird et al., 2000). Unfortunately, SU6668 had poor 
pharmacokinetic properties and aqueous solubility (Faivre et al., 2007; Sun et 
al., 2003). Analysis of crystal structure of FGFR-1 in complex with SU6668 
(Laird et al., 2000) and the subsequent structure-activity relationship (SAR) 
studies confirmed that the substitution at the C4’ position of the pyrrole ring 
affects selectivity profile of kinases, ultimately culminating in the synthesis of 
sunitinib (Sun et al., 2003). 









VEGFR-2      IC50 1.23 uM
PDGFR-beta IC50 22.9 uM







VEGFR-2      IC50 2.43 uM
PDGFR-beta IC50 0.06 uM








VEGFR-2      IC50 0.08 uM
PDGFR-beta IC50 0.002 uM






Figure A1. The chemical structures of SU5416, SU6668 and sunitinib. 
 
In comparison with SU6668, sunitinib showed 30 times greater activity against 
VEGFR-2 and PDGFR-β in biochemical trans-phosphorylation assays, 20 times 
better aqueous solubility in pH 6, more than 500 times better aqueous solubility 
in pH 2, and reduction of protein binding. The in vivo study using mouse 
xenograft preclinical models also demonstrated that sunitinib exerted anti-
tumour activity and inhibited the phosphorylation of VEGFR-2 and PDGFR-β 
(Mendel et al., 2003). In a phase 3 clinical trial, a group of 312 patients with 
advanced GIST after failure of imatinib treatment due to resistance or 
intolerance, was randomised and given sunitinib (daily dose of 50 mg), with 
placebo control, in a cycle of 4-week-on/2-week-off. The efficacy was achieved 
with the median time-to-tumour-progression (TTP) obtained with sunitinib 
treatment being 4 times more than that with placebo, and the adverse events, 
such as fatigue, were easily managed (Demetri et al., 2006). Around almost the 
same time, another phase 3 trial was documented for 750 patients with 
metastatic RCC. Half of the patients were given sunitinib orally, and another 
half received interferon alfa-2a through subcutaneous injection. The results 
showed the significantly longer median progression-free survival (PFS) for the 
sunitinib group (11 months) than interferon alfa-2a group (5 months), and most 
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sunitinib-induced safety issues were ameliorated by dose modification (Motzer 
et al., 2007). Five years later, it was reported that sunitinib was used in a 
placebo-controlled phase 3 trial in 171 patients with advanced pNET. The 
efficacy was shown with the median PFS of 11.4 months, as compared with 5.5 
months in the placebo group, and the safety assessment indicated several 
manageable adverse events which were consistent with previous trials of 
sunitinib (Raymond et al., 2011). The aforementioned success of three phase 3 
trials of sunitinib demonstrated that the rationally designed dual-acting inhibitor 
against VEGFR- and PDGFR-mediated signalling resulted in an effective 
cancer therapy. Although sunitinib was initially thought to be specific for two 
kinases, VEGFR-2 and PDGFR-β, the recent comprehensive testing of its 
interaction patterns across the kinome by competition binding assays identified 
10 kinases with dissociation constant (Kd) < 10 µM (Davis et al., 2011) (Table 
A1). This is attributed to the target promiscuity of kinase inhibitors, and 
therefore caution should be taken when using small-molecule kinase inhibitors 
for assessing physiological roles of these kinases (Cohen, 2010).  
 









VEGFR-2 1.5 DRAK1 1 CSF1R 2.5 PHKG1 5.5 
PDGFR-β 0.075 KIT 0.37 BIKE 5.5 
PDGFR-α 0.79 FLT3 0.41 FLT1 1.8 
 
In addition to targeting multiple kinases as shown in the example of sunitinib 
(i.e. multikinase inhibitors, or MKIs for short), targeting two or more different 
types of proteins is also well documented for cancer polypharmacology. As 
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shown in Figure A2, CUDC-101, currently at phase 1 clinical trial, showed 
activities in patients with head and neck squamous cell cancer (HNSCC) 
through inhibiting the epidermal growth factor receptor (EGFR), histone 
deacetylase (HDAC), and human epidermal growth factor receptor 2 (HER2) 
(Galloway et al., 2015). Niclosamide, an old drug used in helminthosis patients, 
was recently shown not only to have inhibitory effects on several cancer-cell-
associated signalling pathways, such as the Wnt/β-catenin pathway, the signal 
transducer and activator of transcription 3 (STAT3) pathway, the mammalian 
target of rapamycin complex 1 (mTORC1) pathway, the Notch pathway, and 
the nuclear factor-kappaB (NF-κB) pathway, but it also displayed anti-myeloma 
activities mediated by targeting mitochondria (Li et al., 2014). The in vivo 
anticancer efficacy of niclosamide has been demonstrated in xenograft models 
for colorectal cancer (Osada et al., 2011), lung cancer (You et al., 2014), and 
liver metastasis (Sack et al., 2011), rendering niclosamide promising for further 
research. Galeterone, which is under development by Tokai Pharmaceuticals, 
has successfully gone through phase 2 clinical trial in patients with castration-
resistant prostate cancer (CRPC). Its multiple modes of action to treat CRPC is 
through CYP17 lyase inhibition, androgen receptor antagonism, and androgen 
receptor degradation (Njar and Brodie, 2015). The dual-acting agents targeting 
heat shock protein 90 (Hsp90) and tubulin, such as MDG892 (Knox et al., 2009) 
and CDBT (Zhang et al., 2013), represent another examples of cancer 
polypharmacology targeting different types of proteins.    








































Figure A2. The chemical structures of CUDC-101, niclosamide, galeterone, 
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Appendix D. Polypharmacology in Antipsychotics 
Schizophrenia is one of the most debilitating neuropsychiatric disorders, and it 
affects about one percent of world population. It is the consequence of a 
combination of environmental, genetic and neurodevelopmental factors (van Os 
et al., 2010), and its symptoms encompass positive (hallucinations, delusions), 
negative (avolition, diminished emotional expression), and cognitive (reduced 
memory, impaired executive functions) deficits. The molecular lesions in 
schizophrenia include dopamine hyperfunction hypothesis (Snyder, 1976),  
serotonin hypothesis (Gaddum and Hameed, 1954), N-methyl-D-aspartate 
(NMDA) receptor hypofunction hypothesis (Olney et al., 1999), and cholinergic 
hypothesis (Shekhar et al., 2008). The current antipsychotic medications for the 
treatment of schizophrenia involve the typical or first generation antipsychotics 
(FGAs) (e.g. chlorpromazine and haloperidol), the atypical or second generation 
antipsychotics (SGAs) (e.g. clozapine, olanzapine, quetiapine and loxzapine), 
and the third generation antipsychotics (TGAs) (e.g. aripiprazole and 
risperidone). In general, typical antipsychotics have pronounced side effects 
such as tardive dyskinesia, neuroleptic malignant syndrome, and extrapyramidal 
syndrome (EPS), whereas atypical antipsychotics have less propensity to 
develop EPS (Lieberman et al., 2008).  
Early antipsychotic drugs were discovered by serendipity, not by design. 
Thanks to the observations that aniline dyes have sedating properties in the late 
19th century, in the 1950s chemists at the French company Rhone-Poulenc 
synthesised a series of phenothiazine derivatives that led to the first 
antipsychotic drug, chlorpromazine (Figure A3), which was successfully used 
to treat patients with schizophrenic and manic psychoses (Delay et al., 1952). 
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Chlorpromazine was originally intended to act as an anti-histamine agent but 
later experiments, according to the results from DrugBank database (Law et al., 
2014), showed that it interacted with 24 targets and all of which were considered 
to contribute to its clinical effects. Although chlorpromazine showed efficacy 
against positive symptoms, it was plagued by motor side effects such as EPS 
and tardive dyskinesia in 20% of patients. The subsequent discovery of 
haloperidol by Paul Janssen in 1958 based on its cataleptic activity led to the 
then view that Parkinson-like movement syndromes were what a “typical” 
antipsychotic drug should have and were considered to be indicators of 
antipsychotic activity. In the late 1950s, chemists at the Wander Laboratories in 
Switzerland identified a subclass of tricyclic dibenzodiazepines which were 
pharmacologically characterised and administered to patients. In animal 
models, one compound, later named clozapine (Figure A3), showed 
antipsychotic effects similar to those of chlorpromazine but did not produce 
motor side effects at effective doses, which contradicted the then notion of 
“typicality”, and consequently, some clinical investigators did not seriously 
consider proceeding with the development of this compound. After several 
years of clinical testing, clozapine was introduced in Europe in 1971. 
Unfortunately, in 1975, it was reported that 16 Finnish patients treated with 
clozapine developed agranulocytosis, an acute condition characterised by the 
loss of white blood cells, which renders patients prone to infection. Of these 16 
patients, 8 died, resulting in the withdrawal of clozapine from the market 
(Idanpaan-Heikkila et al., 1975). In the ensuing years, many clozapine-treated 
patients showed relapse after being forced to switch medications, and it was this 
pressure from patients as well as lack of more effective agents that led to the 
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reapproval of clozapine and its reintroduction to the market in 1989. Also, 
30~50% of schizophrenics had suicide attempts, and clozapine treatment 
resulted in diminished suicidal behaviour (Meltzer et al., 2003; Meltzer and 
Okayli, 1995). This led FDA to approve clozapine as a treatment against suicide 




















Figure A3. Chemical structures of chlorpromazine (typical), clozapine 
(atypical) and ziprasidone (atypical). 
 
After 43 years (1971–2014) since its inception in clinical use, clozapine still 
remains one of the most effective antipsychotic drugs to treat schizophrenia. 
Indeed, two recent papers show that clozapine is superior to other antipsychotics 
used in the study in efficacy (Leucht et al., 2013; Lieberman et al., 2005). 
During January 2001–December 2004, the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) sponsored by National Institute of Mental 
Health (NIMH) involved 1493 patients diagnosed of schizophrenia, and these 
patients were initially randomly assigned five antipsychotic drugs (without 
clozapine). Discontinuation of treatment occurred over the 18-month period, 
and in the next phase study on medication switching for 99 patients, clozapine 
stood out with longest time until treatment discontinuation, proving that 
clozapine was the most effective in patients who did not improve with the first-
line treatment (McEvoy et al., 2006). Moreover, in a more recent meta-analysis 
whose data were extracted from 212 trials between 1955 and 2012 to compare 
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15 different antipsychotic drugs, the resultant evidence-based hierarchy 
demonstrated that clozapine was significantly more efficacious than all the other 
14 drugs. Whilst clozapine has been confirmed to have some side effects, such 
as agranulocytosis, weight gain, or myocarditis, epidemiologic studies 
(Tiihonen et al., 2009; Walker et al., 1997) suggests that none of the risks 
associated with clozapine should negate its current clinical use. 
The sound efficacy of clozapine in alleviating the positive and negative 
symptoms of treatment-resistant schizophrenia (Kane et al., 1988) as well as in 
reducing the suicidal behaviour (Meltzer et al., 2003) prompted 
pharmacologists to study its pharmacodynamic properties. Clozapine is a broad 
sprectrum drug with a polypharmacological profile of binding to 11 serotonin 
receptors, 5 adrenergic receptors, 5 muscarinic receptors, 5 dopamine receptors, 
2 histamine receptors, δ-opioid receptor, imidazoline I1 receptor, serotonin 
transporter and norepinephrine transporter (data from PDSP Ki database funded 
by the Psychoactive Drug Screening Program, National Institute of Mental 
Health). The lack of EPS after treatment with clozapine may be attributed to its 
transient occupation of, and thus relatively low affinity (Ki = 180 nM, the long 
isoform D2L, [3H]spiperone as the radioligand) (Seeman, 2006) to, dopamine D2 
receptor (40~60% occupancy). This is in contrast with chlorpromazine (one of 
the FGAs) which has prolonged occupation of D2 receptor with >80% 
occupancy (Fakra and Azorin, 2012). The strong histamine H1 receptor affinity 
(Ki = 2 nM) (Kroeze et al., 2003) most likely accounts for its side effect of 
weight gain. There is a consensus that addressing one subtype of receptors alone 
cannot satisfactorily explain the potency displayed, nor eliminate the side 
effects elicited, by clozapine. Obviously, it is the unique blend of numerous 
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receptors involved in the mode of action of clozapine, as well as the extent to 
which this drug binds to different receptors as shown in the measurement of 
dissociation rates (Seeman and Tallerico, 1999), that contributes to its overall 
clinical effect. 
Following the success of clozapine, many efforts have been attempted to search 
for more atypical antipsychotics that does not have EPS. Inspired by a paper 
(McMillen and Mattiace, 1983) that described the anxiolytic drug buspirone 
(Figure A4) reversed haloperidol-induced catalepsy in rats, a group of scientists 
at Pfizer chose 1-naphthylpiperazine (1; Figure A4), which is structurally 
similar to buspirone, as the starting point in search for novel atypical 
antipsychotics (Lowe et al., 1991). Compound 1 was reported to be a potent 5-
HT1 agonist/5-HT2 antagonist (Glennon et al., 1986). At that time, it was known 
that all clinical active antipsychotics share a common factor, namely, the ability 
to antagonise the dopaminergic system directly or indirectly (Lowe et al., 1988), 
so the structure of dopamine (Figure A4) was also taken into consideration in 
the synthesis of derivatives. The strategy to install dopamine-blocking activity 
to compound 1 is based on the rationale that a large lipophilic group appended 
to the amino group of an agonist (dopamine, in this case) binds to the accessory 
site of the receptor and therefore transforms the agonist to an antagonist. The 
modification of the black-dotted square part of compound 103 was to test the 
hypothesis that the hydroxyl group of the serine side chain of dopamine D2 
receptor forms hydrogen bonds with catechol mimics, so both fused and 
appended heterocyclic groups were synthesised to replace the aryl group present 
in dopamine. The assay data confirmed that compound 103, substituting 
catechol group in dopamine with oxindole, not only achieved affinity to D2 and 
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5-HT1A receptors simultaneously but it also showed efficacy by inhibition of 
amphetamine-induced hyperlocomotion and reversal of haloperidol-induced 
catalepsy after oral administration in rats. However, compound 103 showed 
disappointing results in monkeys. 
Binding studies coupled with multivariate analysis on 20 antipsychotics led to 
the hypothesis that the atypicality of drugs is due to the higher antagonistic 
activity at serotonin 5-HT2 than at dopamine D2 receptor (i.e. D2/5-HT2 affinity 
ratio > 1) (Meltzer et al., 1989). In light of this, the same group of scientists at 
Pfizer shifted their focus from 5-HT1A to 5-HT2 receptor, and they were also 
attracted by the structure of tiospirone (Figure A4). The bicyclic 
benzoisothiazole group (black-solid square part shown in Figure A4) in the 
atypical antipsychotic drug tiospirone was designed to mimic the tricyclic 
antipsychotic drugs (e.g. clothiapine, clozapine and loxapine) (Yevich et al., 
1986), and the affinity ratio of tiospirone to D2/5-HT2A was determined to be 
3.6 which met the hypothesis of atypicality. A series of 3-
benzisothiazolylpiperazines were then synthesised in order to improve D2 
receptor affinity. One derivative showed favourable D2/5-HT2 ratio (4.8/0.42 = 
11.4), inhibition of amphetamine-induced hypermotility, blockade of 
conditioned avoidance response, along with the subsequent 9 years of clinical 
trials and 3 years for addressing regulatory requirements. This derivative was 
ultimately marketed as ziprasidone in 2001 (Howard et al., 1996).  




















D2          IC50 38 nM (antagonist)
5-HT1A   IC50 4.87 nM
5-HT2     IC50 20 nM (antagonist)
5-HT1  Ki 5 nM (agonist)














D2          Ki 4.8 nM (antagonist)









Figure A4. Design of ziprasidone with dual D2/5-HT2A antagonism. 
 
The discovery of ziprasidone illustrated many challenges in the rational design 
of a polypharmacological drug. The dopamine hypothesis of schizophrenia 
suggested by Rossum in 1966 (van Rossum, 1966) proposes that the dopamine 
pathways in schizophrenia are hyperactive. After systematic research, evidence 
showed that nanomolar concentrations of FGAs prevented the binding of [3H]-
dopamine (Seeman et al., 1974) and blocked dopamine D2 receptors (Seeman 
et al., 1975). Both post-mortem analysis (Seeman et al., 1984) and positron 
emission tomography (PET) imaging (Farde et al., 1986) revealing the abnormal 
elevation of D2 receptor density in the schizophrenic striatum further 
substantiated the dopamine hypothesis of schizophrenia. In parallel, serotonin 
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(5-hydroxytryptamine or 5-HT) receptors joined dopamine as contributing 
factors to the atypical properties of SGAs. An animal study has shown that the 
administration of a selective 5-HT2A antagonist, MDL-100907 (Sorensen et al., 
1993), potentiated the ability of haloperidol (a D2 antagonist) on the dopamine 
release of medial prefrontal cortex, supporting the importance of 5-HT2A 
receptor antagonism in antipsychotic activities (Liegeois et al., 2002). With the 
information of the importance of dopamine D2 and serotonin 5-HT2A receptors 
on antipsychotics, Pfizer’s approach to modulating these two receptors 
informed by in vitro receptor-binding assays provided an example of targeted 
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Appendix E. GPCR Basics 
G protein-coupled receptors (GPCRs), also known as seven transmembrane 
(7TM) receptors, are encoded by more than 800 human genes and regulate 
nearly all physiological processes ranging from sensory systems such as vision, 
smell and taste, to regulations of behaviours, mood, immune system, 
inflammation, and nervous system. The Cell A communicates with the Cell B 
by secreting hormones or neurotransmitters which are detected by the GPCRs 
located in the plasma membrane of the Cell B followed by the activation of 
effector proteins within the Cell B to alter its function. Historically, the 
controversy and scepticism amongst academic community with regard to the 
existence of GPCRs did not cease (Ahlquist, 1973; Dale, 1943) until the direct 
studies on adrenergic receptors using radioligand binding techniques in the late 
1970s (Williams and Lefkowitz, 1976), leading to the ternary complex model 
(De Lean et al., 1980) as shown in Figure A5. In this model, the low-affinity 
form of the receptor refers to agonist-bound receptor (AR), whereas the high-
affinity form of the receptor is a ternary complex of agonist, receptor, and the 
then “another membrane component (X)”. The ternary complex ARX along 
with guanine nucleotide (i.e. GTP) formation facilitate effector stimulation (E 
to E*). Later studies suggested that, in the classical role of the receptor, X is the 
guanine nucleotide regulatory protein (i.e. G protein) and E is the adenylate 
cyclase. This model also demonstrated the GPCR allostery—the binding of an 
agonist to the receptor enhances the affinity of G protein, as well as the binding 
of G protein to the receptor increases the affinity of an agonist. 




Figure A5. The ternary complex model explaining agonist binding to the β-
adrenergic receptor (Lefkowitz, 2013) (reprinted with permission).  
 
It was extraordinary that the purification of adrenergic receptors were done prior 
to their cDNA cloning. Thanks to affinity chromatography, the daunting 
projects on isolating (Dohlman et al., 1991) adrenergic receptors and validating 
their functions (Cerione et al., 1983) were completed in one decade. Subsequent 
cloning works for adrenergic receptors (Dixon et al., 1986; Kobilka et al., 1987) 
allowed the observation of the 7TM topology as the common structural feature 
of GPCRs. Site-directed mutagenesis (O'Dowd et al., 1988) and chimeric 
receptors (Kobilka et al., 1988) were utilised to confirm the extracellular loops 
of the β2-adrenergic receptor were responsible for the ligand specificity and the 
intracellular regions of the receptor were responsible for the specificity of G 
protein coupling. Large-scale production and purification of sufficient 
quantities of β2-adrenergic receptor (Kobilka, 1995) were later achieved, 
allowing biophysical studies of receptor structure by fluorescence spectroscopy 
(Gether et al., 1995). The three-dimensional structures of inactive-state 
(Rasmussen et al., 2007) and active-state (Rasmussen et al., 2011a; Rasmussen 
et al., 2011b) β2-adrenergic receptor were solved by X-ray diffraction. The 
attempts to capture active states of β2-adrenergic receptor by either X-ray 
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diffraction (Rosenbaum et al., 2011), fluorescence (Yao et al., 2009) or NMR 
spectroscopy (Nygaard et al., 2013) revealed that agonist alone was not 
sufficient to stabilise the active conformation of the receptor, which is in 
agreement with the ternary complex model of receptor activation (Figure A5).  
In addition to ligand-induced cell response, it was discovered that although 
cAMP was elevated when an agonist was added to the β-adrenergic-receptor-
expressed cells, within one minute the cAMP returned to the basal level. With 
photoaffinity probes of β-adrenergic receptor, it was demonstrated that such 
desensitisation was associated with the receptor phosphorylation (Stadel et al., 
1983), leading to the later identification of GPCR kinases (Benovic et al., 1989) 
and arrestins (Lohse et al., 1990). Therefore, in the 1990s, the classical 
consensus in GPCR-mediated cellular regulation was that upon agonist binding 
to the receptor, the G protein was recruited and promoted signalling by second 
messenger systems. This signalling was terminated by phosphorylation of the 
receptor in the carboxyl terminus or in the intracellular loops by GPCR kinases, 
which in turn caused the binding of arrestins to interdict G protein coupling, 
resulting in receptor desensitisation. Interestingly, over the past decade, β-
arrestin-mediated GPCR signalling was increasingly embraced, and this may 
represent a strategy in the discovery of novel therapeutic agents (Lefkowitz and 
Shenoy, 2005). Figure A6 illustrates how a β-arrestin-biased agonist at the 
angiotensin II type 1 receptor (AT1R) may have chance to become an effective 
therapy for heart failure. Angiotensin II, acting as an unbiased agonist at AT1R, 
is a peptide hormone vasoconstrictor and increase the blood pressure. 
Angiotensin receptor blockers (ARBs) are used to treat high blood pressure by 
blocking both G protein-mediated and β-arrestin-mediated pathways. Whilst G 
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protein-mediated pathway is responsible for the hypertensive effect, the β-
arrestin-mediated pathway provides benefits in cytoprotection and anti-
apoptosis. Attempts were therefore made to find the biased ligand that blocks 
the vasoconstrictive effect mediated by G protein but promotes cardiac 
performance mediated by β-arrestin. TRV120027 was identified as an 
antagonist with respect to G protein and an agonist with respect to β-arrestin. 
The cell culture experiments showed that TRV120027 selectively engaged β-
arrestin2 with EC50 of 17 nM without any G protein activation (Figure A6). In 
rat experiment, TRV120027 reduced mean arterial pressure (MAP) (Violin et 
al., 2010). The intravenous infusion of TRV120027 in the first human study 
resulted in significant reduction of MAP in patients with elevated renin activity 
(Soergel et al., 2013). The phase 2b acute heart failure (AHF) trials for 
TRV120027 are currently ongoing. TRV120027 represents an excellent 
prototype of how the emerging paradigm of β-arrestin-mediated signalling 
translates into a possibly therapeutic drug (Figure A7). 
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Figure A6. Biased agonism exemplified by angiotensin II receptor type 1. The 
dose-response curve is reproduced with permission (Violin et al., 2010). 
 
 
Figure A7. TRV027 (i.e. TRV120027) was developed by Trevena, Inc. with a 
unique mechanism that selectively antagonises angiotensin II-stimulated G 
protein coupling in order to reduce blood pressure and fluid retention, whilst 
recruits β-arrestin in order to preserve cardiac output (Violin et al., 2013) 
(reprinted with permission). 
 APPENDICES  
304 
 
Apart from biased agonism, the increasingly complex GPCR pharmacology can 
be appreciated by GPCR dynamics (Manglik and Kobilka, 2014), GPCR 
allostery (Wootten et al., 2013) and GPCR oligomerisation (Ferre et al., 2014). 
Although X-ray crystallography has provided static snapshots of the high-
resolution GPCR structures with the two-state (i.e. inactive and active states) 
mechanism, it fails to trap ensembles of receptor conformations caused by 
different ligands. To study the structural plasticity of GPCRs and better 
understand how a given agonist stabilises specific receptor conformations to 
trigger a distinct or a subset of signalling pathways, biophysical tools such as 
double electron-electron resonance (DEER) spectroscopy (Altenbach et al., 
2008) and NMR spectroscopy (Nygaard et al., 2013) have been harnessed to 
confirm the conformational dynamic properties at the physiological pH. The 
elucidation of the dynamics in structural elements at the extracellular surface 
(Bokoch et al., 2010) and intracellular loops (Kahsai et al., 2011) of GPCRs 
provides insights into the design of pathway-selective therapeutic agents. 
Allosteric modulation of GPCRs refers to the binding of a ligand at the site 
which is topographically distinct from the orthosteric binding site, and could 
either enhance or decrease the affinity of the orthosteric agonist. Given the high 
structural homology in the orthosteric binding pockets amongst subtypes of a 
receptor class, modulators targeting the allosteric binding site within which 
there is relatively greater structural variance in the amino acid sequence open 
up new avenues for novel subtype-selective ligands. Recently, the high-
resolution structures of one muscarinic acetylcholine receptor (M2 subtype) 
bound to a positive allosteric modulator (Kruse et al., 2013), and one 
metabotropic glutamate receptor (subtype 1) in complex with a negative 
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allosteric modulator (Wu et al., 2014), were determined, and it is anticipated 
that the allosteric structural information will facilitate the discovery of more 
efficacious and safer drugs in the near future. Whilst GPCRs are traditionally 
viewed as monomers, where agonist binding to the receptor allosterically causes 
conformational change of the cytoplasmic regions, resulting in the engagement 
of G protein, a large body of evidence coming from biophysical studies (by 
using e.g. atomic force microscopy, single-molecule total internal reflectance 
fluorescence microscopy, and fluorescence correlation spectroscopy) over the 
past two decades supports the existence of higher-order GPCR homomers and 
heteromers in the native membrane (Bouvier, 2001). Receptor homomers 
(heteromers) are defined as the complex, composed of at least two identical 
(different) receptor units, with each unit being able to function on its own, that 
possesses unique physiological functions distinct from what can be achieved by 
either individual component (Ferre et al., 2009). To date, it has been confirmed 
that family C GPCRs (e.g. metabotropic glutamate receptors) form dimers for 
activation (Kniazeff et al., 2011). GPCR oligomerisation, especially 
heteromerisation with unique localisation, has significant pharmacological 
implications. Heteromer-selective antibodies have been developed for δ-µ-
opioid receptor heteromers (Gupta et al., 2010), AT1-CB1 receptor heteromers 
(Rozenfeld et al., 2011), δ-opioid-CB1 receptor heteromers (Bushlin et al., 
2012), and δ-κ-opioid receptor heteromers (Berg et al., 2012) to demonstrate the 
localisation of receptor heteromers in native tissues. In some cases, receptor 
heteromers are disease-specific and are only up-regulated during diseases, thus 
making them possible drug targets. For instance, compounds acting at 
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angiotensin AT1 receptor-bradykinin B2 receptor heteromers, but without 
affecting the homomers, can be used to treat asthma (AbdAlla et al., 2005).          
In an analysis of drugs and their targets from the DrugBank database (Law et 
al., 2014), it was identified that approximately 36% of drugs target GPCRs 
(Rask-Andersen et al., 2011). GPCRs represent ideal drug targets because they 
have ligand-binding sites on the outer plasma membrane and they can adopt 
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Appendix F. Basal Ganglia Motor Circuit 
As shown in Figure A8, the basal ganglia in the vertebrate brain is composed of 
numerous complex subcortical nuclei with the primary afferent component 
being striatum, and it plays important roles in movement (Graybiel, 2005). 
“Disorders of basal ganglia”, which is a synonym for “movement disorders” 
termed by neurologists, are categorised into hyperkinetic disorders 
characterised by uncontrollably rapid acts (e.g. chorea, ballism and tic), 
hypokinetic disorders featured by akinesia and rigidity (e.g. Parkinson’s 
disease), and dystonia consisting of involuntary muscle contractions (Albin et 
al., 1989). Striatum, as the input nucleus of the basal ganglia, receives inputs 
from the cerebral cortex by excitatory glutamatergic neurons. The output nuclei 
of the basal ganglia, which is composed of the internal segment of the globus 
pallidus (GPi) and substantia nigra pars reticulate (SNr), receives information 
from striatum via a monosynaptic direct pathway that promotes movement, and 
a polysynaptic indirect pathway that suppresses movement and includes the 
external segment of the globus pallidus (GPe) and the subthalamic nucleus 
(STN). In the normal brain, the dopamine released from substantia nigra pars 
compacta (SNc) through dopaminergic neurons display dual effects on striatal 
GABAergic neurons through different subtypes of dopamine receptors 
(Beaulieu and Gainetdinov, 2011). The GABAergic neurons which project to 
GPi/SNr are enriched in dopamine D1 receptors, muscarinic M4 receptors, 
dynorphin and substance P, whereas the GABAergic neurons which project to 
GPe are enriched in dopamine D2 receptors, adenosine A2A receptors, and 
encephalin (Valjent et al., 2009). The binding of dopamine to the D1R-
expressing GABAergic neurons increases the activity of the direct 
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(striatonigral) pathway, whereas the binding of dopamine to the D2R-expressing 
GABAergic neurons decreases the activity of the indirect (striatopallidal) 
pathway. That the same ligand (i.e. dopamine) induces opposing cell responses 
mediated by distinct receptor subtypes (i.e D1R and D2R) at the striatal 
signalling for proper motor function is in agreement with the observation that 
D1R, rather than D2R, positively coupled to adenylyl cyclase (Spano et al., 
1978). The inhibition of GPi/SNr via input from the direct and indirect pathways 
causes paused inhibition of thalamocortical and brainstem neurons, hence 
facilitating movement. However, in the parkinsonian brain, the decreased 
dopamine input to the striatum results in the increase in GPi/SNr activity, and 
the resultant excessive reduced thalamocortical neurotransmission leads to 
motor suppression. To continue the cell responses mediated by either D1R or 
D2R activation, dopamine replacement therapies, such as L-DOPA and 
dopamine agonists, have been used to alleviate PD motor symptoms.  
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Figure A8. The traditional (simplified) model (Albin et al., 1989) of basal 
ganglia motor circuit in the normal brain. Green projections are glutamatergic 
neurons which have excitatory effects on the neurons they project to, and red 
projections are GABAergic neurons which have inhibitory effects on the 
neurons they project to. Blue projections are dopaminergic nigrostriatal 
neurons. GPi indicates internal segment of the globus pallidus; GPe, external 
segment of the globus pallidus; SNr, substantia nigra pars reticulate; SNc, 
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Appendix G. Virtual Screening 
Since the 1990s, pharmaceutical companies have made substantial investments 
on high-throughput screening (HTS) technology for the identification of 
potential compound hits. This became more obvious after the completion of 
Human Genome Project (HGP) in 2003, as numerous unprecedented therapeutic 
targets revealed by HGP have no known ligands. Multi-well microtiter plates, 
fluorescence detection systems, and automation robots have been developed to 
screen millions of in-house compound libraries (Smith, 2002) to search for 
active compounds for an individual or a subset of targets. In a study on 58 drugs 
approved between 1991–2008 , it was shown that 19 drugs were discovered by 
HTS (Perola, 2010). Recently, there were 12 drugs, such as chemokine receptor 
antagonists, thrombopoietin receptor agonists, and hepatitis C virus NS5A 
inhibitors, which got approval by FDA in 2003–2009 with origins in HTS 
endeavours (Macarron et al., 2011). Virtual screening (VS), which refers to the 
selection of potentially active compounds from a much larger chemical space 
compared to HTS using in silico approaches, complements HTS in hit 
identification, and offers many more possibilities than HTS on compound 
novelty. The term “virtual screening” was coined in 1997 in a search of 
inhibitors of trypanothione reductase by screening a database of 2500 molecular 
sketches, leading to one structurally distinct compound (Horvath, 1997). Since 
then, different VS methods have been developed, used and compared. VS shares 
the goal with HTS in screening compound libraries and identifying novel hits, 
but distinguishes from HTS in two advantageous aspects. First, whilst HTS aims 
to test experimentally a large number of physically existing compounds, VS 
leverages computational methods in the absence of tangible compounds at hand, 
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and therefore it represents a cost-effective screening tool. Second, VS has the 
capacity to expand the chemical space beyond the possible in-house compound 
pool owned by any pharmaceutical company, or any commercially available 
library provided by external vendors, with an example of chemical universe 
database GDB-17 containing 166.4 billion drug-like compounds (Ruddigkeit et 
al., 2013). Figure A9 shows that VS overcomes the limitation of HTS in terms 
of the number of compounds screened. 
 
Figure A9. Estimated number of compounds in various sources (Boehm, 2011) 
(reprinted with permission).  
 
VS is typically divided into structure-based VS (SBVS) which utilises the three-
dimensional structure of a given drug target (Ripphausen et al., 2012), and 
ligand-based VS (LBVS) which depends on the similarity of reported ligands at 
a particular drug target of interest (Ripphausen et al., 2011) (Figure A10). The 
two main advantages of SBVS are the structural novelty of the hits because the 
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process does not involve the use of any pre-existing ligands, as well as the 
facilitation of lead optimisation through ligand-receptor complex. However, 
SBVS is plagued with inevitable false-positives and false-negatives. The SBVS 
process is composed of two different stages: (i) the docking stage, with the 
attempt to obtain the accurate prediction in silico of the pose of a compound 
within the binding site; (ii) the scoring stage, where the in silico generated 
complexes are assessed by scoring functions to predict the likelihood of the 
ligand to actually bind to the target. Docking algorithms (Jain, 2008) and 
scoring functions require a compromise between prediction accuracy and time 
required for computation. The general consensus is that there is no perfect 
docking programme which excels others in all performances (e.g. docking 
accuracy, hit enrichment), and that the overall docking performance depends on 
the nature of the target protein. The challenge of the scoring function lies in the 
explanation of solvent effects and entropy contributions (Warren et al., 2006). 
Top-ranking compounds are then selected for experimental testing. Importantly, 
drug-relevant GPCR crystal structures were increasingly determined by X-ray 
crystallography over the past seven years (2007–2014), increasing opportunities 
for structure-based discovery of new scaffolds to complement previous ligand-
based approaches in GPCR drug discovery (Congreve et al., 2014). In contrast 
to SBVS, LBVS starts with the use of one or more active compounds as 
templates, and no details about the target are needed. In general, LBVS depends 
on computational descriptors or pharmacophore features, and analyses 
relationships between known actives and compounds in the database. It is 
computationally efficient and can rapidly search very large databases. It is 
therefore often used to sequentially filter large compound sets before more 
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complex tools are applied. There are literally thousands of different descriptors, 
which are derived from the two-dimensional (2D) or three-dimensional (3D) 
distribution of atomic properties in compounds, or from the presence or absence 
of specific structural elements. In LBVS, many methods exist for the 
comparison of the similarity of compounds based on these descriptors—shape  
comparison (Hawkins et al., 2007), pharmacophore searches (Wolber et al., 
2008), and field-based similarity methods (Moffat et al., 2008). If large sets of 
active and inactive compounds are known, machine learning (ML) methods, 
which refer to nonlinear supervised learning methods such as kernel 
discrimination, support vector machines (SVMs), and naïve Bayesian 
classifiers, can be used to train models that distinguish active from inactive 
compounds based on their specific structural features. ML methods are capable 
of generating complex mappings from descriptors without restrictions on 
structural frameworks and without prior knowledge of structure-activity 
relationships (SARs) (Chen et al., 2007). On the whole, the hit lists obtained 
from SBVS and LBVS are generally complementary, not redundant (Krüger 
and Evers, 2010).  
 
Figure A10. The classification of virtual screening. Reprinted with permission 
from (Ripphausen et al., 2010). Copyright (2010) American Chemical Society.   
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In the thesis, only LBVS approaches will be used due to the following 
considerations. First, although there have been several antagonist-bound A2A 
receptor structures determined to date (Congreve et al., 2012; Dore et al., 2011; 
Jaakola et al., 2008), a high-resolution crystal structure of D2 receptor is not 
available yet. In 2010, a crystal structure of D3 receptor in complex with an 
antagonist was solved (Chien et al., 2010). In spite of the high sequence 
homology between D3 and D2 receptors, the antagonist-bound D3 receptor 
structure represents an inactive state of the D3 receptor which cannot fully 
capture the precise active conformations of D2 receptor. The fully activated 
GPCR conformations trapped by X-ray crystallography are heretofore reported 
only for adrenergic β2 receptor (Rasmussen et al., 2011), adenosine A2A receptor 
(Xu et al., 2011), and muscarinic M2 acetylcholine receptor (Kruse et al., 2013). 
Second, even though D2 receptor was available, virtual screening relying on 
GPCR protein structures remains a challenge with much uncertainty. For 
instance, a molecular docking screen of 6.7 million compounds against agonist-
bound A2A crystal structures in an attempt to discover novel A2A agonists was 
conducted recently (Rodríguez et al., 2015). After filters and prioritisation, 20 
compounds were selected for experimentally testing, and intriguingly, none of 
them activated A2A receptor. This contrasts with using the antagonist-bound A2A 
receptor for molecular docking, which yielded some novel and functional 
chemotypes (Carlsson et al., 2010; Katritch et al., 2010). The disparity between 
the docking results of A2A agonists and A2A antagonists implies the more 
complex conformational ensembles in receptor activation compared with 
antagonism. 
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Appendix H. Classification of Adenosine A2A Receptor Antagonists 
Reported adenosine A2A antagonists are generally classified into xanthine-based 
(Figure 12) and non-xanthine-based derivatives, such as those with the core 
structure being nitrogen-containing mono-heterocyclic, fused bi-heterocyclic 
(Figure A11), and fused tri-heterocyclic derivatives (Figure A12) (Manera and 
Saccomanni, 2010). Of numerous reported A2A antagonists, many showed 
promising results in preclinical studies (de Lera Ruiz et al., 2014), and some of 
them are undergoing clinical trials (Pinna, 2014)—tozadenant in phase 2b 
(Hauser et al., 2014), PBF-509 (structure undisclosed) in phase 1, and V81444 
(structure undisclosed) in phase 2a. Most importantly, KW-6002 (Figure 16), 
one of the xanthine-based A2A antagonists, was approved in Japan in March of 


















































Ki(hA2A) = 5 nM
tozadenant VER 6947
ASP5854
Figure A11. Representative nitrogen-containing mono-heterocyclic and bi-
heterocyclic compounds as adenosine A2A receptor antagonists. 
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Figure A12. Representative nitrogen-containing tri-heterocyclic compounds as 
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Appendix I. Collection of Reported Adenosine A2A Receptor Antagonists.  
paper 
code 




1 Chem. Rev. 2008, 108, 238-263 
 
17 0 
2 J. Med. Chem. 2010, 53, 3748-3755 
 
26 2 




4 Curr. Pharm. Des. 2008, 14, 1525-1552 
 
25 0 
5 ChemMedChem 2009, 4, 1010-1019 
 
16 0 












9 J. Med. Chem. 2010, 53, 8104-8115 
 
1 1 
10 J. Med. Chem. 2004, 47, 6218-6229 
 
76 3 
11 J. Med. Chem. 2004, 47, 4291-4299 
 
40 20 
12 J. Med. Chem. 2008, 51, 4449-4455 
 
35 1 




14 J. Med. Chem. 2011, 54, 751-764 
 
24 2 
15 J. Med. Chem. 2000, 43, 1158-1164 
 
37 0 
16 J. Med. Chem. 2005, 48, 2009-2018 
 
54 10 
17 J. Med. Chem. 2010, 53, 1799-1809 
 
56 10 
18 J. Med. Chem. 2002, 45, 3440-3450 
 
36 8 
19 J. Med. Chem. 2008, 51, 400-406 
 
7 3 
20 J. Med. Chem. 2008, 51, 1719-1729 15 0 
 













22 J. Med. Chem. 2008, 51, 7099-7110 
 
27 15 
23 J. Med. Chem. 2008, 51, 1730-1739 
 
22 2 












































35 J. Med. Chem. 2009, 52, 33-47  
 
58 8 




37 Bioorg. Med. Chem. Lett. 2009, 19, 
967-971 
32 14 

















































48 J. Med. Chem. 2009, 52, 709-717 
 
35 1 




50 J. Med. Chem. 2002, 45, 115-126 
 
25 0 




52 J. Med. Chem. 2005, 48, 6887-6896 
 
9 1 




54 Bioorg. Med. Chem. Lett. 2005, 15, 
3675-3678 
13 11 









55 J. Med. Chem. 2003, 46, 1229-1241 
 
28 6 












59 Curr. Opin. Drug Discov. Develop. 
2010, 13, 466-480 
 
45 0 
60 J. Med. Chem. 2011, 54, 877-889  
 
40 0 




























68 Med. Chem. Commun. 2011, 2, 950-965 
 
57 57 
69 ACS Chem. Neurosci. 2011, 2, 526-535 
 
1 1 
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X, Y=N, CH   
(56, 24) 
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Appendix K. Collection of Reported Dopamine D2 Receptor Agonists 
paper 
code 




1 Chem. Rev. 2007, 107, 274-302 
 
6 0 
2 Pharmacol. Ther. 2010, 128, 229-273 
  
7 15 
3 ChemMedChem 2010, 5, 232-246 
  
28 16 
4 J. Med. Chem. 2010, 53, 2510-2520 
 
8 4 
5 J. Med. Chem. 2010, 53, 2114-2125 
 
6 2 
6 J. Med. Chem. 2009, 52, 4923-4935 
 
7 1 
7 J. Med. Chem. 2008, 51, 7806-7819 
 
21 3 
8 J. Med. Chem. 2009, 52, 6860-6870 
 
1 0 
























15 J. Med. Chem. 2007, 50, 171-181 
 
3 3 
16 J. Med. Chem. 2005, 48, 4153-4160 
 
8 8 
17 J. Med. Chem. 2005, 48, 2646-2654 
 
25 7 
18 J. Med. Chem. 2004, 47, 3853-3864 
 
3 2 
19 J. Med. Chem. 2003, 46, 4136-4140 1 1 
    
 
 









20 J. Med. Chem. 2003, 46, 3210-3220 
 
7 7 
21 J. Med. Chem. 2002, 45, 3022-3031 
 
15 1 
22 J. Med. Chem. 2002, 45, 2349-2351 
 
1 1 
23 J. Med. Chem. 2000, 43, 3549-3557 
 
4 3 
24 J. Med. Chem. 2000, 43, 3005-3019 
 
18 16 
25 J. Med. Chem. 2000, 43, 599-608 
 
2 1 
26 J. Med. Chem. 1999, 42, 2007-2020 
 
41 4 
27 J. Med. Chem. 1998, 41, 4915-4917 
 
6 6 
28 J. Med. Chem. 1998, 41, 4385-4399 
 
15 13 
29 J. Med. Chem. 1998, 41, 760-771 
 
27 3 
30 J. Med. Chem. 1997, 40, 4235-4256 
 
73 12 
31 J. Med. Chem. 1997, 40, 250-259 
 
19 4 
32 J. Med. Chem. 1994, 37, 4251-4257 
 
15 12 
33 J. Med. Chem. 1994, 37, 3523-3533 
 
18 1 
34 J. Med. Chem. 1991, 34, 3235-3241 
 
8 1 
35 J. Med. Chem. 1990, 33, 3122-3124 
 
8 1 
36 J. Med. Chem. 1990, 33, 1800-1805 
 
1 1 
37 J. Med. Chem. 1990, 33, 39-44 
 
9 2 
38 J. Med. Chem. 1987, 30, 1166-1176 
 
12 7 
39 J. Med. Chem. 1984, 27, 1607-1613 
 
1 1 








42 Bioorg. Med. Chem. 2008, 16, 3438-
3444 
2 1 





















46 Bioorg. Med. Chem. 1999, 7, 2453-2456 
 
24 24 
















51 Tetrahedron 1998, 54, 7081-7108 
 
7 0 








54 Eur. J. Pharmacol. 2006, 552, 36-45 
 
7 7 




56 Org. Biomol. Chem. 2005, 3, 4077-4081 
 
4 2 
57 Org. Lett. 2005, 7, 3239-3242 
 
2 1 









   













61 Pharm. Res. 2003, 20, 1619-1625 
 
1 1 
62 Eur. J. Pharmacol. 2006, 552, 36-45 
 
1 0 








65 J. Med. Chem. 1997, 40, 639-646 
 
9 2 




















71 J. Med. Chem. 2011, 54, 4324-4338 
 
29 3 
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aThe code below each compound represents the source where it was obtained 
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Appendix O. Crystal Structure Report for Compound 70 
A specimen of C21H25N5O, approximate dimensions 0.480 mm x 0.500 mm x 
0.560 mm, was used for the X-ray crystallographic analysis. The X-ray intensity 
data were measured. 
The integration of the data using a monoclinic unit cell yielded a total of 23666 
reflections to a maximum θ angle of 27.49° (0.77 Å resolution), of which 4263 
were independent (average redundancy 5.551, completeness = 100.0%, Rint = 
3.47%) and 4006 (93.97%) were greater than 2σ(F2). The final cell constants of 
a = 11.700(6) Å, b = 10.888(6) Å, c = 14.943(8) Å, β = 102.421(9)°, volume = 
1859.0(16) Å3, are based upon the refinement of the XYZ-centroids of 
reflections above 20 σ(I). The calculated minimum and maximum transmission 
coefficients (based on crystal size) are 0.6746 and 0.7456.  
 
The structure was solved and refined using the Bruker SHELXTL Software 
Package, using the space group P 1 21/c 1, with Z = 4 for the formula unit, 
C21H25N5O. The final anisotropic full-matrix least-squares refinement on F2 
with 251 variables converged at R1 = 4.43%, for the observed data and wR2 = 
11.33% for all data. The goodness-of-fit was 1.058. The largest peak in the final 
difference electron density synthesis was 0.323 e-/Å3 and the largest hole was -
0.221 e-/Å3 with an RMS deviation of 0.048 e-/Å3. On the basis of the final 
model, the calculated density was 1.298 g/cm3 and F(000), 776 e-.  
 
Sample and Crystal Data for Compound 70. 
Identification code D584 
Chemical formula C21H25N5O 
Formula weight 363.46 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal size 0.480 x 0.500 x 0.560 mm 
Crystal system monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions a = 11.700(6) Å α = 90° 
 b = 10.888(6) Å β = 102.421(9)°
 c = 14.943(8) Å γ = 90° 
Volume 1859.0(16) Å3  
Z 4 
Density (calculated) 1.298 g/cm3 
Absorption coefficient 0.083 mm-1 
F(000) 776 
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Data Collection and Structure Refinement for Compound 70. 
Theta range for data 
collection 1.78 to 27.49° 
Index ranges -15<=h<=15, -14<=k<=14, -19<=l<=19 
Reflections collected 23666 
Independent reflections 4263 [R(int) = 0.0347] 
Max. and min. 
transmission 0.7456 and 0.6746 
Structure solution 
technique direct methods 
Structure solution 
program Bruker SHELXTL 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2013 (Sheldrick, 2013) 
Function minimised Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 4263 / 0 / 251 
Goodness-of-fit on F2 1.058 
Δ/σmax 0.001 
Final R indices 4006 data; I>2σ(I) 
R1 = 0.0443, wR2 = 
0.1119 
 all data R1 = 0.0464, wR2 = 0.1133 
Weighting scheme w=1/[σ2(Fo2)+(0.0533P)2+0.9385P]where P=(Fo2+2Fc2)/3 
Largest diff. peak and 
hole 0.323 and -0.221 eÅ
-3 




























Atomic Coordinates And Equivalent Isotropic Atomic 
Displacement Parameters (Å2) for Compound 70.   
 
U(eq) is defined as one third of the trace of the orthogonalised Uij tensor.  
 x/a y/b z/c U(eq) 
 
O1 0.08563(8) 0.12335(9) 0.63467(6) 0.0234(2) 
N1 0.08706(9) 0.38977(9) 0.94624(7) 0.0182(2) 
N2 0.13692(9) 0.02887(9) 0.77185(7) 0.0173(2) 
N3 0.34484(9) 0.00004(10) 0.90546(7) 0.0193(2) 
N4 0.37742(9) 0.86624(9) 0.02942(7) 0.0176(2) 
N5 0.47832(9) 0.84380(9) 0.90594(7) 0.0183(2) 
C1 0.15574(10) 0.43251(11) 0.88904(8) 0.0167(2) 
C2 0.24042(10) 0.52460(11) 0.90190(8) 0.0199(2) 
C3 0.29696(10) 0.54741(11) 0.83131(9) 0.0216(3) 
C4 0.27074(11) 0.47984(12) 0.74913(9) 0.0218(3) 
C5 0.18572(10) 0.38908(11) 0.73600(8) 0.0184(2) 
C6 0.12647(10) 0.36425(10) 0.80651(8) 0.0154(2) 
C7 0.03660(10) 0.27869(10) 0.81696(8) 0.0157(2) 
C8 0.01568(10) 0.29727(11) 0.90277(8) 0.0173(2) 
C9 0.93337(11) 0.23369(13) 0.95122(9) 0.0245(3) 
C10 0.98032(10) 0.18484(11) 0.74765(8) 0.0175(2) 
C11 0.07089(10) 0.10841(11) 0.71337(8) 0.0168(2) 
C12 0.13043(10) 0.00641(11) 0.86720(8) 0.0174(2) 
C13 0.24184(10) 0.05149(11) 0.93203(8) 0.0183(2) 
C14 0.34824(10) 0.02592(11) 0.81033(8) 0.0193(2) 
C15 0.23949(11) 0.97329(11) 0.74735(8) 0.0199(2) 
C16 0.40143(10) 0.89901(11) 0.94854(8) 0.0162(2) 
C17 0.44026(10) 0.77268(11) 0.07256(8) 0.0188(2) 
C18 0.52390(11) 0.71183(11) 0.03589(8) 0.0210(3) 
C19 0.53925(10) 0.75046(11) 0.95066(8) 0.0191(2) 
C20 0.41585(12) 0.73638(14) 0.16329(9) 0.0284(3) 
C21 0.62432(12) 0.68809(13) 0.90336(9) 0.0272(3) 
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Bond Lengths (Å) for Compound 70.  
 
O1-C11 1.2356(15) N1-C1 1.3741(16) 
N1-C8 1.3786(16) N1-H1N 0.882(18) 
N2-C11 1.3492(16) N2-C15 1.4593(16) 
N2-C12 1.4637(16) N3-C16 1.3709(16) 
N3-C14 1.4582(16) N3-C13 1.4593(16) 
N4-C17 1.3380(16) N4-C16 1.3465(16) 
N5-C19 1.3352(16) N5-C16 1.3500(16) 
C1-C2 1.3937(18) C1-C6 1.4174(17) 
C2-C3 1.3828(18) C2-H2 0.95 
C3-C4 1.4077(19) C3-H3 0.95 
C4-C5 1.3860(18) C4-H4 0.95 
C5-C6 1.4065(16) C5-H5 0.95 
C6-C7 1.4382(16) C7-C8 1.3712(17) 
C7-C10 1.5024(16) C8-C9 1.4936(17) 
C9-H9A 0.98 C9-H9B 0.98 
C9-H9C 0.98 C10-C11 1.5203(17) 
C10-H10A 0.99 C10-H10B 0.99 
C12-C13 1.5282(17) C12-H12A 0.99 
C12-H12B 0.99 C13-H13A 0.99 
C13-H13B 0.99 C14-C15 1.5225(18) 
C14-H14A 0.99 C14-H14B 0.99 
C15-H15A 0.99 C15-H15B 0.99 
C17-C18 1.3884(17) C17-C20 1.4976(18) 
C18-C19 1.3891(18) C18-H18 0.95 
C19-C21 1.5013(17) C20-H20A 0.98 
C20-H20B 0.98 C20-H20C 0.98 
C21-H21A 0.98 C21-H21B 0.98 
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Bond Angles (°) for Compound 70. 
  
C1-N1-C8 109.30(10) C1-N1-H1N 127.0(12) 
C8-N1-H1N 123.4(12) C11-N2-C15 119.40(10) 
C11-N2-C12 126.54(10) C15-N2-C12 113.12(9) 
C16-N3-C14 120.08(10) C16-N3-C13 121.60(10) 
C14-N3-C13 112.85(9) C17-N4-C16 115.79(10) 
C19-N5-C16 116.19(11) N1-C1-C2 130.65(11) 
N1-C1-C6 107.42(11) C2-C1-C6 121.93(11) 
C3-C2-C1 117.81(11) C3-C2-H2 121.1 
C1-C2-H2 121.1 C2-C3-C4 121.43(12) 
C2-C3-H3 119.3 C4-C3-H3 119.3 
C5-C4-C3 120.74(11) C5-C4-H4 119.6 
C3-C4-H4 119.6 C4-C5-C6 119.05(11) 
C4-C5-H5 120.5 C6-C5-H5 120.5 
C5-C6-C1 119.03(11) C5-C6-C7 134.07(11) 
C1-C6-C7 106.90(10) C8-C7-C6 106.72(10) 
C8-C7-C10 127.24(11) C6-C7-C10 126.02(10) 
C7-C8-N1 109.66(10) C7-C8-C9 130.42(11) 
N1-C8-C9 119.92(11) C8-C9-H9A 109.5 
C8-C9-H9B 109.5 H9A-C9-H9B 109.5 
C8-C9-H9C 109.5 H9A-C9-H9C 109.5 
H9B-C9-H9C 109.5 C7-C10-C11 111.76(10) 
C7-C10-H10A 109.3 C11-C10-H10A 109.3 
C7-C10-H10B 109.3 C11-C10-H10B 109.3 
H10A-C10-H10B 107.9 O1-C11-N2 121.56(11) 
O1-C11-C10 119.92(11) N2-C11-C10 118.47(10) 
N2-C12-C13 110.34(10) N2-C12-H12A 109.6 
C13-C12-H12A 109.6 N2-C12-H12B 109.6 
C13-C12-H12B 109.6 H12A-C12-H12B 108.1 
N3-C13-C12 110.25(10) N3-C13-H13A 109.6 
C12-C13-H13A 109.6 N3-C13-H13B 109.6 
C12-C13-H13B 109.6 H13A-C13-H13B 108.1 
N3-C14-C15 109.60(10) N3-C14-H14A 109.7 
C15-C14-H14A 109.7 N3-C14-H14B 109.7 
C15-C14-H14B 109.8 H14A-C14-H14B 108.2 
N2-C15-C14 108.17(10) N2-C15-H15A 110.1 
C14-C15-H15A 110.1 N2-C15-H15B 110.1 
C14-C15-H15B 110.1 H15A-C15-H15B 108.4 
N4-C16-N5 126.45(11) N4-C16-N3 117.47(10) 
N5-C16-N3 116.07(10) N4-C17-C18 122.28(11) 
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N4-C17-C20 116.43(11) C18-C17-C20 121.29(11) 
C17-C18-C19 117.29(11) C17-C18-H18 121.4 
C19-C18-H18 121.4 N5-C19-C18 121.93(11) 
N5-C19-C21 116.45(11) C18-C19-C21 121.62(11) 
C17-C20-H20A 109.5 C17-C20-H20B 109.5 
H20A-C20-H20B 109.5 C17-C20-H20C 109.5 
H20A-C20-H20C 109.5 H20B-C20-H20C 109.5 
C19-C21-H21A 109.5 C19-C21-H21B 109.5 
H21A-C21-H21B 109.5 C19-C21-H21C 109.5 
H21A-C21-H21C 109.5 H21B-C21-H21C 109.5 
 
Torsion Angles (°) For Compound 70.  
 
C8-N1-C1-C2 179.83(12) C8-N1-C1-C6 -0.03(13) 
N1-C1-C2-C3 179.56(12) C6-C1-C2-C3 -0.60(17) 
C1-C2-C3-C4 -0.30(18) C2-C3-C4-C5 0.94(19) 
C3-C4-C5-C6 -0.66(18) C4-C5-C6-C1 -0.21(17) 
C4-C5-C6-C7 -179.45(12) N1-C1-C6-C5 -179.27(10) 
C2-C1-C6-C5 0.86(17) N1-C1-C6-C7 0.16(12) 
C2-C1-C6-C7 -179.71(10) C5-C6-C7-C8 179.08(12) 
C1-C6-C7-C8 -0.23(12) C5-C6-C7-C10 0.9(2) 
C1-C6-C7-C10 -178.39(10) C6-C7-C8-N1 0.21(13) 
C10-C7-C8-N1 178.35(10) C6-C7-C8-C9 -178.82(12) 
C10-C7-C8-C9 -0.7(2) C1-N1-C8-C7 -0.11(13) 
C1-N1-C8-C9 179.04(10) C8-C7-C10-C11 -127.40(12) 
C6-C7-C10-C11 50.40(15) C15-N2-C11-O1 9.66(17) 
C12-N2-C11-O1 177.78(11) C15-N2-C11-C10 -167.59(10) 
C12-N2-C11-C10 0.54(17) C7-C10-C11-O1 -108.21(12) 
C7-C10-C11-N2 69.08(14) C11-N2-C12-C13 -112.56(13) 
C15-N2-C12-C13 56.20(13) C16-N3-C13-C12 -98.53(13) 
C14-N3-C13-C12 55.33(13) N2-C12-C13-N3 -52.15(13) 
C16-N3-C14-C15 95.28(13) C13-N3-C14-C15 -59.02(13) 
C11-N2-C15-C14 110.63(12) C12-N2-C15-C14 -59.02(13) 
N3-C14-C15-N2 58.67(12) C17-N4-C16-N5 2.91(17) 
C17-N4-C16-N3 -175.43(10) C19-N5-C16-N4 -2.68(17) 
C19-N5-C16-N3 175.68(10) C14-N3-C16-N4 -167.58(10) 
C13-N3-C16-N4 -15.57(16) C14-N3-C16-N5 13.90(16) 
C13-N3-C16-N5 165.92(10) C16-N4-C17-C18 -0.87(17) 
C16-N4-C17-C20 179.10(11) N4-C17-C18-C19 -1.08(18) 
C20-C17-C18-C19 178.95(12) C16-N5-C19-C18 0.39(17) 
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C16-N5-C19-C21 179.59(11) C17-C18-C19-N5 1.33(18) 
C17-C18-C19-C21 -177.82(12)   
 
Anisotropic Atomic Displacement Parameters (Å2) for 
Compound 70.  
 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 
+ ... + 2 h k a* b* U12 ]  
 U11 U22 U33 U23 U13 U12 
O1 0.0302(5) 0.0279(5) 0.0124(4) -0.0008(3) 0.0057(3) -0.0012(4) 
N1 0.0224(5) 0.0203(5) 0.0122(5) -0.0004(4) 0.0045(4) 0.0017(4) 
N2 0.0197(5) 0.0199(5) 0.0133(5) -0.0010(4) 0.0059(4) 0.0001(4) 
N3 0.0211(5) 0.0229(5) 0.0149(5) 0.0034(4) 0.0063(4) 0.0055(4) 
N4 0.0172(5) 0.0200(5) 0.0159(5) 0.0016(4) 0.0045(4) -0.0003(4) 
N5 0.0178(5) 0.0217(5) 0.0154(5) -0.0017(4) 0.0034(4) 0.0014(4) 
C1 0.0181(5) 0.0170(5) 0.0145(5) 0.0015(4) 0.0026(4) 0.0042(4) 
C2 0.0210(6) 0.0185(6) 0.0181(6) -0.0015(4) -0.0005(4) 0.0018(4) 
C3 0.0180(5) 0.0194(6) 0.0262(6) 0.0014(5) 0.0019(5) -0.0018(4) 
C4 0.0210(6) 0.0231(6) 0.0228(6) 0.0034(5) 0.0081(5) 0.0001(5) 
C5 0.0203(5) 0.0193(6) 0.0162(5) -0.0002(4) 0.0054(4) 0.0012(4) 
C6 0.0157(5) 0.0157(5) 0.0141(5) 0.0014(4) 0.0017(4) 0.0024(4) 
C7 0.0160(5) 0.0168(5) 0.0142(5) 0.0015(4) 0.0034(4) 0.0016(4) 
C8 0.0177(5) 0.0183(5) 0.0158(5) 0.0015(4) 0.0037(4) 0.0027(4) 
C9 0.0257(6) 0.0304(7) 0.0199(6) 0.0006(5) 0.0104(5) -0.0027(5) 
C10 0.0172(5) 0.0200(6) 0.0143(5) 0.0010(4) 0.0014(4) -0.0013(4) 
C11 0.0192(5) 0.0172(5) 0.0136(5) -0.0028(4) 0.0025(4) -0.0049(4) 
C12 0.0214(6) 0.0170(5) 0.0156(5) 0.0024(4) 0.0079(4) 0.0015(4) 
C13 0.0214(6) 0.0200(6) 0.0142(5) 0.0012(4) 0.0053(4) 0.0053(4) 
C14 0.0212(6) 0.0227(6) 0.0156(5) 0.0045(4) 0.0076(4) 0.0036(4) 
C15 0.0243(6) 0.0209(6) 0.0164(5) -0.0009(4) 0.0089(4) 0.0026(5) 
C16 0.0152(5) 0.0182(5) 0.0145(5) -0.0009(4) 0.0019(4) -0.0013(4) 
C17 0.0189(5) 0.0193(6) 0.0177(5) 0.0019(4) 0.0030(4) -0.0023(4) 
C18 0.0214(6) 0.0195(6) 0.0214(6) 0.0025(5) 0.0027(5) 0.0038(5) 
C19 0.0165(5) 0.0216(6) 0.0182(5) -0.0036(5) 0.0013(4) 0.0007(4) 
C20 0.0288(7) 0.0331(7) 0.0255(7) 0.0126(5) 0.0108(5) 0.0056(5) 
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Hydrogen Atomic Coordinates And Isotropic Atomic Displacement 
Parameters (Å2) for Compound 70.  
 
 x/a y/b z/c U(eq) 
H1N 0.0906(15) 0.4115(17) 1.0036(13) 0.035(4) 
H2 0.2587 0.5702 0.9573 0.024 
H3 0.3547 0.6100 0.8384 0.026 
H4 0.3118 0.4966 0.7021 0.026 
H5 0.1677 0.3443 0.6802 0.022 
H9A -0.1148 0.1753 0.9094 0.037 
H9B -0.1173 0.2945 0.9716 0.037 
H9C -0.0218 0.1895 1.0045 0.037 
H10A -0.0705 0.2271 0.6951 0.021 
H10B -0.0696 0.1299 0.7757 0.021 
H12A 0.1204 -0.0826 0.8767 0.021 
H12B 0.0618 0.0498 0.8809 0.021 
H13A 0.2452 0.1423 0.9301 0.022 
H13B 0.2409 0.0265 0.9956 0.022 
H14A 0.4192 -0.0112 0.7956 0.023 
H14B 0.3515 0.1158 0.8010 0.023 
H15A 0.2405 -0.0081 0.6827 0.024 
H15B 0.2374 -0.1170 0.7546 0.024 
H18 0.5688 -0.3536 1.0678 0.025 
H20A 0.4374 -0.1961 1.2070 0.043 
H20B 0.4618 -0.3367 1.1862 0.043 
H20C 0.3323 -0.2819 1.1561 0.043 
H21A 0.5972 -0.3955 0.8862 0.041 
H21B 0.7015 -0.3153 0.9448 0.041 
H21C 0.6298 -0.2656 0.8482 0.041 
 
Hydrogen Bond Distances (Å) And Angles (°) for Compound 70.  
 
 Donor-H Acceptor-H Donor-Acceptor Angle 
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Appendix Q. HPLC Chromatograms of Compounds 69-72 and 69a-72a  
 HPLC (1) for Compound 69: 










1 0.466 1.6 0.275 29 1.180 
2 1.496 1.5 0.303 35.3 1.436 
3 2.472 1.7 0.137 17.4 0.708 
4 5.618 134.5 0.264 2376.6 96.677 
 
















1 6.803 10.138 0.736 621.742 0.985 
2 12.697 8.901 0.138 79.369 0.126 
3 14.262 39.981 0.128 348.322 0.552 
4 15.511 3020.178 0.33 62026.6 98.291 
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HPLC (1) for Compound 70: 
 










1 8.249 1.1 0.215 15.4 0.056 
2 9.847 1365.8 0.293 27502.7 99.944 
 
HPLC (3) for Compound 70: 
 










1 6.219 8.555 0.178 108.408 0.364 
2 6.892 2.467 0.086 13.955 0.047 
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HPLC (1) for Compound 71: 
 










1 1.599 5.6 0.357 129.5 1.602 
2 10.193 379.5 0.350 7956.6 98.398 
 
HPLC (3) for Compound 71: 
 










1 6.247 11.177 0.214 160.467 1.182 
2 6.856 6.483 0.134 63.112 0.465 
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HPLC (1) for Compound 72: 
 










1 2.603 2.8 0.143 26.7 0.178 
2 11.295 704.2 0.31 14971.2 99.666 
3 16.075 1.8 0.199 23.5 0.156 
 
HPLC (3) for Compound 72: 
 










1 6.254 10.728 0.215 155.383 0.669 
2 6.889 5.870 0.128 54.284 0.234 
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HPLC (2) for Compound 69a: 
 










1 8.538 3086.417 0.169 31894 100 
 
HPLC (3) for Compound 69a: 
 










1 12.045 11.250 0.126 96.709 0.901 
2 14.575 1127.835 0.138 10413.5 97.01 
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HPLC (2) for Compound 70a: 
 







(mAU × s) 
area 
(%) 
1 9.033 3081.408 0.164 31264.3 96.681 
2 9.544 129.115 0.117 1073.337 3.319 
 
HPLC (3) for Compound 70a: 
 










1 13.580 11.343 0.124 93.510 0.412 
2 14.492 2075.449 0.165 21861.500 96.269 
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HPLC (2) for Compound 71a: 
 










1 8.994 3020.587 0.168 30960.4 100 
 
HPLC (3) for Compound 71a: 
 










1 6.517 6.782 0.330 167.186 0.483 
2 6.924 4.775 0.211 78.043 0.226 
3 12.609 22.235 0.247 342.006 0.989 
4 13.417 6.390 0.138 57.874 0.167 
5 13.915 5.490 0.202 83.552 0.242 
6 14.073 3.400 0.106 23.271 0.067 
7 14.444 2719.874 0.197 33279.5 96.221 
8 14.897 44.941 0.137 441.324 1.276 
9 15.577 9.464 0.165 102.782 0.297 
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HPLC (2) for Compound 72a: 
 










1 9.290 2956.135 0.174 31367.3 100 
 
HPLC (3) for Compound 72a: 
 










1 6.212 9.699 0.191 127.402 0.577 
2 6.892 2.450 0.086 13.815 0.063 
3 14.533 35.182 0.080 181.929 0.824 
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Appendix R. Radioligand Competition Assays 
The evaluation of the binding affinity of synthesised compounds for adenosine 
receptor subtypes depended on the use of radioligands. A radioligand is a ligand 
that is labelled with a radioactive isotope (e.g. tritium [3H] or iodine [125I]). 
Important characteristics for a good radioligand include high affinity (ca. KD ~ 
1 nM) and high selectivity at the receptor of interest, as well as low non-specific 
(or, non-receptor) binding. A suitable radioligand is incubated with the receptor 
of interest for an appropriate period of time, and then the radioactivity bound to 
that receptor is measured. Experiments involving radioligand binding include 
saturation (to study the concentration of a receptor), competition (to assess the 
binding of an unlabelled drug), and kinetic (to determine the time-course 
radioligand dissociation and association) assays. Competition binding 
experiments measure the ability of a newly synthesised drug to compete with a 
specific radioligand for binding that receptor, and in the thesis, three 
radioligands were used for human A1 ([3H]-2-chloro-6-cyclopentyladenosine), 
A2A ([3H]-5’-N-ethylcarboxamidoadenosine) and A3 ([3H]-2-hexyn-1-yl-N6-
methyladenosine) subtypes. For the hA2B subtype, compound potency was 
determined in adenylyl cyclase assay, due to the unavailability of a radioligand 
suitable for hA2B receptor. The principle of radioligand competition is given in 
Figure A13. 
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Figure A13. Radioligand competition experiments for receptors. The 
experiment starts with receptor preparation by homogenising the tissue in the 
buffer and centrifugation to obtain the crude membrane pellet (A). The receptor-
bound membranes and a suitable radioligand with a fixed concentration are 
incubated   for a period of time to ensure that equilibrium has been reached. The 
removal of free radioligands from receptor-bound radioligands is usually 
employed by filtration (B). Non-specific binding can be determined by using an 
unlabelled drug that is structurally dissimilar from the radioligand (C). An 
unlabelled drug is tested over a concentration range. A competition curve is 
obtained by plotting the percentage of radioligand binding against the 
logarithmic concentration of the unlabelled drug (D) (Vauquelin and von 
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Appendix T. HPLC Chromatograms of Compounds 73-83  
HPLC (1) for Compound 73: 
 










1 0.502 1.9 0.481 69.6 0.582 
2 2.446 1.1 0.075 5.5 0.046 
3 2.647 2.6 0.148 24.4 0.204 
4 8.688 644.3 0.267 11863.5 99.168 
 
HPLC (3) for Compound 73: 
 










1 6.233 7.873 0.202 106.458 0.510 
2 6.911 2.460 0.085 13.795 0.066 
3 15.412 2035.682 0.147 20739.9 99.256 
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HPLC (1) for Compound 74: 
 










1 0.476 2 0.356 55.6 0.703 
2 1.607 7 0.401 192.1 2.428 
3 2.407 1.3 0.076 6.2 0.078 
4 2.606 2.8 0.163 28.5 0.360 
5 8.542 423.3 0.300 7630.8 96.431 
 
HPLC (3) for Compound 74: 
 










1 6.253 10.087 0.210 139.623 0.889 
2 6.886 5.826 0.131 55.446 0.353 
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HPLC (1) for Compound 75: 
 










1 0.466 2.1 0.356 56.9 0.005 
2 1.596 6.9 0.4 188.5 1.822 
3 2.6 2.8 0.160 27.7 0.268 
4 11.672 467 0.314 10074.2 97.361 
 
HPLC (3) for Compound 75: 
 










1 6.249 8.438 0.201 110.906 0.525 
2 6.915 2.517 0.084 14.143 0.067 
3 14.760 8.823 0.134 79.748 0.377 
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HPLC (1) for Compound 76: 
 










1 0.491 1.8 0.445 59 0.263 
2 2.442 1.3 0.060 5 0.022 
3 2.626 3 0.147 27.3 0.122 
4 8.433 1275.7 0.257 22363 99.59 
 
HPLC (3) for Compound 76: 
 










1 6.235 6.834 0.170 73.556 0.395 
2 6.919 2.500 0.083 13.961 0.075 
3 15.226 1848.640 0.143 18454.7 99.039 
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HPLC (1) for Compound 77: 
 










1 0.567 2.2 0.459 82.3 3.090 
2 2.629 2.9 0.149 26.8 1.006 
3 13.308 108.7 0.392 2553.9 95.903 
 
HPLC (3) for Compound 77: 
 










1 16.398 39.033 0.110 280.676 0.868 
2 16.531 42.877 0.162 492.120 1.522 
3 17.235 2464.557 0.194 31203.5 96.504 
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HPLC (1) for Compound 78: 
 










1 2.657 2.5 0.140 22.6 0.169 
2 10.124 681.5 0.286 13294.6 99.689 
3 11.713 1.1 0.273 18.9 0.142 
 
HPLC (3) for Compound 78: 
 










1 6.212 9.639 0.185 126.722 0.315 
2 6.891 2.605 0.089 15.284 0.038 
3 15.783 2755.873 0.222 39720.5 98.697 
4 16.359 19.860 0.180 249.023 0.619 
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HPLC (1) for Compound 79:  
 










1 2.614 2.9 0.149 26.5 0.249 
2 9.561 572.5 0.270 10575 99.395 
3 13.367 2.2 0.253 37.9 0.356 
 
HPLC (3) for Compound 79: 
 










1 6.269 6.100 0.165 58.142 0.213 
2 6.900 2.227 0.084 11.801 0.043 
3 15.462 2479.533 0.159 27043.5 99.009 
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HPLC (1) for Compound 80: 
 










1 1.540 3.3 0.069 14.8 0.060 
2 2.613 2.8 0.144 24.3 0.098 
3 6.190 1.2 0.204 17.3 0.070 
4 8.521 5 0.251 84.5 0.342 
5 9.271 3.5 0.271 64.3 0.260 
6 10.937 1146.6 0.311 24514.9 99.080 
7 16.714 1.4 0.247 22.3 0.090 
 
HPLC (3) for Compound 80:  
 










1 6.228 7.516 0.181 91.079 0.239 
2 6.912 2.475 0.086 14.032 0.037 
3 15.202 17.453 0.123 141.656 0.372 
4 15.396 23.242 0.175 293.553 0.770 
5 15.843 14.187 0.165 166.697 0.437 
























































 APPENDICES  
404 
 
HPLC (1) for Compound 81:  
 










1 2.641 2.5 0.144 22.2 0.252 
2 9.564 472.7 0.271 8795.7 99.748 
 
HPLC (3) for Compound 81: 
 










1 6.255 7.682 0.188 91.042 0.405 
2 6.908 2.533 0.084 14.222 0.063 
3 15.551 2123.325 0.150 22271.0 99.039 
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HPLC (1) for Compound 82: 
 










1 2.558 3.8 0.182 44.8 0.253 
2 9.452 901.7 0.285 17689.8 99.747 
 
HPLC (3) for Compound 82:  
 










1 6.250 8.079 0.196 102.290 0.604 
2 6.890 2.295 0.083 12.310 0.073 
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HPLC (1) for Compound 83:  
 










1 0.445 3.2 0.360 85.9 0.672 
2 1.602 6.8 0.423 198.8 1.555 
3 2.403 1.3 0.088 7.1 0.056 
4 2.602 2.9 0.161 28.6 0.224 
5 9.162 670.2 0.271 12468.2 97.495 
 
HPLC (3) for Compound 83: 
 










1 6.248 8.366 0.230 130.691 0.488 
2 6.909 2.448 0.087 13.965 0.052 
3 15.309 2450.733 0.159 26582.8 99.168 
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Appendix V. HPLC Chromatograms of Compounds 90-95  
HPLC (2) for Compound 90:  
 










1 12.874 1924.688 0.155 19905.4 96.967 
2 13.349 69.493 0.127 622.641 3.033 
 
HPLC (1) for Compound 91: 
 










1 0.434 3.3 0.365 88.5 1.64 
2 1.592 6.8 0.442 180.5 3.35 
3 11.300 220.3 0.388 5125.7 95.014 
 
 
HPLC (3) for Compound 91:  
 










1 6.227 10.831 0.203 149.800 0.481 
2 6.865 6.054 0.128 56.103 0.180 
3 16.474 2397.941 0.191 30963.2 99.339 
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HPLC (1) for Compound 92: 
 










1 1.561 6.5 0.340 147.5 1.382 
2 2.420 1.1 0.098 6.6 0.062 
3 2.596 2.9 0.146 30.1 0.282 
4 9.752 1.9 0.211 26.9 0.252 
5 11.659 476.2 0.318 10462.7 98.022 
 
HPLC (3) for Compound 92: 
 










1 6.215 5.010 0.049 2.307 0.005 
2 6.892 2.406 0.086 13.567 0.031 
3 16.559 2795.178 0.244 43544.8 99.733 
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HPLC (1) for Compound 93:  
 










1 2.776 3.1 0.343 79 0.759 
2 11.516 2 0.248 33.9 0.326 
3 13.058 411.8 0.360 10289.9 98.915 
 
HPLC (3) for Compound 93: 
 










1 6.250 10.587 0.211 151.576 1.239 
2 6.891 5.781 0.127 53.115 0.434 
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HPLC (1) for Compound 94: 
 










1 0.457 3 0.367 82.9 0.707 
2 1.598 7.3 0.359 173.7 1.481 
3 2.608 2.5 0.148 22 0.188 
4 8.338 3.4 0.198 44.4 0.379 
5 10.620 541.8 0.306 11405.6 97.246 
 
HPLC (3) for Compound 94: 
 










1 6.246 8.918 0.206 122.000 0.758 
2 6.905 2.540 0.087 14.549 0.090 
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HPLC (1) for Compound 95: 
 










1 0.470 3.5 0.430 114.9 0.821 
2 1.610 7.9 0.417 225.8 1.613 
3 2.609 2.6 0.156 24.8 0.177 
4 9.893 1.3 0.208 18 0.129 
5 11.697 615 0.320 13618.3 97.261 
 
HPLC (1) for Compound 95: 
 










1 6.236 9.100 0.184 106.263 0.256 
2 6.860 5.511 0.128 51.084 0.123 
3 16.458 29.455 0.135 260.956 0.628 
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Appendix W. Western Blot Analysis 
 
Lanes 3 and 7: Reaction mixtures before purification. Lanes 4 and 8: Filtrates 
after purification. Lanes 5 and 9: Resuspended retentates after purification. The 
distinct band at 40 kDa resulted from D2 receptor. For more information 
regarding Western blot experiments, readers are referred to the original paper 
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Appendix X. Flow Cytometry Measurements 
 
The decrease in antibody binding for blank polymersomes compared to D2R-
functionalised polymersomes verified the association of polymersomes with 
D2R. For more information regarding flow cytometry experiments, readers are 
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